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ABSTRACT 
Proteins which regulate the expression and activity of the small oncogenic lipids, LPA and 
S1P are important in the development and progression of cancers. This study set out to 
explore the expression of lipid signalling molecules in two types of lymphoid malignancies 
and a few epithelial malignancies and correlate their association with clinicopathological 
parameters. The expression of SPHK1, S1PR1, ABCC1 and ATX in epithelial malignancies 
were studied which included breast, bladder and lung cancer. It is shown that S1PR1 is a poor 
prognostic marker in breast cancer and ATX is a poor prognostic marker in both breast and 
lung cancers. The expression of lipid signalling proteins and mRNA showed that S1PR1 was 
commonly expressed in HL, while S1PR3 was expressed in all HL cases suggesting its role in 
lymphomagenesis. L591 Hodgkin lymphoma cells treated with anti-S1P, Sphingomab showed 
restoration of four B cell receptor genes namely BCL10, RAPGEF1, NFATC3 and MALT by 
gene expression microarray. Sphingomab also showed downregulation of S1PR3 and S1PR5 
genes which may be a possible therapeutic target in cancer. The incidence of EBV
+
 DLBCL 
in this series is 14/300 (4.7%). S1PR1 was commonly expressed in DLBCL and patients with 
S1PR1 expressing tumours were more likely to have more than one extranodal site 
involvement. EBV positivity, presence of B symptoms, bulky disease, BCL6 positivity and 
high IPI  were found to be poor prognostic factors in DLBCL. 
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1.1  Introduction 
In the Introduction (Chapter 1), I will discuss the three major areas of relevance to this study; 
sphingolipid metabolism, Hodgkin lymphoma and Diffuse Large B cell lymphoma (DLBCL), 
including EBV-positive DLBCL of the elderly. This will be followed by the Materials and 
Methods (Chapter 2) that will provide detailed information about the experimental procedures 
carried out during this investigation. 
The remainder of this thesis consists of three studies. Chapter 3 describes the expression of 
SPHK1 and of other related lipid signalling molecules in three types of epithelial 
malignancies; breast, bladder and lung cancer. Chapter 4 investigates the expression of lipid 
signalling molecules in primary HL tissues and HL cell lines as well as the possible 
contribution of S1P signalling to the pathogenesis of HL. Chapter 4 also describes the gene 
expression profiling of the HL cell line L591, after treatment with anti- S1P antibody, 
Sphingomab. In Chapter 5, I estimated the incidence of EBV
+
 DLBCL in a single centre in 
the UK and described the expression of lipid signalling molecules in DLBCL and their 
association with clinicopathological parameters including clinical outcome. 
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1.2  Sphingolipid metabolism  
Lipids are long known to have important roles in cellular metabolism and membrane biology. 
However it is only in the last two decades that lipids have been recognised as cellular 
signalling molecules. The first observation which suggested that lipids could be involved in 
cell signalling was made by Hokin and Hokin in the 1950s. In their pioneering studies, 
pancreatic slices stimulated with acetylcholine resulted in the rapid turnover of inositol 
phospholipids. After a few dormant years, diacylglycerol (DAG) was implicated in regulating 
protein kinase C (PKC), and inositol 1,4,5-triphosphate (Ins (1,4,5)P3) was found to regulate 
calcium release (Nishizuka 1992) leading to various cellular responses. This led to the idea 
that lipids could regulate cell signalling which subsequently ushered the era of bioactive 
lipids. 
The concept of bioactive lipids implies any changes in lipid levels which results in functional 
consequences. The best studied bioactive lipids so far are ceramide, sphingosine (Sph) and 
sphingosine 1-phosphate (S1P). The precursor of these bioactive products is sphingomyelin 
(SM). The name Sphingosine, first described in the 1800s is derived from the word Sphinx, a 
Greek mythological character of a winged lion with a human face. The phosphorylation of 
sphingosine yields S1P. 
Chapter 1  Introduction 
4 
 
1.3  Sphingolipid family 
1.3.1  Ceramide and spingosine, precursors of S1P 
Ceramide is formed from serine and palmitoyl CoA as well as by sphingomyelin 
hydrolysis.(Figure 1.1). Stress stimuli such as chemotherapeutic drug treatment and radiation 
increase its production. Ceramides modulate diverse signal transduction pathways and key 
regulatory enzyme activities including the mitogen activated protein kinases (MAPKs) p42/ 
44, specific serine/ threonine kinases like protein kinase C (PKC), stress-activated protein 
kinases (JNKs), protein kinase B (PKB) and protein phosphatases, phospholipase A2 and 
phospholipase D (Simstein et al., 2003, Ogretmen & Hannun, 2004; Taha et al., 2006). 
Ceramide also mediates growth inhibition, apoptosis, modulation of telomerase activity and 
telomere length and senescence (Ogretmen & Hannun 2004). Ceramide is further metabolised 
by ceramidases to form the single fatty-chain, sphingosine (Baumruker & Prieschl, 2002). 
Sphingosine can then be phosphorylated by sphingosine kinases (SPHKs), to yield S1P (Van 
Brocklyn et al., 1998; Melendez, 2008; Spiegel, 1999). S1P is cleaved by S1P lyase (SGPL1) 
to hexadecenal and ethanolamine 1-phosphate or it can be converted back to sphingosine by 
S1P phosphatases. There are two main S1P phosphatases; S1P phosphatase 1 (SGPP1) and 
S1P phosphatase 2 (SGPP2). (Figure 1.1).  
The sphingolipid metabolites are interconvertible and the dynamic ratio between S1P and 
ceramide determines cell fate, which gives rise to the sphingolipid biostat (Cuvillier et al., 
1996). Conversion of sphingosine to S1P by Sphingosine kinase 1 (SPHK1) leads to enhanced 
cell growth and survival and suppression of apoptosis. In contrast, conversion of S1P to 
sphingosine and then to ceramide leads to cell death ( Spiegel & Milstien, 2002). 
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Figure 1.1: Pathways of sphingolipid metabolism. Sphingomyelin is hydrolysed by 
sphingomyelinase to form ceramide. Ceramide can be metabolized by ceramidases to form 
sphingosine which is then phosphorylated by SPHK1 to generate S1P. S1P is cleared by the 
S1P phosphatases; SGPP1/ SGPP2 or cleaved by S1P lyase (SGPL1) into ethanolamine 1-
phosphate and hexadecenal. Sphingosine can also be formed de novo by the action of serine 
palmitoyl transferase on serine and palmitoyl CoA. 
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1.3.2  Sphingosine 1- phosphate 
S1P regulates a large number of physiological and pathological processes including growth, 
survival, differentiation, cytoskeleton rearrangements, angiogenesis and vascular maturation 
(Anliker & Chun, 2004; Spiegel & Milstien, 2003; Takabe et al., 2008; Young & Van 
Brocklyn, 2006). S1P secreted from the cell binds to transmembrane hepta-helical G-protein 
coupled receptors (GPCRs), termed S1P receptors (S1PRs). In an autocrine manner, S1P 
promotes growth, survival, motility and metastasis and in a paracrine manner, it induces the 
production of endothelial adhesion molecules and promotes angiogenesis (Anelli et al.,2010), 
tumour-stromal interactions and lymphocyte trafficking (Chi 2011) S1PRs were formerly 
known as the endothelial differentiation gene receptors (EDGs). Five S1PRs have been 
identified ie S1PR1-S1PR5. Table 1.1 shows the cellular distributions of S1P receptor 
subtypes. Previously, it was believed that S1P acts as only an intracellular mediator. However 
in 1992, Igarashi's group found that S1P played a role as an extracellular mediator in 
controlling cell motility (Sadahira et al.,992). Independent of its cell surface receptors, S1P 
can act intracellularly by regulating calcium release (Van Brocklyn et al. 1998), cell growth, 
inflammatory responses (Melendez & Khaw 2002) and the suppression of apoptosis (Cuvillier 
et al., 1996). Intracellular S1P also modulates histone acetylation via histone deacetylases 
(HDACs) in breast cancer cells (Hait et al. 2009). From the observations that enzymes 
controlling sphingolipid metabolism (neutral sphingomyelinase and ceramidase) are present in 
the nucleus, it has been suggested that sphingolipids are also metabolised in the nucleus (Albi 
et al., 2008).  
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1.3.3   Cellular production of S1P  
S1P is mainly produced by endothelial cells and platelets (Igarashi and Yatomi, 1998). 
However, epithelial cells, cerebellar granule cells, cerebellar astrocytes (Bassi et al., 2006), 
thrombocytes (Hänel et al., 2007), macrophages, mast cells and dendritic cells (Martino 2007; 
Goetzl & Tigyi 2004) can also produce S1P. Circulating erythrocytes do not produce S1P but 
are capable of storing and releasing it, protecting S1P from degradation. In plasma, S1P 
concentrations can reach a concentration of 0.2 to 0.9 µM where it is mostly bound to high 
density lipoproteins (HDLs). Levels in lymph fluid are about five-fold lower than in plasma. 
Tissue S1P levels are generally low, ranging from 0.5 to 0.75 pmol/mg (Edsall & Spiegel, 
1999). The half life of S1P is less than 15 minutes (Venkataraman et al., 2008). Upon 
production in the cell following agonist-induced activation of SPHK1, S1P is transported to 
the extracellular space by ATP-binding cassette (ABC) transporters including ABCA1 (Sato 
et al., 2007), ABCC1 and ABCG2 (Takabe et al. 2010). ABCC1, also known as Multidrug 
Resistant Protein 1 (MRP1 or MDR), is one of the most extensively characterised ABC 
transporters and is involved in the export of S1P in activated mast cells (Mitra et al., 2006). 
Once in the extracellular space, S1P acts on cell surface S1PRs which interacts with various 
intracellular signaling systems leading to stimulation of Ras/MAPK, PKC, the small GTPase 
Rho pathways, stimulation of the PLC/Ca
2+
 mobilization and inhibition of adenylate cyclase 
(Moolenaar 1995; Meyer zu Heringdorf et al., 1998).  
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1.3.4  G protein coupling of S1PRs and pathways activated 
Each S1PR subtype signals through a set of receptors which result in various downstream 
biological effects. Hence it is important to know which receptors are expressed in various 
organs to predict downstream effects following S1P stimulation. There are four major families 
of heterotrimeric G proteins; Gs, Gi/o, Gq/11, and G12/13. Of these four, S1PRs couple to Gi, Gq, 
and G12/13. Using GTPɣS binding assay, Width et al have shown that S1PR1 exclusively binds 
to Gi (Windh et al., 1999), while S1PR2 and S1PR3 have a broader coupling profile in which 
they binds to Gi, Gq, and G12/13. G protein coupling of each S1PRs and the pathways activated 
will be discussed further under the section ‘S1P receptors’ (1.3.5).  
      
Figure 1.2:. The S1P receptors interact with several G protein families which result in 
subsequent downstream effects on second messenger and effector molecules.  
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Figure 1.3: The pathobiology of S1P. S1P is implicated in various pathophysiological 
conditions affecting almost every organ. Only a few cancer types are shown here (taken from 
Maceyka et al., 2011). 
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1.3.5  S1P receptors  
1.3.5.1  S1PR1 
S1PR1 gene which is located on chromosome 1p21 was the first S1P receptor cloned from 
human endothelial cells and was thus named endothelial differentiation gene- 1 (EDG1)(Hla 
& Maciag., 1990). S1PR1 interacts exclusively with Gi and this interaction is inactivated by 
pertussis toxin. S1P/S1PR1 signalling leads to the activation of P13K, Rac, ERK1 and ERK2 
(Young & Van Brocklyn, 2006)(Figure 1.3). S1PR1 is essential for blood vessel formation 
and vascular maturation. Disruption of S1PR1 in mice led to massive embryonic haemorrhage 
due to a defect in the recruitment of mural cells to vessel walls (Liu et al. 2000). S1PR1 is 
also involved in motility regulation in various cell types and in tumour cell invasiveness. 
Sadahira et al have shown that S1P/S1PR1 signalling inhibits the migration and invasion of 
B16 human melanoma cells and HT1080 human fibrosarcoma cells (Sadahira et al., 1992). 
S1PR1 also interacts with platelet derived growth factor (PDGF) signaling. PDGF has been 
shown to activate SPHK1 and increase the production of S1P. S1P interaction with S1PR1 
leads to Rac activation and an increase in cell migration in human embryonal kidney (HEK) 
cells (Hobson et al., 2001). S1PR1 is also important for lymphocyte trafficking (Chiba et al., 
2006) which will be discussed in more detail later under the section ‘S1P in immune cell 
signalling’ (1.4.2).  
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1.3.5.2  S1PR2  
S1PR2 was isolated from rat vascular smooth muscle cells and rat brain (Okazaki et al.,1993). 
It is highly expressed in brain, heart, spleen and liver. S1PR2 binds to S1P with nanomolar 
affinity and is ubiquitously expressed throughout development and during adulthood (Takabe 
et al., 2008; Anliker & Jerold Chun 2004). By binding to Gi, Gq and G12/13, S1PR2 activates 
ERK/MAP kinase via Gi coupling and activates Rho via G12/13 coupling (Takabe et al., 2008; 
Anliker & Jerold Chun 2004). S1PR2 also activates p38 and Jun N-terminal kinase (JNK) 
MAP kinases (Gonda et al., 1999), phospholipase D (PLD) and NF-ĸB (Siehler et al., 2001). 
S1PR2 activation has been shown to inhibit cancer cell migration, invasion and metastasis 
(Lepley et al., 2005; Young, 2007). S1PR2 was recently shown to be expressed in normal 
germinal centre (GC) B cells in the mouse where it inhibited the chemotaxis of these cells 
towards follicular chemo-attractants and promoted their confinement to the GC (Green et al., 
2011). S1PR2 deficient mice have been shown to develop diffuse large B cell lymphoma 
(Cattoretti et al., 2009). 
 
1.3.5.3  S1PR3 
S1PR3 was cloned from a human genomic library (Yamaguchi et al., 1996). Similar to 
S1PR2, S1PR3 couples to Gi, Gq and G12/13, activating similar pathways to S1PR2 (Windh et 
al., 1999). Mice deficient in both S1PR1 and S1PR3 showed more severe bleeding compared 
with those lacking only S1PR1. This indicates that S1PR3 could play a supportive role in the 
maintenance of vascular barrier homeostasis and vascular development (Kono et al., 2004). 
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S1PR3 is required for normal B-cell development (Donovan et al., 2010) and in the migration 
of dendritic cells (Spiegel & Milstien, 2011), ML-1 thyroid carcinoma cells (Bergelin et al. 
2009) and gastric cancer cells (Yamashita et al., 2006). S1P/S1PR3 signaling is also involved 
in cholestasis-induced liver fibrosis. Therefore, it has been suggested that modulation of 
S1PR3 activity could be a new antifibrotic strategy (Li et al., 2009). 
 
1.3.5.4  S1PR4 
S1PR4 was cloned from in vitro differentiated human and murine dendritic cells (Gräler et al., 
1998). S1PR4 couples to Gi and G12, but not Gq. Through Gi coupling, S1P/S1PR4 signalling 
can activate PLC, ERK and the Rho family small GTPase, Cdc42. Wang et al have shown 
that S1P/S1PR4 signalling inhibits T cell proliferation but not T cell migration (Wang et al., 
2005). S1PR4 can also suppress the generation of IL-2, IFN-α, and IL-4 from T cells while at 
the same time enhancing the secretion of IL-10 (Wang et al., 2005). 
 
1.3.5.5  S1PR5 
S1PR5 which was previously known as nrg-1, was cloned from a rat phaeochromocytoma 
(PC12) cell cDNA library (Glickman et al., 1999). In humans, S1PR5 expression is restricted 
to the brain and the skin. S1PR5 couples to Gi and G12, but not Gq. Gi coupling leads to 
inhibition of cAMP accumulation in both Chinese hamster ovary (CHO) cells (H. Okamoto et 
al., 1998) and rat hepatoma R7777 cells (Im et al., 2000). S1PR5 plays a major role in the 
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regulation of natural killer (NK) cell activity and their egress from bone marrow and lymph 
node (Maghazachi 2003; Jenne et al., 2009). In the brain, S1PR5 regulates the retraction of 
glial processes and inhibits glial cell migration. In contrast to other S1PRs, S1PR5 causes a 
decrease in ERK 1/2 phosphorylation (Malek et al., 2001). 
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Table 1.1: S1PR subtype mRNA distribution and receptor subtype-specific actions in 
distinct cell types and tissues (adapted from Rosen et al., 2009) 
Subtype Distribution (mRNA) Cellular functional expression and consequences 
S1PR1 Brain, heart, spleen, 
liver, lung, thymus, 
kidney, skeletal muscle, 
lymphoid 
Astrocyte: Migration  
B cell: blockade of egress, chemotaxis 
Cardiomyocyte: increased β-AR positive inotropy 
Endothelial cell: early vascular system development, 
adherens junction assembly, activated protein C-mediated 
increased barrier  
Pericyte: early vascular system development 
T cell: blockade of egress, chemotaxis, decreased late-stage 
maturation 
S1PR2 Brain, heart, spleen, 
liver, lung, thymus, 
kidney, skeletal muscle 
Cardiomyocyte: survival to ischaemia-reperfusion 
Epithelial hair cell (cochlea):  integrity/ development 
Endothelial cell (retina): pathological angiogenesis 
Hepatocyte: proliferation/ matrix remodeling 
Mast cell: degranulation 
VSMC: decreased PDGF-induced migration 
S1PR3 Brain, heart, spleen, 
liver, lung, thymus, 
kidney, testis, skeletal 
muscle 
Cardiomyocyte: survival to ischaemia-reperfusion 
Dendritic cell: worsening experimental sepsis lethality/ 
inflammation/ coagulation 
S1PR4 Lymphoid, lung T-cell migration/ cytokine secretion 
S1PR5 Brain, skin, spleen NK cell: trafficking 
Oligodendrocyte: survival 
Oligodendrocyte progenitor cells: glial process retraction, 
inhibition of migration 
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1.3.6  S1P metabolizing enzymes 
1.3.6.1  Sphingosine kinases 
Cellular levels of S1P are low and are tightly regulated by the balance between its synthesis 
and degradation. Sphingosine kinases catalyse the phosphorylation of sphingosine to S1P. 
Two sphingosine kinase genes, SPHK1 and SPHK2, have been cloned (Kohama et al., 1998; 
Liu et al., 2000). These two kinases have different kinetic properties, developmental and 
tissue specific expression suggesting that they have distinct physiological functions. These 
kinases are ubiquitously distributed and are found at high concentration in erythrocytes 
(Pappu et al., 2007) and endothelium (Venkataraman et al., 2006). SPHK1, which 
predominantly localizes in the cytosol, phosphorylates sphingosine to S1P while SPHK2 can 
convert S1P back to sphingosine and then to ceramide (Maceyka et al., 2005). SPHK1 is 
activated by diverse stimuli such as growth factors which include epidermal growth factor 
(EGF), insulin-like growth factor-1 (IGF-1), hormones (estradiol) and the angiogenic factor; 
vascular endothelial growth factor (VEGF) (Alvarez et al., 2007). SPHK1 also upregulates 
NFĸB in response to stress. In contrast to SPHK1, SPHK2 has a putative nuclear localization 
signal and it promotes apoptosis in lymphocytes (Don et al., 2007). A putative BH3-only 
domain has been defined in SPHK2, which may explain its proapoptotic functions (Liu et al., 
2003). SPHK2 has been shown to inhibit DNA synthesis resulting in cell cycle arrest in 
various cell types (Igarashi et al., 2003). Recently, Weigert and co-workers suggested that 
SPHK2 may also play an important role in tumour progression. They showed that SPHK2-
deficient MCF-7 breast tumour xenografts had markedly delayed growth as compared to 
controls (Weigert et al., 2009). 
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The levels of mRNA encoding SPHK1 are about 2-fold higher in tumours of the breast, colon, 
rectum, kidney, uterus,lung, ovary and stomach compared with normal adjacent tissue (French 
et al., 2003). The oncogenic role of SPHK1 was first demonstrated following its 
overexpression in mouse fibroblasts which resulted in H-Ras-mediated cellular transformation 
and tumour formation in nude mice (Xia et al., 2000). Enforced expression of SPHK1 in 
MCF7 breast cancer cells led to increased S1P levels and accentuation of oestrogen dependent 
cell growth and proliferation in soft agar and in nude mice (Nava, 2002). In contrast, loss of 
SPHK1 by siRNA inhibition resulted in cell cycle arrest and induction of apoptosis in MCF7 
cells (Taha et al., 2006). Knockout of both SPHK1 and SPHK2 seized the synthesis of S1P 
leading to vascular and neural defects (Mizugishi et al., 2005).  
 
1.3.6.2  Mechanisms of SPHK1 activation 
SPHK1 activation involves three non-exclusive mechanisms: 1) phosphorylation, 2) 
translocation to the plasma membrane and 3) interaction with acidic phospholipids and/or 
other proteins (Pitson et al., 2003). To obtain full activation, all three mechanisms may be 
required. Upstream activators of SPHK1 include GPCRs, small GTPases, tyrosine kinase 
receptors, pro-inflammatory cytokines, FcgR1 and FcgR1 immunoglobulin receptors, calcium 
and protein kinase activators (M Maceyka 2002). Protein kinase- C (PKC) activation by 
phorbol 12-myristate 13-acetate (PMA) results in activation and translocation of SPHK1 to 
the plasma membrane which leads to the release of S1P to the extracellular medium (Johnson 
et al., 2002). Membrane translocation requires an ERK-dependent phosphorylation of SPHK1 
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at Ser225 (Pitson et al., 2003) which drives its oncogenic signalling (Pitson et al., 2005). 
Besides relocating to the plasma membrane, SPHK1 also traffics to the perinuclear and 
nuclear region (Kleuser et al., 2001). Two nuclear export sequences, NES1 and NES2 have 
been shown to mediate shuttling of SPHK1 from the nucleus to the cytosol (Inagaki 2003). 
Inhibition of the nuclear export receptor, CRM1 (chromosomal region maintenance 1) led to a 
marked nuclear accumulation of SPHK1 suggesting that the shuttling of SPHK1 between the 
cytoplasm and the nucleus is mediated by a CRM1-dependent pathway.  
 
1.3.6.3  SPHK1 inhibitors 
As the phosphorylation of sphingosine by SPHK1 is an established mechanism for the 
production of S1P, SPHK1 is a potential target of cancer therapeutics. Several SPHK1 
inhibitors such as dimethylsphingosine (DMS), SK1-I (BML-248) and SK-II have been 
extensively used in vitro to block the production of S1P by tumour cells. DMS is an N-
methylated metabolite of sphingosine. It inhibits both SPHK1 and SPHK2. It has been shown 
to inhibit the growth of gastric and lung cancer cells in athymic mice (Endo et al.,1991) and to 
decrease lung metastasis of melanoma cells in rodent models (Okoshi et al., 1991). SK1-I is a 
specific inhibitor of SPHK1. It was shown to reduce the survival and growth of human 
leukemia and Jurkat cells and to decrease the growth of acute myeloid leukaemia (AML) 
xenograft tumours (Paugh et al., 2008a). SK-II which is orally available showed significant 
suppression of mammary adenocarcinoma growth in mice (French et al., 2006). SPHK1 
inhibition results in decreased signaling via Ras/mitogen-activated protein kinase (MAPK) 
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proliferation pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt survival pathway 
which leads to inhibition of tumour activity (French et al., 2003b). 
 
1.3.6.4  S1P phosphatases and S1P lyases 
S1P phosphatases and S1P lyases (SGPL1) are the enzymes responsible for S1P catabolism. 
The two S1P phosphatases, SGPP1 and SGPP2, reversibly convert S1P back to sphingosine, 
thus controlling the cellular levels of S1P. S1P can also be converted to palmitaldehyde or 
phosphoethanolamine by SGPL1. Due to the presence of these enzymes, S1P elevation 
following SPHK1 activation is short lasting (Van Veldhoven and Mannaerts, 1991; 
Veldhoven and Mannaerts, 1994; Saba et al., 1997; Zhou and Saba, 1998; Mandala et al., 
1998). Both SGPP1 and SGPP2 are located in the endoplasmic reticulum (ER) (Johnson et al., 
2003). SGPP1 is expressed in most tissues with high levels found in the vascular tissues of 
placenta and kidney (Johnson et al., 2003) whereas SGPP2 is predominantly expressed in the 
heart and kidney (Ogawa et al.,2003). Loss of these phosphatases in yeast results in high S1P 
levels and renders cells more resistant to stress. In mammalian cells, overexpression of 
SGPP1 elevates ceramide levels and enhances apoptosis. siRNA knockdown of endogenous 
SGPP1 resulted in an increase in cellular S1P and a decrease in sphingosine (Johnson et al., 
2003). Although SGPP2 shows similar activity, substrate specificity and localization to 
SGPP1, whether it has similar functions remains to be established (C. Ogawa et al., 2003).  
SGPL1 activity has been reported to be located in the ER and human SGPL1 gene encodes a 
protein of 568 amino acids with a molecular weight of 63.5 kDa. SGPL1 expression has been 
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observed at variable levels in most mammalian tissues with high levels present in the liver, 
kidney and intestine. Lower levels are observed in muscle and brain. Inhibition of SGPL1 
increases S1P levels and induces lymphopenia (Schwab et al., 2005). SGPL1 was also shown 
to be downregulated in human colonic cancer (Oskouian & Saba, 2007) and in metastatic lung 
adenocarcinoma (Ramaswamy et al., 2003). These findings indicate that SGPL1 and S1P 
phosphatases could potentially function as tumour suppressor genes (Oskouian et al., 2006).  
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1.4  Biological activities of S1P 
1.4.1  S1P in cancer 
Accumulating data on aberrant S1P signaling in various types of cancer has suggested that 
this signaling pathway may be involved in carcinogenesis. Among implicated cancers are 
those of the colon, prostate, breast, and head and neck. SPHK1 activation and the production 
of S1P promotes tumour growth, resistance to apoptosis, angiogenesis and metastasis (Pyne & 
Pyne, 2010). Elevated S1P levels were first identified in the ascitic fluid of ovarian cancer 
patients (Tilly & Kolesnick, 2002). The role of SPHK1/S1P in cancer is intricate and is 
influenced by many factors including the type of cells, receptors expressed and tumour micro-
environment. Cells involved in maintaining tumour microenvironment include lymphocytes 
(cytotoxic T cells—CTL- and native killer—NK-), macrophages, dendritic cells, and 
neutrophils. Tumoral microenvironment is important in the regulation of tumour cell growth 
and metastasis. It also determines the tumour response to treatment The polyps of the 
APC
Min
/
+
mouse model of intestinal tumorigenesis showed high levels of S1P and decreased 
SGPL1 activity and expression (Oskouian B & Saba J, 2007). S1P promotes cell growth and 
survival via extracellular signal-regulated kinase (ERK) activation in human glioblastoma 
cells (Kapitonov et al., 2009). In Wilms tumour, S1P was shown to have anti-proliferative 
effects by inducing the expression of connective tissue growth factor (CTGF) an effect 
mediated by S1PR2 (Mei-hong Li et al., 2009). In human prostate cancer PC3 cells, S1P 
induced autophagy through S1PR5 and inhibited rapamycin signalling (Chang et al., 2009). 
S1P also enhances the metastatic potential of tumour cells by promoting their motility and 
Chapter 1  Introduction 
21 
 
invasion (Visentin et al., 2006). These findings demonstrate that S1P is generally a pro-
tumour factor and may be a useful target in anti-cancer therapy. 
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1.4.2  S1P in immune cell signalling 
FTY720 or Fingolimod is an S1P analogue developed to prevent skin allograft rejection and 
to treat autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. The 
discovery of this novel immunosuppressive drug which induces lymphopenia has highlighted 
the significance of S1P in immune cells (Mandala et al., 2002). During normal lymphocyte 
recirculation system, B-cells from the lymphoid tissues and T-cells from the thymus migrate 
towards high S1P levels in the blood which is an S1PR1–dependent chemotactic process 
(Chiba et al., 2006). Upon phosphorylation of FTY720 by SPHK2, FTY720-P downregulates 
S1PR1 and inhibits the migration of lymphocytes to S1P. Hence FTY720-P inhibits 
lymphocytes egress from the lymphoid tissues and the thymus (Chiba et al., 2006) and 
increases the homing of lymphocytes in the circulation to the lymph nodes and Peyer’s 
patches (Mandala et al., 2002). This leads to marked reduction of peripheral blood B and T 
lymphocytes upon FTY720 administration.  
The S1P-S1PR1 axis also controls the trafficking of other immune cells including NK cells, 
dendritic cells, macrophages, mast cells and haematopoietic progenitor cells (Schwab & 
Cyster 2007).  
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1.4.3  S1P in inflammation 
Extensive data shows that S1P is a pro-inflammatory molecule because it increases the 
production of cytokines and prostaglandins by immune effector cells (Kee et al., 2005). For 
example, during allergic reactions, the crosslinking of high affinity IgE receptors on mast 
cells upregulates SPHK1 and SPHK2 and increases the production of S1P (Olivera et al., 
2007). S1P in turn enhances mast cell activation and degranulation, releasing histamine and 
other pro-inflammatory cytokines. Intraperitoneal administration of the SPHK1 inhibitor, 
DMS in a mouse model of asthma has been shown to decrease the infiltration of eosinophils 
and macrophages and also decreased the release of Th2 cell-mediated cytokines (Lai et al., 
2008). Inhaled DMS and SK-I has also been shown to decrease airway hyper-responsiveness 
and inflammation in ovalbumin-sensitized mice (Nishiuma et al., 2008) which has led to 
potentially new directions for asthma therapy.  
  
1.4.4  S1P in cardiovascular disease  
Activation of S1PR1, S1PR2 and S1PR3 leads to distinct set of signalling pathways. S1P 
binds to these three receptors on vascular endothelial cells, vascular smooth muscle cells 
(VSMC) and cardiomyocytes (Takuwa et al., 2008). The S1P/ S1PR1 pathway plays a role in 
the promotion of vascular development in vivo (Argraves et al., 2004; Rosen & Goetzl, 2005) 
and decrease in vascular permeability (Takuwa et al., 2008). Via its action on S1PR1 and 
S1PR3, mediated by Gi, S1P stimulates the proliferation and migration of endothelial cells 
during angiogenesis (Paik et al.,2001)(Figure 1.2). In contrast to S1PR1, S1PR2 inhibits 
Chapter 1  Introduction 
24 
 
VSMC migration and angiogenesis. S1P interaction with S1PR1 and S1PR3 induced 
migration of VSMC from the media to the intima following endothelial injury resulting in 
vascular occlusive lesions, hence inhibition of VSMC migration has potential for the 
treatment of vaso-occlusive diseases (Usui et al., 2004).  
Chae et al. have demonstrated that S1PR1 is upregulated in lung cancer cells during 
angiogenesis and that S1PR1 is required for the angiogenic response of lung cancer in vivo 
(Chae et al., 2004). Stimulation of S1PR3 can also promote angiogenesis and vasculogenesis 
in vitro (Licht et al., 2003). S1P/ S1PR3 signalling is implicated in the constriction of VSMC 
giving rise to hypertensive effects, however in the vascular beds, S1P/ S1PR3 signalling leads 
to an endothelium-dependent dilatory effect which protects the heart from hypoxia (Takuwa 
et al., 2008).  
Sachinidis et al have demonstrated that S1P activities are present in low density lipoproteins 
(LDL) (Sachinidis et al., 1999), and mildly oxidized LDL has also been shown to induce 
contraction of endothelial cells via a Rho-dependent pathway resulting in increased 
endothelial permeability (Essler et al., 1999). Oxidized LDL stimulates the production of S1P 
in the VSMC and induces the proliferation of VSMC (Augé et al., 1999). It is becoming clear 
that S1P is a mediator of atherosclerosis and that S1P is a robust predictor of both the 
occurrence and severity of coronary artery stenosis (Deutschman et al., 2003). 
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1.5  LPA signalling and Autotaxin  
Lysophosphatidic acid (LPA) is a bioactive simple lipid closely related to S1P. It is composed 
of a single fatty acyl chain, a glycerol backbone and a free phosphate group (Wouter H 
Moolenaar 1995). LPA is primarily formed by hydrolysis of lysophosphatidylcholine (LPC) 
by the ectoenzyme ATX via its lysophospholipase D activity. LPA production also occurs 
within the hair follicles. LPA is secreted by activated cells particularly activated platelets in 
the plasma (Eichholtz et al., 1993). Similarly to S1P, LPA binds to specific cell-surface 
GPCRs and evokes its biological effects including enhancing tumour cell proliferation and 
migration, increasing cytokine production in inflammation and promoting survival of many 
cell types (Yanagida et al., 2013). There are at least six recognised LPA receptors, LPAR1-6 
(Choi & Chun 2013). LPAR1 was discovered by Chun’s group in 1996 (Hecht et al., 1996) 
followed by LPAR2 and LPAR3 (Chun et al., 2002). LPAR1 mRNA is elevated in most 
cancer cells (Hecht et al., 1996). LPAR2 and LPAR3 are highly expressed in ovarian cancer 
cells (Yu et al., 2008). LPA, mediated by ATX, promotes angiogenesis (Rivera-Lopez et al., 
2008) and stimulates chemotaxis and proliferation of many cancer cell lines including breast 
cancer cells and human melanoma cells (Umezu-Goto et al., 2002). Therefore, ATX and LPA 
receptors are attractive targets for anti cancer drugs (Xu et al., 2009).  
ATX, also known as an exo-nucleotide pyrophosphatase and phosphodiesterase (ENPP2) is a 
125-kDa glycoprotein, originally identified from human melanoma A2058 cells (Stracke et 
al., 1992). It plays an important role in tumour progression and its mRNA is overexpressed in 
thyroid (Kehlen et al., 2004) and hepatocellular carcinoma (Wu et al., 2010), teratocarcinoma 
and neuroblastome cell lines (Yang et al., 1999). ATX mRNA was found in abundance in 
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human brain, placenta and small intestine (Fuss et al., 1997). Higher expression of ATX 
mRNA was observed in advanced stage of neuroblastoma compared to early stage of disease 
suggesting a role in tumour progression. ATX expression was also greater in poorly 
differentiated non small carcinoma of the lungs (Yang et al., 1999). In breast cancer and 
human melanoma cells, ATX was found to stimulate their motility (Gaetano et al., 2009). 
ATX and LPAR transgenic mice were shown to develop mammary tumours and mastitis (Liu 
et al., 2009a). Aberrant expression of ATX was found in breast cancer cells and was closely 
associated with their invasiveness (Yang et al., 2002). ATX-LPA signalling has also been 
shown to be important in ovarian cancer. High levels of LPA was observed in the ascitic fluid 
of ovarian cancer patients (Kita et al., 1997). Gene expression profiling of ovarian cancer cells 
treated with LPA showed that the LPA-signature-positive ovarian tumours had shorter 
progression free survival and were in advanced stage of disease (Murph et al., 2009). The 
inhibition of ATX has been shown to reduce the invasion and metastasis of human melanoma 
cells (Baker et al., 2006). A potent ATX inhibitor, PF-8380 has been reported to be able to 
reduce LPA levels by more than 95% in the plasma (Gierse et al., 2010).  
 
1.6  S1P targeted therapies 
Several pharmaceutical companies have established investigational programs to elucidate the 
potential of targeting S1P signaling for the treatment of cancer. A murine monoclonal 
antibody (mAb) or anti-S1P mAb (Sphingomab or LT1002) has been designed to neutralise 
extracellular S1P by molecular absorption (O’Brien et al., 2009). Anti-S1P mAb prevents S1P 
from binding to its receptors. S1P has been shown to act synergistically with basic fibroblastic 
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growth factor (bFGF) and vascular endothelial growth factor (VEGF) in stimulating 
angiogenesis (Licht et al., 2003b). Visentin et al have shown that systemic anti-S1P mAb 
treatment induced antiangiogenic and antiproliferative effects and substantially reduced 
tumour progression in mice. Mice implanted with VEGF or bFGF which were then injected 
with anti-S1P mAb showed marked reduction in tumour vasculature as compared to control 
groups (Visentin et al., 2006). Anti- S1P mAb also reduced the metastatic potential of tumour 
cells by reducing neovascularization in multiple tumour cell lines including breast carcinoma 
cells MDA MB-231 and MDA MB-468, the ovarian cancer cell line SKOV3 and A549 lung 
adenocarcinoma cells. Histopathological examination of A549 lung and SKOV ovarian 
tumours treated with anti-S1P mAb showed large areas of necrosis and extensive fibrosis 
when compared to the non-treated tumours. These data suggest that the anti-tumour effects of 
the anti-S1P mAb were not cancer type specific (Visentin et al., 2006) and has potential 
therapeutic use in humans.  
The murine anti-S1P was humanised for clinical trials and is called Sonepcizumab or LT1009 
(O’Brien et al., 2009). Sonepcizumab was formulated into two formulations: i) Asonep, the 
oncology formulation recently used in Phase 1 clinical trials and ii) Isonep, the ocular 
formulation used for treatment of age-related macular degeneration (Sabbadini 2011)  
Some investigations have focused in modulating S1P receptor signalling using the S1P 
agonist, FTY720. FTY720 inhibited tumour development and angiogenesis in mice harboring 
human hepatocellular, bladder and lung cancers (Ho et al., 2005; Salinas et al., 2009). In 
ovarian cancer cells, FTY720 has been reported to induce necrosis and autophagy (Zhang et 
al., 2010). S1PR1 antagonism also inhibits angiogenesis. S1PR1 siRNA decreases 
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angiogenesis and reduces the growth of Lewis lung carcinoma in vivo (Recently, a novel class 
of orally bioavailable S1PR1 antagonists was described with potent anti-tumour effects in  
animal models (Ibrahim et al., 2012). However, targeting S1PRs may be complicated as not 
all S1PRs mediate tumourigenic responses, hence selectivity of receptor antagonism is crucial 
in determining the success of sphingolipid receptor-based therapeutics.   
 
1.7  Hodgkin lymphoma 
1.7.1  History 
The discovery of Hodgkin lymphoma (HL) was attributed to Thomas Hodgkin (Hodgkin 
1832). It was the first lymphoid neoplasm to be defined microscopically and is characterized 
by the presence of mononucleated Hodgkin cells and multinucleated Reed-Sternberg cells. 
These cells were first described by Dorothy Reed and Carl Sternberg in 1902 and 1898 
respectively (Sternberg, 1898, Reed, 1902). Initially, HL was thought by Sternberg to be 
inflammatory in origin and related to tuberculosis, however Reed subsequently found that HL 
and tuberculosis were not related (Dawson 2003). In the 1970s, several cell lines were 
developed from pleural effusions, bone marrow and peripheral blood of patients with 
aggressive HL. Cytogenetic analysis revealed abnormal karyotypes and the aggressive nature 
of the disease was confirmed (Jaffe et al., 2008). 
 
1.7.2  Classification of HL  
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HL is the 3
rd
 commonest lymphoma after diffuse large B-cell lymphoma (DLBCL) and 
follicular lymphoma (FL). The first histological classification of HL was introduced by 
Jackson and Parker in 1947, which was then revised at Rye in 1966. In 1994, the Rye 
classification was incorporated into the Revised European-American Lymphoma (REAL) 
classification (Cartwright & Watkins 2004). Based on the REAL classification, the 2008 
WHO Classification separated HL into classical HL (cHL) and nodular lymphocyte- 
predominant Hodgkin lymphoma (NLPHL). cHL which comprises 95% of all HL cases is 
further subdivided into four subtypes; nodular sclerosis (NS), mixed cellularity (MC), 
lymphocyte-depleted (LD) and lymphocyte-rich (LR) HL. This classification is based on the 
morphology and phenotype of the tumour cells and on the cellular infiltrate surrounding the 
tumour cells. cHL is characterised by the presence of Hodgkin and Reed-Sternberg (HRS) 
cells, while NLPHL is characterised by the presence of L&H—lymphocytic and histiocytic 
cells (Ralf Küppers 2009b). HRS cells as well as L&H cells account for only approximately 
1% of the cells in the tissue. NSHL which comprises 60% of HL in the West is characterised 
by nodules containing HRS cells separated by extensive bands of fibrosis. MCHL accounts 
for 30% of HL cases in the West and exhibits a mixture of inflammatory cells including 
neutrophils, eosinophils, histiocytes and plasma cells. Fibrotic bands are not seen in this 
subtype.  
 
 
1.7.3  Epidemiology of HL  
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The incidence of HL and its association with EBV varies considerably with age, gender, 
ethnicity and geographic location. The highest incidence of HL was reported among 
Caucasians, followed by African Americans and Hispanics. The lowest incidence was found 
among Orientals (Cartwright & Watkins 2004). The incidence of HL in the UK is about 0.6% 
of all cancers. 1,673 new cases of HL were diagnosed in the UK in 2007. Correa and 
O’Connor introduced three epidemiological patterns of HL which were related to the 
urbanization and economic status of a geographical region. Pattern I occurs in developing 
countries and shows a bimodal peak in children and elderly patients. Majority of patients in 
this pattern are of the mixed cellularity and lymphocyte depleted subtypes. Pattern III shows a 
first peak in young adults and the second peak in the older age groups and occurs in 
developed countries. Pattern II is intermediate between these two patterns and occurs in rural 
areas of developed countries. A significantly inverse relationship between rates of HL in 
children and young adults was observed; countries with high rates in children (aged 5–14 
years) have low rates in young adults (aged 20–34 years), and vice versa (Correa & O’Conor 
1971). In 1966, MacMahon suggested that an infectious agent might cause HL in young 
adults (Macmahon & June 1966). The risk of HL was suggested to be linked to social class 
background in childhood. Individuals from higher social class with better education and from 
a smaller family size and early birth order position have a higher risk of developing HL 
(Guttensohn & Cole., 1980). As the population moved to a higher living standard, the age of 
acquiring the primary EBV infection increases giving rise to a shift of incidence from children 
to young adult age group. In the USA and West Europe, the incidence of HL is higher among 
young adults as compared to children. 
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1.7.4  Biology of HL 
In 1990, using the PCR technique and primers specific for target sequences of the IGH@ and 
T-cell receptor (TCR) loci on microdissected single HRS cells, these cells were confirmed to 
derive from mature B cells at a GC or post GC stage of differentiation (Küppers et al., 1994). 
This was based on the detection of clonally rearranged immunoglobulin V (IgV) heavy and 
light chain genes with many somatic mutations; somatic hypermutation of IgV genes occuring 
in antigen-activated B cells within GC (Küppers, 2009b). It is believed that HRS cells derive 
from crippled or non-functioning, pre-apoptotic germinal centre B cells (Kuppers & 
Rajewsky, 1998). Despite their origin from B cells, HRS cells have undergone 
reprogramming of gene expression and have lost most of their expression of the typical B-cell 
genes while at the same time acquiring expression of molecules of non B cells. Typically 
HRS cells express CD30, CD15, PAX5, NOTCH1, JUN, JUNB, STAT5A and STAT5B. 
They can also express T- cell markers, CD3 and CD4, the cytotoxic T cell marker, granzyme 
B and the dendritic markers, fascin and CCL17 (Ralf Küppers 2009c). However Tzankov et al 
found that the expression of T-cell markers is rare in HL comprising only 5% of HL cases and 
that less than 1% of cHL are of T-cell origin (Tzankov et al., 2005). 
 
1.7.5  Epstein-Barr virus 
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EBV is a gammaherpes virus that results in infectious mononucleosis and which is associated 
with several malignancies including HL, Burkitt’s lymphoma (BL), as well as some gastric 
cancers and nasopharyngeal carcinoma (NPC)(see Table 1.3). EBV has a large genome of 172 
kb in length which has been entirely cloned and sequenced (Kutok & Wang 2006). The virus 
is composed of a toroid shaped protein core wrapped by linear double-stranded DNA which 
circularizes to form extrachromosomal episomes within the nuclei of infected cells (Figure 
1.3). 95% of adults are infected with EBV and the infection persists for life. The virus gains 
entry into the main target, the naïve B-cell, by interaction of the viral envelope protein 
gp350/220 with CD21, the B-cell surface molecule. EBV can also infect epithelial cells, 
mesenchymal cells and T cells. EBV has two phases of its life cycle; the latent phase in which 
there is no viral replication and the replicative or lytic phase when infectious virus is 
produced, eventually killing the infected cells and releasing the virus particles (Rickinson & 
Kieff, 2001). In underdeveloped countries, EBV infection occurs in early childhood; while in 
developed countries, infection occurs most often in teens and young adults, one- third of cases 
manifesting clinically as acute infectious mononucleosis. In developed countries of low 
socioeconomic status, infection generally occurs in an intermediate age group, usually by the 
age of 15. 
The immediate early genes expressed includes BZLF1 and BZRF1 which encode the Z and R 
proteins, respectively,which are responsible for the activation of the virus lytic cycle. In the 
latent phase, the virus persists as 1-100 episomes which rarely integrate into the human 
genome. During the latent phase, there is no production of infectious viruses. Latent genes 
expressed include six nuclear antigens; EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and 
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EBNA leader protein (LP), three membrane proteins; LMP1, LMP2A, and LMP2B; and two 
small nonpolyadenylated EBV-encoded small RNAs; EBER1 and EBER2, and the EBV 
encoded micro-RNAs encoded in BamH1 region (BART).  
 
Table 1.2: Patterns of latent infection gene expression in EBV infected cells.  
Latency 
programme 
EBV genes expressed Occurence 
0 EBERs, LMP2A (?) Memory B cells in peripheral blood 
I EBERs, EBNA1 BL, primary effusion lymphoma 
II EBERs, EBNA1, LMP1, LMP2A HL, NPC 
III EBERs, EBNA1, EBNA2, EBNA3, 
EBNA-LP, LMP1, LMP2A 
PTLD, PCNSL 
PCNSL= primary central nervous system lymphoma 
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The Epstein-Barr Virus 
                                  
             
Figure 1.4: Map of EBV genome. EBV genome has five unique regions of DNA, punctuated 
by four internal repeat regions and capped on either end by a terminal repeat region (purple 
shaded region). The red and green arrows represent genes encoding the latent proteins (from 
Murray and Young 2002) 
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1.7.6  EBV gene expression in normal cells and in tumours 
EBV can establish different latent states (i.e. infections not leading to replication of new virus 
particles) in normal and malignant B cells. EBV has growth- transforming property, in culture 
it infects resting primary B cells transforming them into lymphoblastoid cell lines (LCLs) 
(Henle W et al., 1967). EBV transformed LCLs express at least 6 nuclear antigens (EBNA1, 
EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP) and three membrane proteins 
(LMP1, LMP2A and LMP2B). This pattern of gene expression is referred as Latency III. In 
this latency pattern, the EBNA transcripts are driven by one of two upstream promoters, Cp or 
Wp, in the BamHI C or W regions of the genome respectively. Latency II was originally 
identified in undifferentiated NPC and subsequently in EBV-associated gastric carcinomas, 
Hodgkin lymphomas and NK/T cell lymphomas (Rowe et al., 2009). This type of latency is 
characterized by expression of LMP1 and LMP2A/B in addition to Qp-driven EBNA1 but no 
expression of the other EBNAs. In gastric cancer, EBNA1 expression is associated with low 
LMP2. Even in a type of malignancy, the levels of LMP1 and LMP2 can be quite variable. 
For instance, LMP2A transcripts are consistently expressed in NPC but LMP1 transcripts are 
detected in only a proportion of cases (Khabir et al., 2005). In Latency I, EBNA1 transcripts 
are driven by the Qp promoter. In latency 0, no viral antigens are expressed. This is found in 
the memory B cells of asymptomatic EBV carriers. The EBERs are non-coding RNAs which 
are expressed at high copy number in all forms of latency, and which are useful for detecting 
EBV in tissues using in situ hybridization. Presence of EBV DNA in HL tissue was first 
demonstrated by Weiss and co-workers using the cloned BamH1 W fragment of EBV as an in 
situ hybridization probe (Weiss et al., 1991). 
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1.7.7  Pathogenic role of EBV in Hodgkin lymphoma 
EBV is found in HRS cells in approximately 40% of HL patients in developed countries and 
in a higher proportion in tumours from patients in developing countries. EBV is more 
frequently associated with mixed cellularity subtype and more often in males with HL 
(Anagnostopoulos et al., 1996). In AIDS patients with cHL, almost all cases are EBV 
positive. In paediatric HL in Central and South America, EBV association is almost 90% 
(Dolcetti et al., 2001; Kutok & Wang, 2006). Flavell et al. have shown a strong association 
between EBV positivity and South Asian ethnicity in paediatric HL patients from the UK (K. 
J. Flavell et al. 2001). EBV infection of B cells stimulates CD8
+
 T cell response. These 
activated T cells give the appearance of atypical lymphocytes in the peripheral blood of 
infectious mononucleosis sufferers. Subsequently, EBV-specific T cell immunity develops, 
killing and reducing the number of infected B cells. In immunocompetent hosts, the infection 
is controlled and the virus enters a latent phase in a few infected B cells. In 
immunocompromised conditions, the cytotoxic T cell surveillance is decreased resulting in 
the development of EBV-associated diseases such as PTLD and OHL (Kutok & Wang 2006). 
The development of EBV-associated malignancies such as HL, BL, gastric carcinoma and 
NPC in non-immunosuppressed individuals might be a result of other co-factors besides 
persistent EBV infection. The first evidence that EBV is associated with HL was provided by 
the detection of raised antibody titres to EBV antigens in patients with HL when compared to 
patients with other lymphoproliferative diseases (McCormick et al., 1976). 
Multiple signalling pathways have been shown to be activated in HRS cells including Janus 
kinase (Jak)-Stat and nuclear factor-ĸβ (NF-ĸβ). Activation of NF-ĸβ occurs through both 
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canonical and non-canonical pathways via signalling of members of Tnfr family such as 
CD40, CD30 and TAC1. NOTCH1 also contributes to the activation of NF-ĸβ in HRS cells 
(Cheng et al., 2001). Constitutive activation of NF-ĸβ may contribute to the development of 
HL by rescuing HRS cells from apoptosis.  
EBNA1 which is expressed in all proliferating EBV-infected cells is very important in the 
replication and maintenance of the viral episome. This is achieved by sequence-specific 
binding of EBNA1 to the plasma origin of viral replication, OriP. The interaction results in a 
single replication of the EBV genome during S phase and subsequently segregation of 
replicated EBV genomes to progeny cells (Levitskaya et al., 1995). Latently infected B cells 
persistently expressing EBNA1 may evade elimination by the immune system (Levitskaya et 
al., 1997). EBV positive B cells expressing only EBNA1 are not recognized by cytotoxic T 
cells because EBNA1 is not presented by MHC class I molecules (Levitskaya et al., 1995). 
LMP1 is an oncogene expressed on the HRS cell membrane mimicking an active CD40 
receptor, thereby inducing constitutive NF-κB activation. LMP1 transgenic mice has been 
shown to develop B-cell lymphomas (Kulwichit et al., 1998). LMP1 can also activate AP1, 
p38, PI3K and Jak–Stat signalling (Young & Murray, 2003). LMP1 and LMP2 contribute to 
the downregulation of B-cell phenotype in EBV-positive HRS cells (Vockerodt et al., 2008). 
LMP2A expression in EBV infected B-cells was associated with activated and proliferative 
state which could lead to the development of HL (Portis et al., 2003). Caldwell’s group also 
found that LMP2A can mimic a B-cell receptor (BCR) and LMP2A expression in a transgenic 
mouse model led to the survival of BCR-deficient B-lineage cells (Caldwell et al., 1998). This 
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showed that the survival signals for B-cells that are normally mediated by the expression of 
BCR can be replaced by LMP2A. 
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Table 1.3: Epstein-Barr virus associated diseases 
Lymphomas/lymphoproliferative diseases 
    Burkitt lymphoma 
    Classical Hodgkin lymphoma 
    Extranodal NK/ T cell lymphoma 
    Angioimmunoblastic T cell lymphoma 
    EBV-associated haemophagocytic lymphohistiocytosis (HLH) 
    AIDS-associated B-cell lymphomas: Plasmablastic lymphoma, PCNSL 
    PTLD 
    Lymphomatoid granulomatosis (LYG) 
    EBV+ DLBCL of the elderly 
    Primary effusion lymphoma (PEL) 
Carcinomas 
    Nasopharyngeal carcinoma 
    Lymphoepithelioma-like carcinoma (salivary glands, liver, thymus, lungs, stomach) 
Mesenchymal tumours 
    Follicular dendritic cell sarcoma 
    Smooth muscle tumours 
Non malignant diseases 
    Infectious mononucleosis 
    Oral hairy leukoplakia 
    Chronic active EBV (CAEBV) 
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1.8  Diffuse large B- cell lymphoma 
1.8.1  Introduction  
Diffuse large B-cell lymphoma (DLBCL) is the commonest lymphoma accounting for nearly 
40% of lymphoid neoplasms (Armitage et al., 1998). In the past it was known by many names 
which included reticulum cell sarcoma, diffuse histiocytic lymphoma followed by diffuse 
mixed lymphoma, diffuse large cell lymphoma, or immunoblastic lymphoma—terms from the 
Working Formulation. It was in the 1994 Revised European-American lymphoma (REAL) 
classification system that it was referred to as DLBCL. It is so named based on the diffuse 
effacement of normal lymph node or extranodal site architecture by malignant B cells. 
DLBCL is heterogeneous in morphological appearance (Table 1.5), immunophenotype, and 
biological behaviour. It may arise de novo or develop as a transformation from an underlying 
low-grade lymphoproliferative disease particularly follicular lymphoma. Less frequently, this 
transformation may occur in patients with chronic lymphocytic leukemia/ small lymphocytic 
lymphoma giving the eponym of Richter transformation. (Ghofrani et al., 2007; Tsimberidou 
& Keating, 2005). Patients in this category have poorer prognosis and poorer response to 
therapy. 
The age range of DLBCL patients is broad with a median of 70 years old. Patients usually 
present with rapidly enlarging lymph nodes. Clinical outcome and response to chemotherapy 
also vary. For several decades, the CHOP (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) chemotherapy regimen combined with field radiation was the mainstay of 
therapy. In 1997, the anti-CD20 monoclonal antibody, Rituximab was added into the 
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chemotherapy regime which resulted in markedly improved survival for DLBCL patients 
(Saini et al., 2011). 
 
1.8.2  Microscopic pathology and differential diagnoses 
DLBCL is characterised, in most cases, by effacement of normal lymph node architecture by 
sheets of large, atypical lymphoid cells. The cells may be divided by fine or broad bands of 
fibrosis. The 2008 WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues 
is the most comprehensive classification system which includes morphological and clinical 
features, immunohistochemical, molecular, and genetic aspects of malignant lymphoid 
disorders (Nakamura S, Jaffe E 2008). Based on this classification, DLBCL is divided into 
centroblastic, immunoblastic, T-cell/ histiocyte-rich, and anaplastic, as well as the rarer 
entities, plasmablastic and anaplastic lymphoma kinase (ALK)–positive DLBCL (Table 1.4). 
The centroblastic variant which accounts for 80% of cases, is composed of cells resembling 
germinal centre centroblasts. The immunoblastic variant which accounts for 10% of cases 
comprises more than 90% immunoblasts. The microscopic description of each variant is given 
in Table 1.5. The plasmablastic variant of DLBCL may overlap with plasmablastic lymphoma 
showing CD79α and CD138 expression but typically lack EBER positivity. Plasmablastic 
lymphoma which typically presents in immunocompromised patients is negative for CD20 
and is typically positive for CD138 and EBER.  
The morphological differential diagnoses of DLBCL include carcinoma and malignant 
melanoma which also exhibit large malignant cells. Both of these malignancies are 
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distinguishable by immunohistochemical techniques with carcinoma being cytokeratin 
positive and melanoma being S100, HMB-45, and/or Melan A positive. Burkitt lymphoma, 
mediastinal large B-cell lymphoma, plasmablastic lymphoma, and plasmablastic myeloma are 
among haematological malignancies to be considered as differential diagnoses.   
Another distinct clinicopathological entity having a similar immunophenotypic profile to 
systemic DLBCL is primary mediastinal large B-cell lymphoma (PMBL). It was listed as a 
separate entity in the 2000 WHO Classification of Hematopoietic and Lymphoid Tumour 
Tissue. Typically, it presents in young women with a mediastinal mass exhibiting distinctive 
clear-cell morphology and sclerosis and it can be distinguished immunohistochemically from 
DLBCL by the co-expression of c-Rel and TRAF1. 53% of PMBL exhibit c-Rel and TRAF1 
expression while only 2% of DLBCLs are positive for these two proteins.  
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Table 1.4:  The 2008 WHO Classification of Diffuse Large B cell lymphoma: variants, 
subgroups and subtypes/entities 
Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)   
Common morphological variants     
       Centroblastic       
       Immunoblastic       
       Anaplastic       
 
Rare morphological variants 
     
Molecular subgroups      
       Germinal centre B cell-like (GCB)     
      Activated B cell- like (ABC) 
Immunohistochemical subgroups 
 
      CD5-positive DLBCL  
      Germinal centre B cell-like (GCB) 
      Non Germinal centre B cell-like (Non GCB)  
 
   
Diffuse large B-cell lymphoma subtypes     
      T cell/ histiocyte rich large B-cell lymphoma    
      Primary DLBCL of the CNS      
      Primary cutaneous DLBCL, leg type     
      EBV-positive DLBCL of the elderly     
Other lymphomas of large B cells     
      Primary mediastinal (thymic) large B- cell lymphoma   
      Intravascular large B-cell lymphoma     
      DLBCL associated with chronic inflammation    
      Lymphomatoid granulomatosis     
      ALK-positive LBCL      
      Plasmablastic lymphoma      
      Large B cell ymphoma arising in HHV-8-associated multicentric Castleman disease 
      Primary effusion lymphoma     
Borderline cases       
     B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-  
     cell lymphoma and Burkitt lymphoma  
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-   
cell lymphoma and classical Hodgkin lymphoma 
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Table 1.5: Microscopic features of DLBCL variants 
DLBCL variants Microscopic features 
Centroblastic  Exhibits vesicular nuclei with smooth chromatin, multiple small 
nucleoli, and scant cytoplasm. Occasionally, polylobated nuclei 
are present. 
Immunoblastic Shows single, prominent, centrally located nucleolus and has 
slightly more cytoplasm. 
T-cell/ histiocyte-rich   Composed primarily of non-neoplastic small T cells with variable 
numbers of admixed histiocytes. The large, malignant B cells 
represent fewer than 10% of all cells. 
Anaplastic  Characterised by very large, often cohesive cells with extensive 
pleomorphism of the nuclei. 
Plasmablastic Morphologically resembles the immunoblastic variant but may 
also show eccentric nuclear placement with more eosinophilic 
cytoplasm 
*from Gatter & Pezzella, 2010. 
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1.8.3  Molecular classification of DLBCL 
Using DNA microarray, Alizadeh et al found two molecularly distinct forms of DLBCL 
showing gene expression patterns of different stages of B cell differentiation. One group 
expressed genes characteristic of germinal centre B cells (GCB-like DLBCL) and the other, 
genes normally induced during the in vitro activation of peripheral blood B cells; referred to 
as activated B- cell-like (ABC) DLBCL. Based on this gene expression profiling, DLBCL is 
now divided into two prognostically significant subtypes (Alizadeh et al. 2000). Although 
patients with GCB subtype have been shown to have better survival than those with the ABC 
subtype, all patients are still treated in a similar way as studies have so far failed to show 
superiority of specific regimens for each subtype. In terms of prognosis, there was no 
correlation found between these two subgroups of DLBCL and the different morphological 
variants listed in Table 1.5 (Rosenwald et al., 2002). In 2000, Hans and co-workers developed 
a reproducible immunohistochemical algorithm using CD10, BCL6 and MUM1 which 
showed approximately 80% concordance with the gene expression profiling (GEP) 
classification of DLBCL (Hans et al., 2004). Nine years later Choi et al. proposed a new 
algorithm using GCET1, CD10, BCL6, MUM1, and FOXP1 which showed a higher (93%) 
concordance with GEP classification (W. W. L. Choi et al. 2009). Both algorithms are shown 
in Figure 1.5. Clinical characteristics of both GCB and ABC subtypes are listed in Table 1.6. 
BCL2 gene rearrangement as t(14;18)(q32;q21) was found to occur almost exclusively in the 
GCB subtype (Sharon LB et al. 2003; Jardin et al. 2006). GCB DLBCL cases mostly show 
centroblastic monomorphic morphology while the ABC DLBCL subtype mostly show 
immunoblastic and centroblastic polymorphic features (Rosenwald et al., 2002). 
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New algorithm 
 
Hans algorithm 
 
 
Figure 1.5: Decision tree for subtyping of DLBCL cases according to the A) New 
algorithm and B) Hans algorithm (adapted from Choi et al., 2009). 
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Table 1.6: Characteristics of GCB and ABC DLBCL 
  GCB DLBCL ABC DLBCL 
Postulated normal 
counterpart   
Germinal center B cell Post-germinal center B-cell 
Clinical outcome (5 year OS) 59% 30% 
Oncogenic mechanism REL amplification Constitutive activation of NF-kB 
 BCL2 translocation  
Chromosomal alterations Gain 12q12 Trisomy 3 (FOXP1?) 
 t(14;18) Gain 3q 
  Gain 18q21–q22 (BCL2) 
    Deletion 6q21–q22 (BLIMP1) 
Abbreviations: ABC, activated B-cell; DLBCL, diffuse large B-cell lymphoma; GCB, 
germinal centre; NF-kB, nuclear factor kappa B: OS, overall survival. (Adapted from De 
Paepe & De Wolf-Peeters 2007) 
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1.8.4  Risk stratification of DLBCL patients 
The International Prognostic Index (IPI) has been shown to be one of the best predictors of 
outcome. This model was developed to predict the outcome of patients with aggressive NHL 
based on their pre-treatment clinical characteristics (Shipp et al., 1993). The IPI categorised 
patients into prognostic groups based on the anatomic stage, ECOG performance status, the 
number of extranodal sites, serum lactate dehydrogenase (LDH) level, and age at diagnosis. 
For full index IPI, one point/ factor is allotted for the prognostic factors (Table 1.7). Based on 
the sum of the points allotted, patients are then assigned to one of four risk groups having 
different five year survival rates: The age- adjusted IPI is used to compare patients within an 
age group (i.e. 60 or younger, or over 60) and includes only 3 prognostic factors (Table 1.8).  
 
Table 1.7: The Full International Prognostic Index 
Prognostic factor Risk category and factor 5 year survival 
Age older than 60 years 
Performance status of 2 or higher 
LDH level greater than 1x normal 
Extranodal sites of 2 or more 
Stage III or IV 
Low risk, factor 0 or 1 
Low-intermediate risk, factor 2 
High-intermediate risk factor 3 
High risk, factor 4 or 5 
73% 
51% 
43% 
26% 
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Table 1.8: The Age-adjusted International Prognostic Index 
Prognostic factor Risk category and factor 5 year survival 
Performance status higher than 1 
LDH level greater than 1x normal 
Stage III or IV 
  
Low risk, factor 0  
Low-intermediate risk, factor 1 
High-intermediate risk, factor 2 
High risk, factor 3 
83% 
69% 
46% 
32% 
 
Table 1.9: ECOG performance status (from Oken et al., 1982) 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to to carry out work 
of a light or sedentary nature eg., light house work, office work. 
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up 
and about more than 50% of waking hours. 
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking 
hours. 
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair. 
5 Dead 
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1.9  EBV-positive diffuse large B- cell lymphoma of the elderly  
1.9.1  Introduction 
“EBV-positive diffuse large B cell lymphoma of the elderly (EBV+ DLBCL-E)” is a new 
entity included in the 2008 WHO Classification of Tumours of Hematopoietic and Lymphoid 
Tissues. It is defined as an EBV
+
 DLBCL of patients older than 50 years, without any known 
underlying immunosuppression or prior lymphoma. The median age is 71 with a slight male 
predominance. Male to female ratio is 1.4:1 (Nakamura & Jaffe, 2008). The clinical course of 
this entity is usually aggressive with a median survival of 2 years and an overall 5- year 
survival of 25% (Oyama et al., 2007; Park et al., 2007). Although patients can present with 
lymphadenopathy, 70% of the cases show extranodal disease involving the skin, lung or 
gastrointestinal tract with associated moderate to severe clinical B symptoms. Age-related 
EBV
+
 DLBCL was first described by Oyama et al. who performed a clinicopathological 
evaluation on 22 Japanese patients aged more than 60 years old without predisposing 
immunodeficiency. This entity is believed to be related to immunosenescence or 
immunological deterioration due to the aging process (Oyama et al. 2003). Subsequently 
Oyama et al evaluated the presence of EBV by EBER in situ hybridization in 1792 DLBCL 
cases and found 156 (8.7%) of EBV
+
 cases without any predisposing immunodeficiency. 
Age-related DLBCL shows an EBV latency type 2 or 3 pattern and is associated with a poorer 
prognosis compared to age-matched EBV-negative DLBCL (Oyama et al. 2007). Most data to 
present has been obtained from Asian patients (Japan and Korea) with a prevalence of 8 to 
11.4% (Kuze et al., 2000; Park et al., 2007), however the prevalence of this disease in the 
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Western population is much lower indicating a possible ethnic or geographic predisposition. 
In 2009, Gibson and Hsi found five cases of EBV
+
 DLBCL-E in the United States from 2000 
to 2007 and the clinical outcome of all these patients was poor despite multi-agent 
chemotherapy (Gibson & Hsi 2009). In addition, the authors also analysed 90 cases of 
DLBCL aged 60 and above and found that none of these patients was EBER positive. This 
suggests that the prevalence of this DLBCL subtype is very low in the United States as 
compared to Asian population. Hoeller et al. analysed 258 DLBCL cases from central Europe 
and found 8 (3.1%) patients who fit the criteria for EBV
+
 DLBCL-E (Hoeller et al., 2010). 
Hofscheier et al. performed a comparison between Mexican and German cohort in parallel 
and found that the prevalence of EBV
+
 DLBCL-E in Germany was 2% as compared to 7% in 
the Mexican population. (Hofscheier et al. 2011) 
  
1.9.2  Histology and immunophenotype of EBV
+
 DLBCL of the elderly 
Two histological subtypes of EBV
+
 DLBCL have been delineated (Asano et al., 2009). The 
commoner subtype is the polymorphous subtype which exhibits a broad range of malignant 
B-cells of varying maturation including centroblasts, immunoblasts, plasmablasts admixed 
with small lymphocytes, plasma cells, histiocytes, and epithelioid cells. HRS-like cells can 
also be present (Shimoyama et al. 2008). The second subtype is the monomorphic subtype 
which is composed of sheets of large transformed B-cells. It was later shown that both 
subtypes are actually different points in the disease progression and do not indicate any 
clinical importance (Oyama et al. 2007). Asano et al. observed that a significant proportion of 
Chapter 1  Introduction 
52 
 
EBV
+
 lymphoproliferative disease (LPD) have large areas of geographical necrosis (Asano et 
al. 2009). Gibson and Hsi also suggested a few pathological features other than necrosis that 
provide clues for EBV association which include polymorphic infiltrate, plasmacytic 
morphology, angioinvasion, and a non-germinal centre B-cell or the ABC immunophenotype 
(Gibson & Hsi 2009). 
The neoplastic immunoblasts show positivity for EBER, CD20/CD79α and PAX-5, with 
variable expression of CD30, LMP-1 and EBNA-2. CD15, CD10 and BCL6 are usually 
negative. Expression of Ki-67 is high in the neoplastic cells. Differential diagnoses include 
EBV
+
 B-cell LPD, cHL and EBV
–
DLBCL. Presence of abundant HRS-like cells may pose a 
problem in differentiating this tumour from EBV
+
 cHL presenting in elderly patients. 
Although the HRS–like cells in EBV+ DLBCL of the elderly are occasionally CD30-positive, 
the typical inflammatory infiltrate of HL is absent and the HRS–like cells are strongly 
positive for CD20 or CD79α and CD45 and are negative for CD15, thus excluding the 
diagnosis of cHL. OCT2 and BOB1 positivity are also useful in supporting the diagnosis of 
EBV
+
 DLBCL-E (Adam et al., 2011).  
Docjinov et al. observed that age related EBV
+
 B-cell LPD in the Western population 
encompasses a wide range of both reactive and neoplastic conditions which includes EBV-
associated reactive hyperplasia, polymorphic extranodal LPD, polymorphic nodal LPD and 
DLBCL (Dojcinov et al. 2011). Similar authors have also identified a new subset of patients 
with localised extranodal disease manifesting as EBV mucocutaneous ulcer (EBVMCU) 
which has a good prognosis and high rate of spontaneous remission. This disease is 
characterized by a well circumscribed superficial ulcer containing abundant HRS-like cells, 
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prominent apoptosis with a rim of reactive T lymphocytes at the base of the ulcer. EBVMCUs 
usually occur in patients with iatrogenic suppression eg by methotrexate, cyclosporine A or 
Azathioprine. Withdrawal of the causative agent leads to spontaneous remission of the ulcer. 
Differentiating benign from malignant EBV
+
 LPD can be difficult, hence clonality study 
might be useful. EBV associated RH lacks clonal IG rearrangements while clonal B-cell 
population is found in polymorphic nodal LPD and DLBCL. T-cell clonality would suggest 
the diagnosis of angioimmunoblastic T-cell lymphoma, a tumour containing abundant EBV
+
 
B cells. The authors also suggested that routine EBER testing to be done in patients older than 
50 years suspected to have an aggressive B-cell lymphoma and those with atypical nodal, 
mucosal or cutaneous B-cell LPDs (Dojcinov et al. 2011).  
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2.1  Collection and preparation of clinical samples and cell lines 
2.1.1  Collection of tissue biopsy specimens 
Ethical approval for the work within this thesis was provided from the West Midlands 
Research Ethics Committee (REC 08/H1210/142). All formalin-fixed paraffin-embedded 
tissue biopsy specimens were obtained from various sources as described below. 
Paraffin blocks of breast cancer, bladder cancer and DLBCL cases were from the Department 
of Pathology, Queen Elizabeth Hospital. Bladder cancer paraffin blocks were courtesy of Dr. 
Rik Bryan from Urology Department, Queen Elizabeth Hospital. Lung tissue microarray 
sections were courtesy of Maria Janikova and Dr Jozef Skarda from the Department of 
Pathology and Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, 
Palacky University, Olomouc, Czech Republic. Formalin-fixed paraffin-embedded tissues 
were obtained from archive of lung carcinomas derived from patients operated in the period 
between 1996 to 2000.   
 
2.1.2  Tissue sectioning 
Tissue sectioning was performed with a model AS325 microtome (Thermo Electron 
Corporation, Basingstoke, UK) to cut 3-4 micrometer (µm) sections from paraffin-embedded 
tissues. Gloves were worn at all times. Before cutting tissues for EBER ISH, the microtome 
blade (Surgipath Europe Ltd., Peterborough, UK) and cutting area was cleaned and sterilised 
with absolute alcohol between each tissue block to avoid cross-contamination. Tissue sections 
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were harvested from water bath containing distilled water at 50
o 
C and placed onto RNase-
free adhesive-coated slides and incubated in a 60
o 
C incubator for 1 hour to adhere tissue 
sections onto the slides. All tissue sections were stored at room temperature in RNase-free 
conditions until further use in immunohistochemistry or in situ hybridisation. Sectioning was 
performed by Kaisheng Wen and Souad Messahel.  
 
2.1.3  Preparation of deoxyribonuclease (DNase)/ribonuclease (RNase)-free equipment 
All glassware was washed, dried and covered in aluminium foil. For DNase/RNase-free 
conditions, glassware was baked in a dry oven at 240
o 
C for a minimum of 4 hours. All 
microscope slides used for histology sections were placed in 25-place slide racks (VWR 
International Ltd., Poole, United Kingdom (UK), wrapped in aluminium foil and baked at 
250
o 
C for a minimum of 4 hours. Filter pipette tips were bought as certified DNase/RNase-
free (Starlab UK, Ltd., Milton Keynes, UK). All Gilson micropipettes (Anachem Ltd., Luton, 
UK) were wiped with absolute alcohol and exposed to ultraviolet (UV) light for 1 hour before 
use. DNase/RNase-free sterile water was obtained Sigma-Aldrich Company Ltd., Gillingham, 
UK. 
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2.1.4  Haematoxylin and eosin staining 
Haematoxylin and eosin staining of tissue sections from each patient were performed to allow 
assessment of tissue samples before immunohistochemical staining or in situ hybridization. 
Tissue sections on adhesive-coated slides were dewaxed through Histoclear (Fisher Scientific 
UK Ltd., Loughborough, UK) for 10 minutes and then through ethanol (Sigma-Aldrich 
Company Ltd., Gillingham, UK) for 10 minutes, and washed under running tap water. Slides 
were then immersed in Mayer’s haematoxylin (VWR International Ltd., Poole, UK) for 2 
minutes before washing thoroughly in tap water. Scott’s tap water (Surgipath Europe Ltd., 
Peterborough, UK) was then used to ‘blue’ the haematoxylin for 2 minutes and washed again 
in tap water. The slides were immersed in eosin (VWR International Ltd., Poole, UK) for 2 
minutes before rinsing with tap water. Tissue sections were then dehydrated through ethanol 
twice, each time for 5 minutes and then through histoclear twice, each time for 5 minutes. 
Sections were mounted using coverslips with a drop of DPX (both Surgipath Europe Ltd., 
Peterborough, UK) and dried flat overnight. 
 
2.2  Immunohistochemistry 
2.2.1  Principles of immunohistochemistry 
Immunohistochemistry is the process of detecting antigens or proteins in cells of a tissue 
section by application of antibodies which bind specifically to the cells. It is widely used in 
diagnostic surgical pathology for typing of tumours. To allow visualization of the antigen-
antibody (Ag-Ab) reaction, labels or reporter molecules are attached to the primary, 
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secondary, or tertiary Abs. There are a variety of labels including enzymes, fluorescent dyes, 
biotin, colloidal gold and metals. The commonest type of label is an enzyme which can  
include peroxidase, alkaline phosphatase or glucose oxidase. In the presence of a specific 
substrate and a chromogen, enzymes will produce a coloured precipitate at the site of the Ag-
Ab reaction. Detection systems can be classified as direct and indirect methods. The direct 
method is a one step process in which primary Ab is conjugated with a reporter molecule. 
This method is quick but is less sensitive in detecting most Ags in routinely processed tissues. 
The indirect method, which has higher sensitivity, involves a two-step model. The first layer 
of Ab is unlabelled, but the second layer, raised against the primary Ab, is labelled. There are 
multiple methods including the avidin-biotin complex (ABC), labelled streptavidin-biotin 
(LSAB), peroxidase-antiperoxidase (PAP), polymeric labelling two-step method and tyramine 
amplification method (Ramos-Vara 2005).  
 
2.2.2  Preparation of cultured cells for immunohistochemistry  
Adhesive-coated slides were placed on Cytoclips™ (Thermo Electron) followed by filter 
cards and Cytofunnel® disposable sample chambers instructions and were inserted into the 
Shandon Cytospin centrifuge (Thermo Electron). 2 x 10
6
 cells were harvested and re-
suspended in 1 ml PBS and fixed in 100 μl 10% formalin. 100 μl of fixed cells were 
transferred into the Cytofunnels®. Cells were adhered to slides by centrifugation in the 
Cytospin at 1000 rpm for 5 minutes. Cytospinned cells were air dried and stored at room 
temperature. 
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2.2.3  Preparation of tissue biopsy sections for immunohistochemistry 
Sectioned paraffin-embedded tissue biopsies were placed in 25-place microscope slide racks 
and immersed in Histoclear (Fisher Scientific UK Ltd., Loughborough, UK) for 10 minutes to 
dewax. Slides were then placed in a staining jar (Surgipath Europe Ltd., Peterborough, UK) 
filled with ethanol for 10 minutes to rehydrate the tissue and then rinsed under running tap 
water for 5 minutes before proceeding to immunohistochemistry.  
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2.2.4  Immunohistochemistry protocol 
2.2.4.1  Blocking of endogenous peroxidase activity and antigen retrieval 
To reduce background staining, endogenous peroxidase activity was blocked by 10-minute 
incubation in 3% hydrogen peroxide in methanol (both Sigma-Aldrich Company Ltd., 
Gillingham, UK .Slides were then rinsed thoroughly in running tap water. Antigen retrieval 
was performed by microwaving the slides in citric acid buffer at pH 6.0 in a standard 750 watt 
(W) microwave oven. Citrate buffer was heated at high power for 10 minutes, the slides were 
immersed and heated at medium power for 10 minutes and low power for 10 minutes. Citric 
acid buffer was prepared by dissolving 0.25 g citric acid (VWR International Ltd., Poole, UK) 
and 1.26 sodium citrate in 800 ml distilled water; pH was adjusted to 6.0 using concentrated 
NaOH. Distilled water was then added to make 1000 ml citrate buffer solution. After 
microwaving, slides were allowed to cool in the citric acid buffer at room temperature for 30 
minutes before washing under running tap water for 5 minutes.  
 
2.2.4.2  Detection of antigen 
Slides were placed in a metal microscope slide staining tray (Richardsons of Leicester Ltd., 
Leicester, UK). The area of the slide around the cells/ tissue was carefully dried with a tissue 
and a ring of wax applied using a PAP pen (Cambridge BioScience Ltd., Cambridge, UK). 
Slides were conditioned in 1X TBS for 2 minutes, then blocked with 5X casein blocking 
solution (Vector laboratories) for 10 minutes followed by incubation with appropriately 
Chapter 2  Materials and Methods 
61 
 
diluted primary antibody in PBS overnight at 4ºC in humidified covered slide trays to 
minimize evaporation. For negative controls, primary antibody was replaced with nonimmune 
serum of the same IgG subclass. On the next day, samples were washed in TBST for 5 
minutes. Secondary antibody (DakoChemate envision) was added to each tissue section for 30 
minutes and then washed again in TBST for 5 minutes. 
 
2.2.4.3  Visualization and counterstaining 
Visualization was performed using diaminobenzidine (DAB) (Vector laboratories). 20 µl of 
DAB was added to 1 ml of substrate solution. 100 µl of this DAB substrate solution was 
applied to each tissue section for 5 minutes. The substrate was converted to an insoluble 
brown product by the antigen-bound peroxidases. Slides were rinsed with TBST, 
counterstained with Mayer’s haematoxylin for 2 minutes and washed under running tap water 
Slides were then dehydrated through ethanol and Histoclear for 10 minutes each before being 
mounted with coverslips with a drop of DPX mounting medium. Slides were dried flat 
overnight before microscopic analysis.  
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Table 2.1: Primary antibodies for immunohistochemical staining 
Primary antibody Species Dilution Supplier 
SPHK1 (AP7237c) Rabbit 1: 50 Abgent 
S1PR1 (sc-25489) Rabbit 1: 200 Santa Cruz 
S1PR2 (13488)  Rabbit 1: 50 Sigma 
S1PR3 (LS-A 1031) Rabbit 1: 400 MBL International Corp. 
S1PR4 (LS-B513/ 20935) Rabbit 1: 150 Lifespan Biosciences 
ABCC1 (M9067) 
ATX 
LMP1 (M0897) 
EBNA2 (PE2) 
CD10 
BCL6 (M7211) 
MUM1 (M7259) 
Mouse 
Rabbit 
Mouse 
Mouse 
Mouse 
Mouse 
Mouse 
1: 3000 
1:300 
1: 50 
1: 50 
1:400 
1:50 
1:400 
Sigma 
University of Cambridge 
Dako 
Dako 
Novocastra 
Dako 
Dako 
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2.2.4.4  Scoring system for immunohistochemical staining 
Scoring for all epithelial and lymphoid malignancies was based on the DAKO HercepTest
TM
 
scoring system which considers staining intensity and percentage of positive tumour cells as 
detailed out in Table 2.3.  
 
Table 2.2: The DAKO HercepTest
TM
 scoring system used in this study 
Score Protein expression Staining pattern 
0 negative No reactivity or positivity in less than 10% of 
tumour cells 
1 negative Faint/barely perceptible positivity in ≥ 10% of 
tumour cells 
2 positive Weak to moderate staining in ≥ 10% of tumour 
cells 
3 positive Strong staining in ≥ 10% of tumour cells 
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2.3  EBER in situ hybridisation protocol 
2.3.1  Section pre-treatment and digestion 
Sections were dewaxed in two washes of Histoclear for 5 minutes, rehydrated in two washes 
of absolute ethanol and 95% ethanol for 5 minutes, rinsed with two washes of distilled water 
for 5 minutes, and then digested with 100 µl proteinase K (Sigma-Aldrich Company Ltd., 
Gillingham, UK) in 50 mM Tris/HCI buffer pH 7.6 for 30 minutes at 37 °C. Slides were 
rinsed in TBS for 5 minutes and sections were dehydrated in two washes of 95% ethanol and 
absolute ethanol for 5 minutes each before being air dried. A ring of wax was applied 
encircling the tissue using PAP pen. 
 
2.3.2  Hybridisation 
50 μl 1:7 dilution of Leica NovocastraTM Fluorescein-conjugated probe solution (NCL-EBV-
K) was pipetted onto the tissue and a plastic coverslip was placed on the top-slowly spreading 
the probe mixture evenly over the tissue section without trapping air bubbles . Slides were 
incubated in the oven at 55º C for 1 hour and a half. The plastic coverslips.were then removed 
and slides were washed in TBST for 5 minutes.  
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2.3.3  Detection 
Prior to detection, slides were blocked for 10 minutes with rabbit serum diluted 1:5 in TBS, 
3% w/v BSA, 0.1% v/v Triton X-100. The blocking solution was then tipped off and detection 
was performed by 30 minute incubation with 50 ul rabbit F(ab’) anti-FITC/AP (Vial A, 
Vector Labs) diluted 1:200 in TBS, 3% w/v BSA, 0.1% v/v Triton X-100. Slides were washed 
with TBST for 2 x 3 minutes. 100 µl of enzyme substrate (Vial B) 1:50 in 100 mM Tris/HCI, 
50 mM MgCI2, 100 mM NaCI pH 9.0 mixed with 1 μl of inhibitor (levamisole) (Vial C) to 
each ml of diluted enzyme substrate was pipetted onto the slides. Slides were incubated at 
room temperature in the dark overnight. Slides were washed with TBST, counterstained in 
fast red for 6 minutes and mounted with DPX. Slides were dried flat overnight before 
microscopic analysis of EBER. 
 
2.4  Tissue culture 
2.4.1  Collection and general culture of cell lines 
The HL-derived cell lines used in this study are listed in Table 2.4 below. All cell lines were 
cultured in a humidified incubator at 37
o 
C in 5% carbon dioxide (CO2) in normal growth 
media which was RPMI-1640 supplemented with 10% fetal calf serum (FCS), 2 mM 
glutamine (all Invitrogen Ltd., Paisley, UK) and 0.5% penicillin-streptomycin solution 
(Sigma-Aldrich Company Ltd., Gillingham, UK). Cell lines were subcultured twice a week in 
50 cm
2 
flasks. 
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2.4.2  Cryopreservation of cells  
1 x 10
7 
cells were pelleted by centrifugation at 1000 rpm in a 5810R Eppendorf centrifuge for 
5 minutes and re-suspended in 1 ml freezing solution (RPMI-1640 supplemented with 40% 
v/v FCS and 10% v/v dimethylsulphoxide (DMSO; Sigma). Cells were then transferred to 
cryopreservation vials and placed in a freezing container at -80ºC freezer. A day later, cells 
were moved to liquid nitrogen freezer at -180ºC for long-term storage. 
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Table 2.3: HL cell lines used 
Cell lines Origin Growth media 
L591 EBV-positive HL cell line, from the pleural effusion of 
a nodular sclerosis female HL patient (Diehl et al., 
1992). 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep. 37ºC in 
5% CO2 
L1236 EBV-negative cell line from the peripheral blood of an 
advanced HL patient (Wolf et al., 1996). The HRS cell 
origin of L1236 cells has been confirmed by the 
finding of identical Ig gene rearrangement sequences 
in L1236 cells and HRS cells of the same patient's 
bone marrow (Kanzler et al., 1996). 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep. 37ºC in 
5% CO2 
L540 EBV-negative HL cell line derived from the pleural 
effusion of an HL patient. Genomic analysis of the cell 
line has revealed monoclonal rearrangements of T-cell 
receptor beta and gamma loci and germ line 
configuration of Ig genes, suggesting a T-cell origin   
(Falk et al., 1987; Drexler et al., 1988). 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep. 37ºC in 
5% CO2 
KMH2 EBV-negative cell line originally established from the 
pleural effusion of a mixed cellularity HL patient 
(Kamesaki et al., 1986) 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep. 37ºC in 
5% CO2 
L428 EBV-negative cell line established from the pleural 
effusion of an HL patient (Schaadt et al., 1980). 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep. 37ºC in 
5% CO2 
 HDLM2 EBV-negative cell line established from the pleural 
effusion of an HL patient (Schaadt et al., 1980). 
RPMI 1640, 2mM 
glutamine, 10% FCS, 
1%, pen/strep.   
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2.4 3  Recovery of cells from nitrogen storage  
Cells were thawed quickly at 37ºC to minimize exposure to DMSO and transferred to a 15 ml 
falcon tube. Warmed RPMI with supplements was added gradually to the cells to dilute the 
DMSO. Cells were then pelleted by centrifugation at 1000 rpm in a 5810R Eppendorf 
centrifuge for 5 minutes, re-suspended in 10 ml medium and transferred to a 25 cm
3
 flask and 
incubated at 37ºC. 
 
2.4.4  Determination of cell number in culture 
Disposable Glasstic
™
 slides (Hycor Biomedical Ltd., Edinburgh, UK) were used for counting 
cells in culture. 100 µl of cell suspension was aspirated from culture and mixed with 100 µl of 
Trypan blue. 20 µl of this mixture was aspirated and pipetted into the Glasstic
™
 slide well. 
Using an inverted light microscope, all viable cells (bright spherical cells) contained within 
four diagonal zones of the Glasstic
™
 grid were counted. This number was divided by four to 
obtain an average count of cell number per zone. This average value was then multiplied by 
10
4
 to obtain the number of cells per ml of culture medium.  
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2.4.5  Treatment of L591 cells with Sphingomab 
Prior to plating, cells were washed twice with Optimem and re-suspended in 14 ml Optimem. 
1 ml of solution containing 2.5x 10
6
 cells were plated in each well in a 48 well plate. The 
experiment was set up in triplicate at 2 time points; 2 hours and 12 hours. Sphingomab 
antibody (LT1002, LPath) concentration was 12.0 mg/ ml. To make a 3 mg/ ml working 
stock, a 4 fold dilution was made. 601. 7 µl PBS was added to 198.4 µl Sphingomab stock to 
achieve 800 µl antibody working solution. 250 µl antibody solution was added to each well. 
For control wells, 250 µl PBS was added. Cells were incubated at 37ºC for 2 and 12 hours. 
Cells were aspirated and spun down at 400 g for 5 minutes and RNA was harvested using 
QIAGEN RNeasy
™
 mini kit
 
 as described in section 2.7.1.2. RNA was stored at -80C for gene 
expression microarray as described in section 2.8.  
 
2.5  Transfection of plasmid DNA into mammalian cells 
Transfection was done using Cell Line Optimization Nucleofector® Kit (Amaxa). Prior to the 
day of transfection, cells were plated in 1 ml of culture media in a 12 well plate in a 
humidified 37ºC/5% CO2 incubator. An aliquot of cells were aspirated to determine the cell 
density. After centrifugation, cells were re-suspended in 1 ml nucleofector solution. 
Nucleofector solution was prepared by mixing 0.2 ml supplement to 0.9 ml Nucleofector 
solution. One nucleofection sample required 1x10
6
 to 5x10
6
 cells, 100 µl nucleofector 
solution and 2µg pmaxGFP. 100 µl sample was carefully transferred into an amaxa certified 
cuvette, avoiding air bubbles and closed with the blue cap. The appropriate nucleofactor 
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programme was selected and the cuvette inserted into the cuvette holder. The programme. was 
started and once ‘ok’ was displayed, the cuvette was immediately removed from the holder to 
avoid cell damage. 500 µl of pre-warmed culture media was added to the cuvette and the 
mixture was transferred to a 12 well plate and incubated at 37ºC. Sample was ready for 
analysis of gene expression.  
 
2.6  Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.6.1  RNA extraction from cultured cells 
2.6.1.1  Cell lysis 
5 x 10
6
 cells were pelleted by centrifugation at room temperature for 5 minutes at 400 g and 
the supernatant discarded. RNA was extracted using QIAGEN RNeasy
TM
 mini kit (QIAGEN 
Ltd., West Sussex, UK). Lysis buffer was prepared by adding 1 µl of β-mercaptoethanol to 
every 100 µl of Buffer RLT. Cells were lysed using 350 µl of this lysis buffer and incubated 
at room temperature for 5 minutes.  
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2.6.1.2  RNA extraction 
Total RNA was isolated from cells using the QIAGEN RNeasy
™
 mini kit
 
according to the 
manufacturer's protocol. Cell lysates were mixed with 350 µl of 70% ethanol diluted in 
DNase/RNase-free water and transferred to spin columns placed in collection tubes. Columns 
were then centrifuged at 8000 g for 15 seconds. The flow-through was discarded and 700 µl 
Buffer RW was pipetted into spin columns before being centrifuged again at 8000 g for 15 
seconds. The flow-through was discarded and columns were transferred to fresh collection 
tubes. 500 µl of Buffer RPE was pipetted into spin columns before being centrifuged at 8000 
g for 15 seconds. Flow-through was discarded and another 500 µl Buffer RPE was added. 
Columns were centrifuged at 8000 g for 2 minutes. Flow-through and collection tubes were 
discarded and columns were centrifuged with the lids open for 1 minute at 16000 g to 
completely dry the membrane in the columns. Columns were transferred to fresh centrifuge 
tubes and RNA was eluted in 30 µl of DEPC water by centrifugation for 1 minute at 8000 g. 
    
2.6.1.3  Determination of RNA concentration 
The RNA concentration of each sample was measured on a NanoDrop ND-1000 
Spectrophotometer: To initialize the NanoDrop, 2 µl of DNase/RNase-free water was applied 
to the sample well. The sample well was wiped clean with tissue, 1 µl RNase-free water (from 
RNeasy
™
 kit) was applied and used as a blank measurement. Again the sample well was 
wiped clean and 1 µl of eluted RNA was used to obtain the concentration and quality (ratio 
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260/280) of RNA for each sample. The sample well was wiped clean before applying a new 
sample of RNA. 
 
2.6.2  cDNA synthesis 
Complementary (c) DNA was synthesized using Qiagen reverse transcriptase kit. 1 µg RNA 
from each sample was pipetted into sterile 0.2 ml PCR tubes and 2 µl 7x gDNA wipeout 
buffer was added. The volume was made up to 14 µl using DNase/RNase-free water. A 
negative control (no RNA) was set up in parallel, consisting of DNase/RNase-free water and 2 
µl 7x gDNA wipeout buffer only. The tubes were preheated for 2 minutes at 42ºC. In the 
mean time, a Reverse Transcriptase (RT)-reaction master mix consisting of the following 
components was prepared per reaction. 4 µl 5x Quantiscript RT buffer, 1 µl RT primer mix 
and 1 µl quantiscript reverse transcriptase. This master mix was added to each preheated tubes 
and mixed well. Using an Eppendorf Thermal Cycler, c-DNA was synthesized at 42
o 
C for 30 
minutes, and at 95ºC for 3 minutes to inactivate quantiscript reverse transcriptase. cDNA was 
stored at -20
o 
C until required.  
 
2.6.3  TaqMan quantitative polymerase chain reaction (Q-PCR) 
Real time PCR amplifies and simultaneously quantifies a targeted DNA molecule against a 
known standard. The quantity of PCR product is directly proportional to the amount of 
nucleic acid template. Each well of a RT-Q-PCR reaction comprised 20 µl reaction volume 
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including 5 µl of input cDNA. A PCR-reaction master mix consisting of the following 
components was prepared per reaction: 10 µl of 2x Taqman Univesal PCR Mastermix, 1 ul of 
commercial primers/probe (Applied Biosystems), 1 ul reference gene (GAPDH) and 3 ul of 
DNA/RNAse free water. 15 ul of master mix was pipetted into each well in a 96 well plate 
followed by 5 ul of cDNA. Each reaction was assayed in triplicates. For control wells, cDNA 
was replaced by 5 ul of DNA/RNAse free water. The 96 well plate was sealed with an 
adhesive cover and spun at 900g for 1 minute and then placed in the 7500 Real-Time PCR 
System (Applied Biosystems) for thermocycling and fluorescence detection. Initial heating 
was at 95ºC for 10 minutes to activate the polymerase enzyme, followed by 40 cycles of 
denaturation at 95ºC for 15 seconds and primer annealing and extension at 60ºC for 60 
seconds. Data was analysed using 7500 system software v1.4.0 (Applied Biosystems) and 
Excel (Microsoft 2010). The average Ct value was calculated for both target and reference 
gene and the dCt (Cttarget-CtGAPDH) was obtained. The ddCt (dCttarget-dCtcontrol) was 
determined and the relative fold change of gene expression in HL cell lines was calculated 
using the formula 2^-ddCt.  
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Table 2.4: Taqman primer and probe mixes 
Gene ABI Q-PCR Primer/Probe 
Reference Number 
SPHK1 Hs 00184211_m1 
S1PR1 Hs 00173499_m1 
S1PR2 Hs 01055393_m1 
S1PR3 Hs 00245464_s1 
S1PR4 Hs 02330084_s1 
S1PR5 Hs 00924881_m1 
REL Hs 00968440_m1 
TOP2B Hs 00172259_m1 
CCDC88A Hs 01559767_m1 
BDP1 Hs 01055393_m1 
RPL 35 Hs 00855441_gH 
HAT1 Hs 00186320_m1 
GAPDH 4310884E 
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2.7  Microarray expression analysis 
2.7.1  Introduction to microarray expression analysis 
DNA microarray measures the expression of large numbers of genes simultaneously. In this 
study, the Affymetrix GeneChip® Whole Transcript (WT) Sense Target (ST) Labeling Assay 
was used. This array was designed to generate amplified and biotinylated sense-strand DNA 
targets from the entire expressed genome. using1 µg Total RNA Labeling Protocol. It started 
with the reduction of a ribosomal RNA (rRNA) where the 28S and 18S rRNA population is 
reduced from the total RNA (Figure 2.3). Subsequently, double-stranded cDNA is synthesized 
which then acts as a template producing copies of antisense cRNA by the action of T7 RNA 
polymerase. Second cycle of single stranded cDNA is synthesized following reverse 
transcription of the cRNA. During this process, dUTP is incorporated into the DNA followed 
by addition of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 
(APE 1) which breaks the DNA strand. DNA is labeled by terminal deoxynucleotidyl 
transferase (TdT) with the Affymetrix® proprietary DNA Labeling Reagent that is covalently 
linked to biotin. Sufficient target is then generated for hybridization to a single array. The 
hybridisation of target sequences to oligonucleotide probes is detected by staining with a 
streptavidin-phycoerythrin conjugate and measuring the light emitted at 570 nm. The signal 
produced is proportional to the amount of bound target at each location on the array and 
reflects the transcript levels present in the original target population. A series of control genes 
are used to allow normalization and scaling between each array so that differences in signal 
intensities can be compared. 
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Figure 2.1 GeneChip® Whole Transcript Sense Target Labeling Assay (from 
www.affymetrix.com) 
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2.7.2  rRNA Reduction and Preparation of Total RNA with Diluted Poly-A RNA 
Total RNA was extracted from the cells (Section 2.7.1.1 and 2.7.1.2) and prepared for 
hybridization to the arrays using GeneChip® Poly-A RNA Control Kit (Affymetrix). Three 
series of dilution was made by adding Poly-A Control Dilution Buffer to Poly-A RNA 
Control Stock. The Third Dilution was added to 1 µg of total RNA to make up the Total 
RNA/ Poly-A RNA Controls Mix. 5.2 µl Total RNA/Poly-A Controls Mix, 0.8 µl RiboMinus 
Probe (100 pmol/µL) and 30 µl Hybridization buffer with betaine was mixed, spun and 
incubated at 70°C for 5 minutes in a thermal cycler. The hybridized sample was added to the 
magnetic beads and incubated at 37ºC for 10 minutes, and spun again to obtain the rRNA-
probe pellet. The supernatant was pipetted into a 1.5 ml non-stick RNAse free tube on ice. 
The beads were re-suspended again in hybridization buffer with betaine and incubated at 50ºC 
for 5 minutes. The supernatant was added to the previous supernatant containing rRNA-
reduced total RNA/Ploy-A RNA control mix. Sample was cleaned up using GeneChip IVT 
cRNA cleanup kit. The quality of the concentrated RNA sample was then determined by 
running the Eukaryotic Total RNA Nano Assay in the bioanalyzer. On average, > 100 ng of 
rRNA-reduced sample may be recovered from 1 µg of total RNA starting material.  
  
2.7.3  First-strand cDNA synthesis  
10 µg RNA was reverse transcribed to first-strand cDNA by adding 5 µL of the First-Cycle, 
First-Strand MasterMix to the tube containing concentrated rRNA and spun down. The 
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reaction was incubated at 25°C for 10 minutes, 42°C for 60 minutes,70°C for 10 minutes and 
cooled at 4°C for 2 minutes and continued to the First-Cycle, Second-Strand cDNA synthesis 
 
2.7.4  Second-strand cDNA synthesis 
An RNase H-mediated second-strand cDNA synthesis reaction was performed using 10 µl of 
a master mix containing; 4 µl MgCl2, 0.4 µl 10 mM dNTP Mix, 0.6 µl DNA Polymerase I, 0.2 
µl RNase H and DNA/RNAse free water added to each of the first strand reaction tubes and 
incubated at 16ºC for 2 hours.and at 75ºC for 10 minutes with heated lid. Sample was cooled 
down for 2 minutes at 4ºC. 
 
2.7.5  First cycle, cRNA synthesis and cleanup 
The GeneChip® WT cDNA Amplification Kit and the GeneChip® Sample Cleanup Module 
were used for this procedure. IVT Master Mix (containing 5 µl 10x IVT Buffer, 20 µl IVT 
NTP Mix, 5 µl IVT Enzyme Mix) was added to each sample and incubated at 37ºC for 16 
hours. Sample was cleaned up using cRNA Cleanup Spin Columns. The eluted cRNA 
concentration was measured using the NanoDrop ND-1000. 
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2.7.6  Second cycle, first strand cDNA synthesis 
cRNA sample was mixed with 1.5 µl random primers and 8 µl RNAse free water and 
incubated at 70ºC for minutes, 25ºC for 5 minutes and 4ºC for 2 minutes. Second cycle, first 
strand cDNA synthesis Master Mix was added and the sample was incubated at 25ºC for 10 
minutes, 42 ºC for 90 minutes, 70 ºC for 10 minutes and 4 ºC for at least 2 minutes. 
 
2.7.7  Hydrolysis of cRNA and cleanup of single-stranded DNA 
1 µL of RNase H was added to each sample and incubated at 37°C for 45 minutes,95°C for 5 
minutes and 4°C for 2 minutes. Sample was cleaned up using cDNA Cleanup Spin Columns 
from the GeneChip® Sample Cleanup Module according to the manufacturer’s protocol.   
 
2.7.8  Fragmentation and labelling of single stranded DNA 
Fragmentation Master Mix was prepared and added into the sample and incubated at 37°C for 
60 minutes, 93°C for 2 minutes, 4°C for at least 2 minutes GeneChip® WT Terminal 
Labeling Kit was used for labelling of fragmented single stranded DNA. Labelling reaction 
was added to the sample and incubated at 37°C for 60 minutes, 70°C for 10 minutes and 4°C 
for at least 2 minutes.  
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2.7.9  Hybridization, washing, staining and scanning 
Hybridization cocktail (containing fragmented and labeled DNA target, control 
oligonucleotide B2, 20X eukaryotic hybridization controls, 2X hybridization mix, DMSO and 
nuclease free water) was prepared and heated at 99°C for 5 minutes, cooled to 45°C for 5 
minutes, and centrifuged at maximum speed for 1 minute. Sample was injected into the 
GeneChip® ST array through one of the septa and placed in 45°C hybridization oven, at 60 
rpm, and incubated for 16 hours. The array was removed from the oven and the hybridization 
cocktail was aspirated through the septa and the array probe was filled with Wash Buffer A 
for 10 cycles at 30ºC and then with Wash Buffer B for 4 cycles at 50ºC. The probe array was 
stained for 300 seconds with Stain Cocktail 1 at 35°C and then washed with Wash Buffer A at 
30°C. Staining was repeated for 300 seconds with Stain Cocktail 2 at 35°C and for 300 
seconds with Stain Cocktail 1 at 35°C followed by a final 15 cycle wash with Wash Buffer A 
at 35°C. The probe array was then filled with array holding buffer and scanned on the 
GeneChip Scanner 3000. 
 
2.7.10 Data analysis using R and Microsoft Excel software packages.  
The analysis of these arrays was performed with the help of Dr. Wenbin Wei and Prof Ciaran 
Woodman. Images of the microarrays were analysed using Affymetrix microarray Suite 5.0. 
Probe level quantile normalization and robust multiarray analysis on the raw CEL files were 
performed using the Affymetrix Bioconductor package (http://www.bioconductor.org) 
Differentially expressed genes were identified using GeneSpring GX software Version12.5. 
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2.8  Statistical Package 
Statistical Package for the Social Sciences 21.0 (SPSS 21.0) was used for all statistical 
analysis. Associations between clinical parameters and S1P signaling molecule expression 
were assessed by chi-square tests. Survival probabilities were calculated using Kaplan–Meier 
method. Differences between the curves were evaluated with log–rank test. Overall survival 
time was defined as the period between the time of diagnosis and the time of death. Disease-
free survival time was defined as the period between the time of complete remission and the 
time of death or relapse. Survival times of patients who were still alive were censored with the 
last follow-up date. Logistic regression models and Cox regression analysis were used to 
assess the independent effects of co-variables on survival. 
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3.1  Introduction 
Although cHL is largely a curable disease, about 10% of patients do not respond to 
chemotherapy. The widely accepted standard chemotherapy regime consists of doxorubicin 
(Adriamycin), bleomycin, vinblastin and dacarbazine (ABVD) with or without consolidation 
radiotherapy. Patients who relapse may require salvage chemotherapy and stem cell 
transplantation. Novel prognostic biomarkers are still being investigated to improve survival 
rates of cHL patients which include CD20, BCL2, MAL and Ki67 (Huang et al. 2007; Sup et 
al. 2005; Hsi et al. 2006; Morente et al. 1997).  
Upregulation of SPHK1 protein and mRNA was observed in cases of Non Hodgkin 
lymphoma and correlates with increasing clinical grade (Bayerl et al. 2008) suggesting 
SPHK1 as a possible target for therapeutic intervention in these patients. ABCC1 
overexpression has been shown to confer resistance to multidrug treatment in cHL patients. 
ABCC1 overexpression is also associated with refractory disease and poorer failure-free 
survival in cHL patients (Greaves et al. 2012). 
The aims of this study are to: 
i) examine the expression of SPHK1, S1PR1, S1PR3, ABCC1 and ATX in HL cell lines 
and primary HL tissue samples and correlate their expression with clinicopathological 
variables. 
ii) determine if a humanised monoclonal antibody against S1P, Sphingomab could reverse 
the B cell receptor phenotypes in L591 cells. 
3.2  Antibody specificity testing 
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Similarly to SPHK1 and S1PR1 antibodies, I also established the specificity of S1PR3 
antibodies prior to performing immunohistochemistry on the HL cases. DG75 BL cell lines 
transfected with S1PR3 plasmids or with an empty vector were fixed in formaldehyde, 
cytospun and stained to confirm antibody specificity. Immunocytochemistry demonstrated 
that S1PR3 was strongly expressed in transfected cells compared to cells with empty vector 
(Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Cells transfected with plasmids expressing SPHK1 and S1PR1 were 
immunostained with respective antibodies.  
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                A      
   B        
Figure 3.2: Cells transfected with plasmid expressing S1PR3 were immunostained with 
respective antibody.A) DG75 BL cells with empty vector, B) DG75 BL cells with S1PR3 
vector 
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3.3  Re-analysis of expression of lipid signalling molecules on 'Brune' array 
The re-analysis of a published dataset (18; GEO database no GSE12453) revealed that the 
expression of SPHK1 was increased in micro-dissected HRS cells compared to normal 
centrocytes, the presumed progenitors of HRS cells (Table 3.1,Figure 3.3) S1PR1 was 
expressed in HRS cells but was not significantly changed compared to centrocytes (Table 3.2, 
Figure 3.3). The expression of S1PR3 was significantly increased in micro-dissected HRS 
cells compared to centrocytes.  
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Table 3.1: Expression of SPHK1 in primary HRS cells compared with normal 
centrocytes 
Gene Gene expression in HRS cells 
compared with centrocytes (mean 
fold change) 
Number of present 
calls in HRS cells 
(n=12) 
Number of 
present calls in 
centrocytes (n=5) 
SPHK1 +2.56 10 0 
 
Table 3.2: Expression of S1P receptors in primary HRS cells compared with normal 
centrocytes 
Gene Gene expression in HRS cells 
compared with centrocytes 
Number of present 
calls in HRS cells 
(n=12) 
Number of 
present calls in 
centrocytes (n=5) 
S1PR1 No significant change 6 2 
S1PR2 -3.37 10 5 
S1PR3 +2.75 5 0 
S1PR4 +1.79 3 1 
S1PR5 No significant change 0 0 
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      A    
      B  
Figure 3.3: Differential expression of A) SPHK1 and B) S1PR1 receptor in primary 
HRS cells and different B cell subsets. Re-analysis of a published dataset (18; GEO 
database no GSE12453) revealed that the expression of SPHK1 was increased and that of 
S1PR1 was not significantly changed compared to centrocytes (CC). 
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Figure 3.4: Differential expression of S1PR3 in primary HRS cells and different B cell 
subsets. Re-analysis of a published dataset (18; GEO database no GSE12453) revealed that 
when compared to centrocytes (CC), the expression of S1PR3 was increased in HRS cells. 
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3.4  Expression of lipid signalling molecules in normal lymphoid tissue 
Along with staining on primary HL tissue, immunohistochemical staining using antibodies to 
SPHK1, S1PR1, S1PR3, ABCC1 and ATX were performed on normal lymphoid tissue. 
SPHK1 was detectable in the germinal centre B cells of reactive tonsils (Figure 3.6). The 
follicular mantle cells were negative for SPHK1. Fibroblasts, macrophages, plasma cells and 
endothelial cells lining the blood vessels were positive for SPHK1 and served as internal 
positive control. S1PR1 was strongly expressed in the mantle zone surrounding the germinal 
centres. Germinal centre cells were negative for S1PR1. Positive staining was observed in the 
endothelium of blood vessels. S1PR3 was expressed in the germinal centres of normal 
lymphoid tissue, but showing weaker intensity to that found in HRS cells. Endothelium of 
blood vessels showed strong positivity for S1PR3. ABCC1 was negative in the germinal 
centre cells but show strong positivity in the endothelium of blood vessels. ATX was 
expressed in the germinal centre cells and in the endothelial cells of blood vessels (Figure 
3.9). 
 
3.5  Expression of lipid signalling molecules in primary HL tissue 
61 cases of HL were obtained from the Pathology Department, Queen Elizabeth Hospital, 
Birmingham. Histopathological review to confirm the diagnosis and subtype of HL was 
performed by Dr Claudia Roberts, Consultant Haematopathologist from the same department. 
Paraffin sections from each case were stained with antibodies to SPHK1, S1PR1, S1PR3, 
ABCC1 and ATX. LMP1 staining was also performed to determine the EBV status of these 
patients. Staining was scored according to the criteria set out in Section 2.2.4.4. The clinical 
characteristics of these HL cases are shown in Table 3.3. The expression of lipid signalling 
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proteins in HL is summarised in Figure 3.5. Immunohistochemistry showed that SPHK1 was 
expressed in HRS cells in 25/61 (41%) cases. SPHK1 was localised to the cytoplasm of HRS 
cells (Figure 3.6). S1PR1 was strongly expressed in HRS cells in 48/61 cases (78.7%) and 
was localised to the cell membrane of HRS cells (Figure 3.7). Strong S1PR3 expression in 
HRS cells was observed in all samples of HL (100%) and was localised to the cytoplasm of 
these cells (Figure 3.8). ABCC1 was expressed in HRS cells in 44/61 cases (72.1%). Staining 
was observed in the cytoplasm of HRS cells. ATX was expressed in the cytoplasm of HRS 
cells in 69% of cases (Figure 3.9).  
Chapter 3  Results 
93 
 
Table 3.3: Clinical characteristics of 61 HL cases 
Characteristic All patients (%) 
Age  
    15-34 years 25 (41.0) 
    35-44 years 10 (16.4) 
    ≥ 45 years 26 (42.6) 
Gender  
    Male 37 (60.7) 
    Female 24 (39.3) 
Disease subtype  
    Nodular sclerosis 34 (55.7) 
    Mixed cellularity 27 (44.3) 
    Lymphocyte predominant 0 (0.0) 
    Lymphocyte depleted 0 (0.0) 
EBV status  
    Positive 24 (39.3) 
    Negative 37 (60.7) 
Stage  
    I-II, limited 31 (59.6) 
    III-IV, advanced 21 (40.4) 
Treatment  
    chemotherapy only 30 (49.2) 
    radiotherapy only 9 (14.8) 
    chemotherapy and radiotherapy 10 (16.4) 
    palliative 2 (3.3) 
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Figure 3.5: Summary of expression of lipid signalling molecules in Hodgkin lymphoma 
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                       A  
                      B   
Figure 3.6: SPHK1 expression in reactive tonsil and HL tissue. A) SPHK1 was expressed 
in the GCB cells and endothelial lining of blood vessels (E). B) SPHK1 was expressed in  the 
cytoplasm of HRS. 
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                            A  
                B  
Figure 3.7: S1PR1 expression in reactive tonsil and in HL tissue A) S1PR1 was expressed 
in the mantle zone (MZ) surrounding germinal centres (GC) of reactive tonsil (x200) B) 
S1PR1 was expressed in the cell membrane of HRS cell of HL (x600). 
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Figure 3.8: S1PR3 expression in reactive tonsil and HL tissue. A) S1PR3 was expressed 
in the germinal centre of lymphoid follicles (GC) and blood vessels (V) B) Strong S1PR3 
expression was seen in the cytoplasm of HRS cells (x 400). 
Chapter 3  Results 
98 
 
        A     
        B     
Figure 3.9: Expression of ATX in reactive tonsil and HL tissue. A) ATX was weakly 
expressed in the germinal centre cells (GC) of reactive tonsil and was strongly expressed in 
the endothelial cells of blood vessels (V). B) ATX was strongly expressed in the cytoplasm of 
HRS cells of HL (x600). 
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3.5.1  Expression of lipid signalling molecules in HL and their relationship with 
clinicopathological parameters 
Tables 3.4-3.8 summarises the expression of each lipid signalling molecules in HL in relation 
to clinicopathological parameters. I found that EBV positivity was not significantly 
associated with any clinicopathological parameter (Table 3.4). More patients expressing 
SPHK1 and ATX were treated with chemotherapy only (p=0.024 and p=0.041 
respectively)(Table 3.5 and Table 3.8). S1PR1 expression was associated with lower stage 
disease (p=0.035)(Table 3.6).  
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Table 3.4: Clinical characteristics of 61 cases of HL by EBV positivity 
Characteristic All patients 
(%) 
EBV+ EBV- χ2 
value 
p value 
Age       
    15-34 years 25 (41.0) 10 (41.7) 15 (42.1) 0.724 0.697
#
  
    35-44 years 10 (16.4) 5 (20.8) 5 (13.2)    
    ≥ 45 years 26 (42.6) 9 (37.5) 17 (44.7)    
Gender       
    Male 37 (60.7) 15 (62.5) 22 (57.9) 0.056 0.812
#
  
    Female 24 (39.3) 9 (37.5) 15 (42.1)    
Disease subtype       
    Nodular sclerosis 34 (55.7) 14 (58.3) 20 (55.3) 0.108 0.742
#
  
    Mixed cellularity 27 (44.3) 10 (41.7) 17 (44.7)    
    Lymphocyte predominant 0 (0.0) 0 (0.0) 0 (0.0)    
    Lymphocyte depleted 0 (0.0) 0 (0.0) 0 (0.0)    
Stage       
    I-II, limited 31 (59.6) 15 (62.5) 16 (42.1) 1.162 0.281
#
  
    III-IV, advanced 21 (40.4) 7 (29.2) 14 (39.5)    
Treatment       
    chemotherapy only 30 (58.8) 13 (61.9) 17 (56.7) 4.806 0.187
#
   
    radiotherapy only 9 (17.6) 4 (19.0) 5 (16.7)    
    chemotherapy & radiotherapy 10 (19.6) 2 (9.5) 8 (26.7)    
    palliative 2 (3.9) 2 (9.5) 0 (0.0)    
         
#
Chi square test, *Fisher’s exact test 
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Table 3.5: Expression of SPHK1 in 61 cases of HL by clinicopathological variables 
Characteristic All 
patients 
(%) 
SPHK1 + SPHK1 - χ2 value p value  
Age      
    15-34 years 25 (41.0) 10 (37.0) 15 (44.1) 0.605 0.739
#
 
    35-44 years 10 (16.4) 4 (14.8) 6 (17.6)   
    ≥ 45 years 26 (42.6) 13 (48.1) 13 (38.2)   
Gender      
    Male 37 (60.7) 15 (55.6) 22 (64.7) 0.528 0.467
#
 
    Female 24 (39.3) 12 (44.4) 12 (35.3)   
Disease subtype      
    Nodular sclerosis 34 (55.7) 16 (59.3) 18 (52.9) 0.244 0.622
#
 
    Mixed cellularity 27 (44.3) 11 (40.7) 16 (47.1)   
    Lymphocyte predominant 0 (0.0) 0 (0.0) 0 (0.0)   
    Lymphocyte depleted 0 (0.0) 0 (0.0) 0 (0.0)   
EBV status      
    Positive 24 (39.3) 13 (48.1) 11 (32.3) 1.513 0.210
#
 
    Negative 37 (60.7) 14 (51.9) 23 (67.6)   
Stage      
    I-II, limited 31 (50.8) 13 (48.1) 18 (52.9) 0.550 0.458
#
 
    III-IV, advanced 21 (34.4) 11 (40.7) 10 (29.4)   
Treatment      
    chemotherapy only 30 (58.8) 17 (73.9) 13 (46.4) 8.359 0.024* 
    radiotherapy only 9 (17.6) 5 (21.7) 4 (14.3)   
    chemotherapy & radiotherapy 10 (19.6) 1 (4.3) 9 (32.1)   
    palliative 2 (3.9) 0 (0.0) 2 (7.1)   
       
  
#Chi square test, *Fisher’s exact test 
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Table 3.6: Expression of S1PR1 in 61 cases of HL by clinicopathological variables 
Characteristic 
All 
patients 
(%) S1PR1+ S1PR1- 
χ2 
value 
p value   
Age 
   
 
     15-34 years 25 (41.0) 19 (39.6) 6 (46.2) 0.185 0.916
#
 
     35-44 years 10 (16.4) 8 (16.7) 2 (15.4)  
     ≥ 45 years 26 (42.6) 21 (43.8) 5 (38.5)  
 Gender 
   
 
     Male 37 (60.7) 30 (62.5) 7 (53.8) 0.321 0.571
#
 
    Female 24 (39.3) 18 (37.5) 6 (46.2)  
 Disease subtype 
   
 
     Nodular sclerosis 34 (55.7) 27 (56.2) 7 (53.8) 0.024 0.877
#
 
    Mixed cellularity 27 (44.3) 21 (43.8) 6 (46.2)  
     Lymphocyte predominant 0 (0.0) 0 (0.0) 0 (0.0)  
     Lymphocyte depleted 0 (0.0) 0 (0.0) 0 (0.0)  
 EBV status 
   
 
     Positive 24 (39.3) 21 (43.8) 3 (23.1) 1.832 0.176
#
 
    Negative 37 (60.7) 27 (56.2) 10 (76.9)  
 Stage 
   
 
     I-II, limited 31 (59.6) 28 (66.7) 3 (30.0) 4.424 0.035* 
    III-IV, advanced 21 (40.4) 14 (33.3) 7 (70.0)  
 Treatment 
   
 
     chemotherapy only 30 (58.8) 25 (61.0) 5 (50.0) 6.094 0.075* 
    radiotherapy only 9 (17.6) 9 (22.0) 0 (0.0)  
     chemotherapy & radiotherapy 10 (19.6) 6 (14.6) 4 (40.0)  
      palliative 2 (3.9) 1 (2.4) 1 (10.0)  
   
   
 
 
  #Chi square test, *Fisher’s exact test 
Chapter 3  Results 
103 
 
Table 3.7: Expression of ABCC1 in 61 cases of HL by clinicopathological variables 
Characteristic 
All 
patients 
(%) ABCC1+ ABCC1- 
 
χ2 value 
p 
value   
Age 
   
 
     15-34 years 25 (41.0) 15 (34.1) 10 (58.8) 3.716 0.156# 
    35-44 years 10 (16.4) 9 (20.5) 1 (5.9)  
     ≥ 45 years 26 (42.6) 20 (45.5) 6(35.3)  
 Gender 
   
 
     Male 37 (60.7) 27 (61.4) 10 (58.8) 0.033 0.856# 
    Female 24 (39.3) 17 (38.6) 7 (41.2)  
 Disease subtype 
   
 
     Nodular sclerosis 34 (55.7) 24 (54.5) 10 (58.8) 0.091 0.763# 
    Mixed cellularity 27 (44.3) 20 (45.5) 7 (41.2)  
     Lymphocyte predominant 0 (0.0) 0 (0.0) 0 (0.0)  
     Lymphocyte depleted 0 (0.0) 0 (0.0) 0 (0.0)  
 EBV status 
   
 
     Positive 24 (39.3) 17 (38.6) 7 (41.2) 0.033 0.856# 
    Negative 37 (60.7) 27 (61.4) 10 (58.8)  
 Stage 
   
 
     I-II, limited 31 (50.8) 23 (60.5) 8 (57.1) 0.049 0.825# 
    III-IV, advanced 21 (34.4) 15 (39.5) 6 (42.9)  
 Treatment 
   
 
     chemotherapy only 30 (58.8) 23 (62.2) 7 (50.0) 2.140 0.549* 
    radiotherapy only 9 (17.6) 7 (18.9) 2 (14.3)  
     chemotherapy and radiotherapy 10 (19.6) 6 (16.2) 4 (28.6)  
     palliative 2 (3.9) 1 (2.7) 1 (7.1)  
       
   
 
 
 #Chi square test, *Fisher’s exact test 
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Table 3.8: Expression of ATX in 45 cases of HL by clinicopathological variables 
Characteristic All 
patients 
(%) 
ATX+ ATX- χ2 
value 
p value 
Age      
    15-34 years 19 (42.2) 12 (38.7) 7 (50.0) 0.646 0.724
#
 
    35-44 years 9 (20.0) 7 (22.6) 2 (14.3)   
    ≥ 45 years 17 (37.8) 12 (38.7) 5 (35.7)   
Gender      
    Male 26 (57.8) 16 (51.6) 10 (71.4) 1.552 0.213
#
 
    Female 19 (42.2) 15 (48.4) 4 (28.6)   
Disease subtype      
    Nodular sclerosis 25 (55.6) 18 (58.1) 7 (50.0) 0.254 0.614
#
 
    Mixed cellularity 20 (44.4) 13 (41.9) 7 (50.0)   
    Lymphocyte predominant 0 (0.0) 0 (0.0) 0 (0.0)   
    Lymphocyte depleted 0 (0.0) 0 (0.0) 0 (0.0)   
EBV status      
    Positive 19 (42.2) 15 (48.4) 4 (28.6) 1.552 0.213
#
 
    Negative 26 (57.8) 16 (51.6) 10 (71.4)   
Stage      
    I-II, limited 24 (60.0) 15 (51.7) 9 (81.8) 3.009 0.088* 
    III-IV, advanced 16 (40.0) 14 (48.3) 2 (18.2)   
Treatment      
    chemotherapy only 21 (53.8) 17 (60.7) 4 (36.4) 8.273 0.041* 
    radiotherapy only 9 (23.1) 7 (25.0) 2 (18.2)   
    chemotherapy & radiotherapy 7 (17.9) 2 (7.1) 5 (45.5)   
    palliative 2 (5.1) 2 (7.1) 0 (0.0)   
 
#
Chi square test, *Fisher’s exact test 
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3.5.1  Co-expression of lipid signalling molecules in HL 
I used chi square and Fisher’s exact tests to determine if there was any evidence of co-
expression of lipid signalling molecules in HL. As shown in Table 3.9, this analysis revealed 
that tumours which were positive for SPHK1 (52%) were also positive for S1PR1 (p =0.018). 
No other significant co-expression was observed. These data might suggest that S1P 
signaling mediated through S1PR1 regulates SPHK1 expression or vice versa. Figure 3.10 
illustrates my hypothesis ie. tumours are more likely to be S1PR1 positive if they also express 
SPHK1, in other words S1PR1 increases the expression of SPHK1 in HL. 
  
Figure 3.10 showing the suggested hypothesis that overexpression of S1PR1 increases 
the expression of SPHK1 in HL.
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Table 3.9: Co expression of lipid signalling molecules in HL. 
Lipid signalling 
molecule 
Associated lipid signalling 
molecule (%) 
χ2 value 
p value 
 
S1PR1+ S1PR1-  
 SPHK1 + 25 (52.1) 2 (15.4) 5.584 0.018
#
 
SPHK1 - 23 (47.9) 11 (84.6)  
 
 
ATX+ ATX-  
 SPHK1 + 1 (25.0) 26 (45.6) 0.296 0.586
#
 
SPHK1 - 3 (75.0) 31 (54.4)  
 
 
ABCC1+ ABCC1-  
 SPHK1 + 21 (47.7) 6 (35.3) 0.768 0.381
#
 
SPHK1 - 23 (52.3) 11 (64.7)  
 
 
ABCC1+ ABCC1-  
 S1PR1+ 33 (75.0) 15 (88.2) 1.260 0.319* 
S1PR1- 11 (25.0) 2 (11.8)  
 
 
ATX+ ATX-  
 
S1PR1+ 26 (83.9) 10 (71.4) 0.912 0.428* 
S1PR1- 5 (16.1) 4 (28.6)  
 
 
ATX+ ATX-  
 
ABCC1+ 25 (80.6) 8 (57.1) 2.724 0.099
#
 
ABCC1- 6 (19.4) 6 (42.9)  
 
  
#Chi square test, *Fisher’s exact test 
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3.6  Profiling the mRNA expression of S1P signalling molecules in HL cell lines 
After examining the expression of lipid signalling molecules at the protein level by 
immunohistochemistry, I next wanted to investigate which of HL cell lines were 
representative of the primary tumours. Therefore, I profiled the expression of these lipid 
signalling molecules at the mRNA level by RT Q-PCR. All data was normalised to GAPDH 
transcript level. 
I found that SPHK1 mRNA was upregulated in HL cell lines compared to tonsils and BL cell 
lines (Figure 3.11). EBV negative L540 cells exhibit the highest SPHK1 mRNA level 
followed by EBV negative L428 cells, L1236 and EBV positive L591 cells.  
Compared to GCB cells, S1PR1 mRNA levels were elevated in EBV positive L591 cells and 
in EBV negative L428 and HDLM2 cells (Figure 3.12) S1PR3 was only expressed at high 
levels in L428 cells (Figure 3.13).  
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Figure 3.11: Expression of SPHK1 in tonsils, BL and HL cell lines by RT Q-PCR. 
SPHK1 mRNA was upregulated in HL cell lines compared to GCB cells and BL cell lines. 
All data is normalised to GAPDH transcript levels. Data is expressed relative to GC B cells 
of Tonsil 1, assigned as value of 1 (Data by Nicola Ruth). 
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Figure 3.12: Expression of S1PR1 in tonsils, BL and HL cell lines by RT Q-PCR. S1PR1 
was markedly elevated in L591 cells and was expressed in other HL cell lines. All data is 
normalised to GAPDH transcript levels. Data is expressed relative to GC B cells of Tonsil 1, 
assigned as value of 1 (Data by Nicola Ruth). 
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Figure 3.13: Expression of S1PR3 in tonsils, BL and HL cell lines by RT Q-PCR. 
Expression of S1PR3 was increased in tonsils and was markedly increased in L428 HL cell 
line. All data is normalised to GAPDH transcript levels. Data is expressed relative to GC B 
cells of Tonsil 1, assigned as value of 1 (Data by Nicola Ruth). 
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3.7 Gene expression profiling after treatment of HL derived cell line, L591 with 
Sphingomab 
The objective of this experiment is to profile the genes upregulated and downregulated by 
Sphingomab and show whether the B-cell phenotype is restored in the HL cell line. I treated 
L591 cells with Sphingomab, a human monoclonal Ab which binds to S1P and prevents its 
interaction with its receptors. I then extracted the RNA from these cells at 2 and 12 hours 
time points.  Gene expression profiling was performed using GeneChip Whole Transcript 
Sense Target Labelling Assay as described in section 2.7. Microarray data was then analysed 
using Genespring GX version 12.5 as described in section 2.8. 
 
3.7.1 Quality control of samples 
Quality control of each sample was determined using Principal Component Analysis (PCA). 
Figure 3.14 shows PCA of 2 hour and 12 hour samples in triplicates. The samples were coded 
into two different colours, blue are the control samples, red are the treated samples. For 2 
hour samples, the plot seem to be quite scattered from each other but are still in the same 
plane. The plot of 12 hour samples seem to show better distribution compared to 2 hour 
samples.  
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Figure 3.14: Principal component analysis of 2 hour samples (A) and 12 hour sample 
(B). 
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3.7.2  Selection of differentially expressed genes: 
A gene was considered to be differentially expressed if the fold-change was more than 1.2 
and the p value was < 0.05. When the fold change was set at 2 and 1.5, no genes were 
differentially expressed, therefore a fold change of 1.2 was used. For 2 hour samples, 841 
genes were obtained and when fold change was set at 1.2, 94 genes were expressed in which 
15 genes were upregulated and 79 genes were downregulated (Table 3.10). As for 12 hour 
samples, 1301 genes were obtained and after fold change of 1.2 was set, 237 genes were 
differentially expressed, of which 27 genes were upregulated and 207 genes were 
downregulated (Table 3.11). Figure 3.15 shows hierarchical clustering of 2 hour and 12 hour 
samples and Figure 3.16 and Figure 3.17 show gene expression profiles for 2 hour and 12 
hour samples respectively. The list of top 20 genes (lower p values) upregulated and 
downregulated by Sphingomab are detailed in Table 3.10-3.13. Table 3.14 showed the list of 
eight B-cell receptor signaling genes which were differentially expressed following treatment 
with Sphingomab (p< 0.005). However the fold change of these genes range from -1.07 to 
1.02. Figure 3.18 shows the B cell receptor pathway and these eight genes are highlighted 
yellow. The summary of the roles of these eight B cell receptor signaling genes are shown in 
Table 3.15. Two S1P signaling genes were expressed in this array ie S1PR3 was found to be 
downregulated by Sphingomab at 12 hours and S1PR5 was downregulated at 2 hours (these 
genes are highlighted in the tables in the Appendix). 
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A  
B  
Figure 3.15 Hierarchical clustering of 2 hour samples (A) and 12 hour samples (B) after 
treatment with Sphingomab. Relative expression of each gene is shown in red indicating 
upregulation and green indicating downregulation. The horizontal lines indicate each gene. 
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A  
B  
Figure 3.16 Gene expression profile of 2 hour samples. A) 15 genes were upregulated and 
B) 79 genes were downregulated by Sphingomab (control samples are on the left and treated 
samples are on the right of each diagram). 
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A  
B  
Figure 3.17 Gene expression profile of 12 hour samples. A) 23 genes were upregulated and 
B) 207 genes were downregulated by Sphingomab (control samples are on the left and treated 
samples are on the right of each diagram).
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Table 3.10 List of all 15 genes upregulated by Sphingomab at 2 hours post treatment (fold change > 1.2, p value < 0.05). 
Transcript ID Gene symbol Gene description p value Fold 
change 
3737677 LOC100129503                  uncharacterised 0.003402 1.242232 
3755316 MLLT6|LOC100129395 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 6 | NS5ATP13TP1 
0.006773 1.212979 
3249043 REEP3 receptor accessory protein 3 0.00698 1.325794 
3716048 TAOK1 TAO kinase 1 0.007025 1.205202 
2409069 CCDC23 coiled-coil domain containing 23 0.007082 1.311701 
2464484 FAM36A|NCRNA00201 family with sequence similarity 36, member A | non-protein coding 
RNA 201 
0.011231 1.203204 
2717481 AFAP1-AS AFAP1 antisense RNA (non-protein coding) | actin filament 
associated protein 1 
0.020966 1.227855 
3645764 OR1F1 olfactory receptor, family 1, subfamily F, member 1 0.023378 1.201179 
2514441 PPIG peptidylprolyl isomerase G (cyclophilin G) 0.025828 1.218231 
2783473 C4orf3 chromosome 4 open reading frame 3 0.029463 1.409258 
2418339 LRRIQ3 leucine-rich repeats and IQ motif containing 3 0.031467 1.201805 
2766262 TLR6 toll-like receptor 6 0.033284 1.285438 
2620150 ZNF660|ZNF197 zinc finger protein 660 | zinc finger protein 197 0.033869 1.284663 
2383524 ZNF678 zinc finger protein 678 0.045883 1.212393 
3625674 RFX7 regulatory factor X, 7 0.049481 1.23359 
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Table 3.11 List of top 20 out of 79 genes downregulated by Sphingomab at 2 hours post treatment   
Transcript 
ID 
Gene symbol Gene description p value Fold 
change 
2902609 C6orf25 chromosome 6 open reading frame 25 3.28E-04 1.224931 
2445876 NCRNA00083 non-protein coding RNA 83 0.001321 1.212823 
3596263 FOXB1 forkhead box B1 0.001523 1.213903 
2472054  GDF7 growth differentiation factor 7   0.001704 1.294686 
3349948 REXO2 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 0.002165 1.284174 
3673880 C16orf81 chromosome 16 open reading frame 81 0.002187 1.255238 
2532626 C2orf82 chromosome 2 open reading frame 82 0.003264 1.315103 
3339722 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 0.004045 1.20298 
2948810 PSORS1C2 psoriasis susceptibility 1 candidate 2 0.004198 1.225966 
2641479 GP9 glycoprotein IX (platelet) 0.004377 1.22743 
3272706 VENTX VENT homeobox homolog (Xenopus laevis) 0.004462 1.263463 
3744127 HES7 hairy and enhancer of split 7 (Drosophila) 0.004808 1.245594 
3745287 MYH1|MYH2|MYH8 myosin, heavy chain 1, skeletal muscle, adult | myosin, heavy chain 2, skeletal 
muscle, adult | myosin, heavy chain 8, skeletal muscle, perinatal 
0.005257 1.228423 
3023964 CPA1 carboxypeptidase A1 (pancreatic) 0.00529 1.205926 
3474418 PXN paxillin 0.005522 1.280956 
3380126 FGF19 fibroblast growth factor 19 0.005533 1.232402 
3579114 BCL11B B-cell CLL/lymphoma 11B (zinc finger protein) 0.006832 1.260329 
3404823 PRH2 proline-rich protein HaeIII subfamily 2 0.007001 1.22648 
3204285 CCL19 chemokine (C-C motif) ligand 19 0.007718 1.253403 
3273110 DUX4L4|DUX4L7|DUX4L2 
|DUX4L3|DUX4L5|DUX4L6 
double homeobox 4 like 4 | double homeobox 4 like 7 | double homeobox 4 like 2 | 
double homeobox 4 like 3 | double homeobox 4 like 5 | double homeobox 4 like 6 
0.008839 1.339572 
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Table 3.12 List of all 23 genes upregulated by Sphingomab at 12 hours post treatment  
Transcript 
ID 
Gene symbol Gene description p value Fold change 
3951190 C2orf27A|DUXAP10|FLJ39632 chromosome 2 open reading frame 27A | double homeobox A pseudogene 10 | hypothetical 
LOC642477 
0.006769 1.231519 
3929664 TMEM50B transmembrane protein 50B 0.037376 1.202532 
3873086 DEFB129 defensin, beta 129 0.005991 1.348438 
3843399 ZNF134|ZNF211 zinc finger protein 134 | zinc finger protein 211 0.029627 1.287905 
3826504 ZNF431|ZNF714 zinc finger protein 431 | zinc finger protein 714 0.028561 1.265593 
3811086 PIGN phosphatidylinositol glycan anchor biosynthesis, class N 0.044249 1.237523 
3764872 PTRH2 peptidyl-tRNA hydrolase 2 0.035615 1.231048 
3760268 ARL17A|ARL17B|LOC100294341 ADP-ribosylation factor-like 17A | ADP-ribosylation factor-like 17B | ADP-ribosylation factor-
like protein 17-like 
0.020879 1.236461 
3727510 STXBP4 syntaxin binding protein 4 0.0138 1.296312 
3722286 RUNDC1 RUN domain containing 1 0.046301 1.458222 
3666282 ZFP90 zinc finger protein 90 homolog (mouse) 0.045151 1.224183 
3561110 RALGAPA1 Ral GTPase activating protein, alpha subunit 1 (catalytic) 0.047613 1.217444 
3547375 GPR65 G protein-coupled receptor 65 0.040823 1.281755 
3526425 PCID2 PCI domain containing 2 0.030258 1.295463 
3489212 FNDC3A fibronectin type III domain containing 3A 0.038012 1.221823 
3425134 TMTC3 transmembrane and tetratricopeptide repeat containing 3 0.041587 1.279973 
3392996 SIK3 SIK family kinase 3 0.019756 1.309694 
3382596 PRKRIR protein-kinase, interferon-inducible double stranded RNA dependent inhibitor, repressor of (P58 
repressor) 
0.041219 1.301903 
3352485 TMEM136 transmembrane protein 136 0.04574 1.220377 
3249043 REEP3 receptor accessory protein 3 0.02051 1.250174 
3182984 NIPSNAP3B|LOC286367 nipsnap homolog 3B (C. elegans) | FP944 0.047097 1.211697 
3150663 TAF2 TAF2 RNA polymerase II 0.048844 1.237538 
3136178 PLAG1 pleiomorphic adenoma gene 1 1.86E-05 1.240392 
2349848 PRMT6 protein arginine methyltransferase 6 0.011779 1.232427 
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Table 3.13 List of top 20 out of 207 genes downregulated by Sphingomab at 12 hours post treatment 
Transcript 
ID 
Gene symbol Gene description p value Fold 
change 
3002183 POM121L12 POM121 membrane glycoprotein-like 12 1.42E-05 1.25003 
4032271 GOLGA2P2Y| 
GOLGA2P3Y|CSPG4P5 
golgin A2 pseudogene 2, Y-linked | golgin A2 pseudogene 3, Y-linked | chondroitin 
sulfate proteoglycan 4 pseudogene 5 
1.27E-04 1.202986 
3726537 EPN3 epsin 3 1.33E-04 1.21147 
3259959 C10orf62 chromosome 10 open reading frame 62 6.05E-04 1.253822 
3332964 C11orf66 chromosome 11 open reading frame 66 6.97E-04 1.277711 
3704928 SPATA2L spermatogenesis associated 2-like 0.001033 1.2394 
4010183 SPIN3 spindlin family, member 3 0.001286 1.245429 
2576608 C2orf27B|C2orf27A|C9orf172 chromosome 2 open reading frame 27B | chromosome 2 open reading frame 27A | 
chromosome 9 open reading frame 172 
0.001336 1.209652 
3233182 NET1 neuroepithelial cell transforming 1 0.001428 1.421568 
2352338 FAM19A3 family with sequence similarity 19 (chemokine (C-C motif)-like), member A3 0.001693 1.213123 
3706113 HIC1 hypermethylated in cancer 1 0.001701 1.202551 
3662093 MT3 metallothionein 3 0.001709 1.330172 
3934573 KRTAP10-1|KRTAP10-11 keratin associated protein 10-1 | keratin associated protein 10-11 0.002112 1.214363 
3858993 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha 0.002587 1.25142 
3227070 PTGES prostaglandin E synthase 0.002637 1.201343 
3713278 FLJ35934  0.002705 1.257513 
3031399 ZNF775|LOC728743 zinc finger protein 775 | similar to GLI-Kruppel family member HKR1 0.002811 1.231678 
3707950 FAM64A family with sequence similarity 64, member A 0.002832 1.297886 
3483046 GSX1 GS homeobox 1 0.003022 1.235101 
3590275 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 0.003309513 1.2028043 
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Table 3.14 List of B cell receptor signaling genes expressed after treatment with 
Sphingomab 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
Transcript ID Gene symbol Expression p value Fold change 
2420808 BCL10 up 6.07E-04 1.0468156 
3227696 RAPGEF1 up 0.033392854 1.0243601 
3666033 NFATC3 up 0.005136701 1.0350204 
3790259 MALT1 up 0.017520413 1.0423235 
2436985 SHC1 down 0.026881663 -1.0422614 
2438207 MEF2D down 0.016683191 -1.0548377 
2505529 PTPN18 down 0.009659263 -1.0770031 
2881300 CAMK2A down 0.001493649 -1.064041 
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Table 3.15 Summary of the roles of B cell receptor signaling genes 
Gene Summary 
BCL10 Translocates in mucosa-associated lymphoid tissue (MALT) lymphoma and 
is an apoptosis-associated gene via the activation of NF-κB signaling (Zhu 
et al., 2013). 
RAPGEF1 Binds to GTP to regulate proliferation, differentiation and apoptosis. 
Hypomethylation is frequent in gastrointestinal and gynecological cancers 
(Samuelsson et al., 2011). 
NFATC3 Targets of immune receptor signals in B lymphocytes leading to a rapid rise 
of intracellular calcium and controlling proliferation and survival (Rudolph 
et al., 2014).  
MALT1 Involved in the pathogenesis of mucosa-associated lymphoid tissue 
(MALT) lymphoma via the activation of NF-κB. Has anti-apoptotic effect 
and regulates the subcellular location of BCL10 (Hosokawa 2005). 
SHC1 Regulates the transfer of mitogenic signals in cells, to participate in p53-
dependent apoptosis under oxidative stress, regulates lifespan, and drug 
resistance in mammalian cells (Kashkin et al., 2013). 
MEF2D Mediates response to mitogenic signals and survival of neurons and T-
lymphocytes and contributes to the pathogenesis of acute lymphoblastic 
lymphoma (ALL) (Prima et al., 2005). 
PTPN18 Regulates cell growth, differentiation, mitotic cycle, and oncogenic 
transformation. Involved in leukaemogenesis via bcr-abl signaling (Rubhi et 
al., 2011). 
CAMK2A Involved in cell survival, apoptosis, cytoskeletal re-organization and 
learning and memory. Plays an important role in the growth of 
osteosarcoma (Yuan et al., 2007). 
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3.8  Discussion 
I found that SPHK1 was overexpressed in HRS cells in 27/61 (44 %) of HL cases. Bayerl et 
al reported that SPHK1 protein and mRNA was significantly higher in NHL as compared to 
lymph nodes with reactive hyperplasia (Bayerl et al. 2008). Increases in SPHK1 protein and 
mRNA have also been reported in several human malignancies such as breast, brain, colon, 
ovary, stomach, kidney, uterus, prostate and small intestine (French et al., 2003a). High levels 
of SPHK1 is associated with increased proliferation and resistance to chemotherapy. 
Preliminary studies in situ and in animal models indicate that SPHK1 inhibitors prevent 
cancer cell proliferation and tumour growth. As pro-mitogenic S1P formation is catalysed by 
SPHK1, blockade of SPHK1 is thought to be a promising target in cancer treatment (Ader et 
al., 2009). Importantly, down-regulation of SPHK1 leads to increased cytotoxicity of 
chemotherapeutic drugs and chemosensitivity restoration of multidrug resistance HL60 AML 
cells (Bonhoure et al., 2006). 
S1PR1 was commonly expressed in HRS cells in 48/61 (79%) of cases and S1PR1 expression 
was significantly associated with SPHK1 expression. Significantly enhanced expression of 
S1PR1 was observed in HRS cells and the staining pattern exhibited strong association with 
S1PR1 mRNA expression by RT Q-PCR. Amongst all types of lymphomas, S1PR1 
expression has only been reported in classical mantle cell lymphoma. A study by Nishimura 
et al showed that S1PR1 was expressed in all cases of mantle cell lymphoma suggesting that 
S1PR1 could be useful in reaching a histological diagnosis of mantle cell lymphoma 
(Nishimura et al., 2010).  
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S1PR3 was strongly expressed in all 61 HL cases, however the mRNA levels were only 
increased in L428 cell lines. This discrepancy could be explained that the protein and mRNA 
expression was not a case by case basis. There are novel S1PR3 antagonists, and inhibition of 
these receptors with these compound may inhibit cancer cell growth. 
In a previous study, ABCC1 was found to be expressed in 20% of HL patients and was 
associated with failure to respond to chemotherapy (Greaves et al. 2012). In this study, I 
found that ABCC1 protein was expressed in 78% of HL cases exhibiting moderate to strong 
staining pattern. This difference in the percentage of cases expressing ABCC1 might be 
attributed to the different antibodies used.  
ATX was the only lipid signalling molecule which showed significant association with OS. 
Baumforth et al have shown that high ATX expression in HRS cells was found in EBV 
positive HL cases and that ATX upregulation led to increased growth and survival of HL 
cells. Downregulation of ATX led to reduced cell growth and viability (Baumforth et al. 
2008). These findings suggest that ATX could a promising target for therapeutic intervention. 
Gene expression microarrays have emerged as powerful tool in molecular biology and offer 
high throughput analysis of gene expression on a large genomic scale. The initial microarray 
analysis was using SAM analysis (data not shown here) which found a different list of genes. 
Using SAM analysis, only one B cell receptor gene named SOS1 was differentially 
expressed. Therefore I have re-analysed this array using GeneSpring software as shown in 
this chapter. GeneSpring analysis showed that eight B cell receptor genes were expressed at 
after treatment with Sphingomab. Sphingomab seemed to upregulate the expression of 
BCL10, RAPGEF1, NFATC3 and MALT1 which suggests that Sphingomab could possibly 
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restore the B cell phenotype in HL. However the low fold change observed, could be 
contributed by technical errors. There are many steps which could lead to errors in 
microarray experiments, from sample preparation to data analysis. The quality of RNA is of 
utmost importance. DNA contamination, RNA degradation and traces of phenols could 
contribute to poor labelling and quality of signals. During data visualization and 
interpretation, raw images are captured using a laser imaging system, analysed and filtered. 
Statistical methods are then applied for interpretation.  
BCL10 was identified by its translocation in a case of MALT lymphoma. It forms a complex 
with MALT1 gene and activates NF-κB signaling. BCL10 is mutated in multiple types of 
malignant tumour cell lines including colon cancer, mesothelioma, germ cell tumour, 
follicular lymphoma, Sezary syndrome and T-ALL ( Willis et al., 1999). MALT1 is mucosa 
associated lymphoid tissue lymphoma translocation gene 1 and is involved in the nuclear 
export of BCL10. Chromosomal aberration of MALT1 is recurrent in low-grade mucosa-
associated lymphoid tissue (MALT lymphoma) which is a slow growing indolent lymphoma. 
RAPGEF1 is Rap guanine nucleotide exchange factor 1 which belongs to the adaptor-type 
Src homology (SH)2-containing molecules. It is involved in signal transmission from the cell 
surface to the nucleus (Samuelsson et al., 2011). NFATC3 is a member of the nuclear factors 
of activated T cells DNA-binding transcription complex. It regulates gene expression in T 
cells and immature thymocytes (Rudolph et al., 2014). 
Considering that this array is working, it could shed some light on the molecular mechanism 
of HL. Perhaps the four B cell receptor genes upregulated by Sphingomab could be evaluated 
further to determine their significance in the pathogenesis of HL.   
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CHAPTER 4 
ANALYSIS OF EBV STATUS AND EXPRESSION OF LIPID SIGNALLING 
MOLECULES IN A COHORT OF DIFFUSE LARGE B CELL LYMPHOMAS 
FROM THE UNITED KINGDOM 
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4.1 Introduction 
In 2007, Park et al studied the impact of EBV status on the clinical outcome of 380 DLBCL 
patients aged ≥ 18 years in Korea. 34 cases (9.0%) were identified to be EBV+. In this series, 
EBV
+
 status was significantly associated with age > 60 years, more advanced stage, more 
than one extranodal involvement, higher IPI, presence of B symptoms, poorer outcome to 
clinical treatment and poorer overall survival and progression-free survival (Park et al. 2007). 
The non-GCB DLBCL showed poorer overall survival compared to the GCB DLBCL. In 
2008, Cho et al. identified 29/387 (7.5%) EBV
+
 DLBCL among Korean patients. A study in 
Peru reported a prevalence of 14.1% of EBV
+
 DLBCL-E. These cases were associated with 
non GCB subtype, advanced stage, high IPI score and short overall survival (Beltran et al. 
2011). 
In contrast to a relatively high incidence of EBV
+
 DLBCL in the Asian countries, Hoeller et 
al reported an EBV positivity in only 3.1% of EBV
+
 DLBCL of the elderly (EBV
+
 DLBCL-
E) in European populations (Hoeller et al., 2010). The majority of these cases showed EBV 
latency II (62.5%) and latency III (25.0%). A markedly worse survival rate of 5.5 months was 
observed for latency III patients with diseases, compared to 103 months in other DLBCL 
patients aged > 50 years. A recent Turkish study showed a prevalence of 5.3% for EBV
+
 
DLBCL and 3.5% for EBV
+
 DLBCL-E (Uner et al. 2011). Little is known about the 
incidence and the clinicopathological characteristics of EBV
+
 DLBCL in the UK. The 
prognostic implications of EBV in DLBCL has also not been widely studied in this 
population. 
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4.2  Aim of study 
The aims of this study were to:  
 i)        estimate the incidence of EBV
+
 DLBCL including EBV
+
 DLBCL-E in the UK.   
i) determine the clinicopathological characteristics of EBV+ DLBCL and EBV+ 
DLBCL-E in these populations. 
ii) determine the impact of EBV on the clinical outcome of DLBCL patients 
iii) classify the EBV+ tumours according to their pattern of EBV gene expression. 
iv)      determine the expression and prognostic significance of lipid signalling molecules 
(SPHK1, S1PR1, ABCC1 and ATX) in EBV
+
 DLBCL compared to the EBV
-
 
DLBCL. 
  
4.3  Case selection 
A list of DLBCL cases was obtained using an electronic search of histopathological reports 
from the Pathology Department of the Queen Elizabeth Hospital, Birmingham searching on 
‘High grade lymphomas’ and ‘DLBCL’ over a 15 year period from 1996 to 2010. Reports 
from 550 patients were retrieved. Sufficient paraffin material was available in 300/550 cases. 
All 300 cases were subjected to EBER in situ hybridization to detect EBV according to the 
methods described in section 2.3. Known EBV
+
 HL cases were included as positive controls. 
Cases were recorded as ‘EBV-positive’ if > 10% of tumour cells were positive. Cases in 
which non-malignant cells were EBER-positive were recorded as negative. 
Immunohistochemistry for LMP1 and EBNA2 were performed to classify cases into one of 
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three EBV latency types. EBV
+
 DLBCL-E were selected using the following criteria; age > 
50 years, no history of immunosuppression including immunodeficiency, transplantation, 
autoimmune disease or prior lymphoma. All cases were also stained for CD10, BCL6 and 
MUM1 for subtyping. Based on the Hans algorithm, cases were recorded as the GCB subtype 
if CD10 alone was positive or if both CD10 and BCL6 were positive. If both CD10 and 
BCL6 were negative, cases were categorised as the Non-GCB subtype. If BCL6 was positive 
and CD10 negative, MUM1 expression was used; if MUM1 was negative, the case was 
assigned to the GCB group and if MUM1 was positive, the case was categorised into the 
Non-GCB subtype. Immunohistochemistry was also performed for SPHK1, S1PR1, ABCC1 
and ATX.  
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Figure 4.1: Flow chart for the characterization of DLBCL patients. 
550 FFPE DLBCL cases from 1996-2010 
300 cases with available tissue 
tissue 
Characterization of EBV 
latency pattern 
Expression of S1P signaling 
molecules by IHC 
SPHK1, S1PR1, ABCC1, 
ATX 
EBER ish, LMP1, EBNA2 Subtyping of 
DLBCL 
CD10, BCL6, 
MUM1 
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4.4  Analysis of clinical data 
Clinical data for each patient was retrieved, noting the age, gender, site of specimen, disease 
subtype, number of extranodal sites involved, ECOG performance status, presence or absence 
of B symptoms, LDH level, Ann Arbor stage of disease, type of treatment, response to 
treatment, survival (dead or alive) and survival time. Based on the negative prognostic factors 
at the time of diagnosis ie age > 60 years, stage III/IV disease, elevated LDH level, ECOG 
performance status ≥2 and more than one extranodal involvement, patients were categorised 
into four outcome groups (low, low to intermediate , high to intermediate and high risk 
groups) in standard IPI and 3 outcome groups (very good, good and poor) in R-IPI. The 
median follow up time was 26 months (range 0-193 months). Overall survival time was 
measured from the date of initial diagnosis to the date of death or until date of last known 
follow up. Event free survival time was calculated from the date of diagnosis to the date of 
first relapse after treatment.   
 
4.5  Statistical methods 
Statistical analysis was performed on all patient data to ascertain which variables influenced 
the outcomes in terms of survival. Cox proportional analysis and logistic regression analysis 
were used to identify factors which influenced survival. Chi square (2) test was used to 
evaluate the association between categorical variables. Univariate analysis: Survival curves 
were calculated using the Kaplan-Meier method. Patients who were alive at last contact were 
censored in the overall survival analysis. Differences between the curves were analysed using 
the log-rank test. Multivariate analysis: A Cox stepwise proportional hazard model was used 
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to identify any factors that might be of independent significance in influencing survival. 
Variables included in the maximum models were age, gender, histological subtype (GCB or 
non-GCB), clinical stage of disease, type of therapy, presence or absence of B symptoms, 
LDH level, ECOG performance status, number of extranodal sites involved, standard and 
revised IPI scores. Statistical Package for the Social Sciences 21.0 (SPSS 21.0) was used for 
all statistical analysis. 
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4.6  Results 
4.6.1  Clinical characteristics of 300 DLBCL patients 
300 patients with DLBCL were analysed including 171 (57.0%) with nodal disease and 123 
(41.0%) with extranodal disease (22 gastrointestinal, 15 ear/nose/throat/oral cavity, 16 central 
nervous system, 6 genital, 11 mediastinal, and 19 skin, 3 breast, 7 thyroid, 4 bladder, 2 ocular 
adnexa, etc). 6 patients (2.0%) had both nodal and extranodal involvement. 
171 (57.0%) patients were male and 129 (43.0%) were female. The mean age of male patients 
was 63 years (median: 65 years; range: 25 – 96 years) and the mean age for female patients 
was 68 years (median: 71 years; range: 24 - 93 years). 
254 patients (8 EBV
+
 and 246 EBV
-
) were aged ≥ 50 years. 67 (22.3%) patients presented 
with stage 1 disease, 97 (32.3%) with stage 2, 65 (21.7%) with stage 3, and 71 (23.7%) with 
stage 4. International Prognostic Index data were available for 298 patients; 33 (11.0%) 
presented with an index of 0, 94 (31.5%) with an index of 1, 92 (30.4%) with an index of 2, 
63 (21.1%) with an index of 3,14 (4.7%) and 2 (0.7%) with an index of 5.  
Most patients received chemotherapy with R-CHOP (54.9%) and those who received 
combination of chemotherapy and radiotherapy was 21.9% of total patients. Radiotherapy 
alone was given in 2.4% of cases and 16.0% of patients received palliative treatment. 
Complete remission was achieved in 66.7% of cases, 9.0% achieved partial remission, 15.7% 
had progressive disease and 4.7% had stable disease (Table 4.2). The mean follow-up time 
was 43 months (median: 27 months; range: 0 - 193 months). Of the 157 patients who died, 
the cause of death was known in 124 patients, of which 57 died of disease, 4 died of 
 Chapter 4  Results    
135 
 
complications of fungal infection and septicaemia and 63 died of unrelated causes including 
secondary malignancies and cardiovascular diseases. The median survival for the patients 
who died was 7 months. 141 (47.3%) patients were alive at last contact. The clinical 
characteristics of all DLBCL patients are summarised in Table 4.1.
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Table 4.1: Clinical characteristics of DLBCL patients  
Clinical characteristic All patients 
Sex   
    Male 171 (57.0) 
    Female 129 (43.0) 
Age group  
    < 60 years 99 (33.0%) 
    ≥ 60 years 201 (67.0%) 
ECOG PS   
     ≤1 66 (75.0%) 
     >1 22 (25.0%) 
 B-symptoms  
     Present 155 (51.7%) 
     Absent 145 (48.3%) 
LDH level (n=297)  
     Low (≤ 450 U/I) 153(51.5%) 
     High (> 450 U/I) 144(48.5%) 
Ann Arbor stage  
     1/II 164 (54.7%) 
     III/IV 136 (45.3%) 
Subtype  
    GCB 132 (44.0%) 
    Non GCB 168 (56.0%) 
Site of involvement  
     Nodal  171 (57.0%) 
     Extranodal 123 (41.0%) 
     Both 6 (2.0%) 
Extranodal involvement 
    ≤ 1 site 270 (90.6%) 
    > 1 site        29 (9.4%) 
Standard IPI (n=298)  
    Low  127 (42.6%) 
    Low to intermediate 92 (30.9%) 
    Intermediate to high 63 (21.1%) 
    High 16 (5.4%) 
Revised IPI  (n=298)  
    Very good  31 (10.3%) 
    Good 188 (62.7%) 
    Poor 81 (27.0%) 
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Table 4.2: Management, treatment response and clinical outcome of 300 DLBCL 
patients   
 Clinical characteristic All patients   
Management (n=288)  
    Chemotherapy 158 (54.9%) 
    Radiotherapy 7 (2.4%) 
    Chemotherapy &  radiotherapy 63 (21.9%) 
    Surgery 14 (4.9%) 
    Palliative 46 (16.0%) 
  
Treatment response (n=288)  
    Complete remission 200 (66.7%) 
    Partial remission 27 (9.0%) 
    Stable disease 14 (4.7%) 
    Progressive disease 47(15.7%) 
 
Clinical outcome (n=124) 
 
    Died of disease 57 (46.0%) 
    Died of complications   4 (3.2%) 
    Died of unrelated cause 63 (50.8%) 
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            A        
               B      
Figure 4.2: Histological findings of an EBV+ DLBCL. A) centroblastic morphology (x 
400) B) angioinvasion (x 400).   
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                A      
                B      
Figure 4.3: EBER positivity in EBV
+
 DLBCL A) Nuclear positivity of EBER (x 200), B) 
Nuclear positivity of EBER (x400). 
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                      A     
                      B     
Figure 4.4 A) LMP1 positivity in EBV
+
 DLBCL (x 400) B) EBNA2 positivity in EBV
+
 
DLBCL (x 400). 
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4.7  Clinical relevance of CD10, BCL6 and MUM1 expression in DLBCL 
4.7.1  Expression of CD10, BCL6 and MUM1 in DLBCL 
DLBCL can be stratified into GCB and non-GCB subtype based on the immunohistochemical 
profile of CD10, BCL6 and MUM1. Subgrouping of DLBCL patients into these two groups 
allows prediction of the clinical outcome of patients. In this section, I used 
immunohistochemistry to separate DLBCL into GCB and non-GCB subtypes based on their 
expression of CD10, BCL6 and MUM1. Figure 4.5 showed the proportion of patients whose 
tumours expressed CD10, BCL6 and MUM1. 
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Figure 4.5: Expression of CD10, BCL6 and MUM1 in all DLBCL patients. 
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4.7.2  Co-expression of CD10, BCL6 and MUM1 in DLBCL 
Co-expression of CD10 and BCL6 was observed in 52 (44.1%) cases. MUM1 expression 
showed a significant inverse association with the expression of CD10 and BCL6 (p < 0.001); 
90% of tumours expressing MUM1 were negative for CD10 and 81% of tumours expressing 
CD10 were negative for MUM1 (Table 4.3). The expression of MUM1 and BCL6 also 
showed an inverse association; 52.9% of tumours expressing BCL6 were negative for MUM1 
and 69.8% of tumours expressing MUM1 were negative for BCL6 (Table 4.3). Table 4.4 
shows that all EBV
+
 DLBCL patients were CD10 negative (p=0.002) and MUM1 positive 
(p=0.002). Patients whose tumours expressed BCL6 had longer overall survival (p=0.001) 
and event free survival (p=0.002)(Figure 4.6). Patients whose tumours expressed MUM1 had 
shorter event free survival rate (p=0.05)(Figure 4.7). CD10 expression showed no significant 
association with overall and event free survival. 
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Table 4.3: Co- expression of markers in DLBCL 
Markers Associated markers ᵡ2 
value 
p value 
 BCL6+ BCL6-   
CD10+ 52 (44.1%) 64 (35.2%) 2.393 0.122
#
 
CD10- 66 (55.9%) 118 (64.8%)   
 MUM1+ MUM1-   
CD10+ 18 (10.1%) 98 (81.0%) 153.85 < 0.01
#
 
CD10- 161 (89.9%) 23 (19.0%)   
 MUM1+ MUM1-   
BCL6+ 54 (30.2%) 64 (52.9%) 15.62 < 0.01
#
 
BCL6- 125 (69.8%) 57 (47.1%)   
#
 chi square test 
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Table 4.4: Expression of CD10, BCL6 and MUM1 by EBV positivity 
Markers EBV+ EBV- x2 value p value 
CD10
+
 0 (0.0%) 116 (40.6%) 9.258 0.002
#
 
CD10
-
 14 (100.0%) 170 (59.4%)   
BCL6
+
 6 (42.9%) 112 (39.2%) 0.076 0.782
#
 
BCL6
-
 8 (57.1%) 174 (60.8%)   
MUM1+ 14 (100.0%) 165 (57.7%) 9.927 0.002
#
 
MUM1- 0 (0.0%) 121 (42.3%)   
#
 chi square test 
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Figure 4.6: Kaplan Meier overall and event free survival curves for DLBCL patients 
expressing CD10.   
p=0.174 
p=0.173 
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Figure 4.7: The Kaplan Meier overall and event free survival curves for DLBCL 
patients expressing BCL6.   
p=0.001 
p=0.002 
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Figure 4.8: The Kaplan Meier overall and event free survival curves for DLBCL 
patients expressing MUM1.   
p=0.073 
p=0.050 
 Chapter 4  Results    
148 
 
4.7.3 Association of GCB and non-GCB subtypes with clinicopathological 
characteristics 
Of the 300 tumours, 132 (44%) were categorized into GCB and 168 (56%) were non-GCB 
subtype. Table 4.5 illustrates the clinical characteristics of DLBCL patients separated into 
GCB and non-GCB subtypes. None of the clinical variables showed significant association 
with any of the subtypes. The median survival time for patients with the GCB subtype was 
6.5 years and 3.4 years for the non-GCB subtype. Log rank test showed that there was no 
significant difference in the overall survival of patients with GCB and non-GCB subtypes (p 
=0.092), however the non GCB subtype showed a shorter event free survival (p-
0.056)(Figure 4.12).  
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Table 4.5: Clinical characteristics of DLBCL patients by GCB and Non GCB subtypes.   
Clinical characteristic 
All patients 
(n=300) GCB Non-GCB ᵡ2 value 
p 
value 
Sex  
         Male 171 (57.0) 75 (56.8%) 96 (57.1%) 0.003 0.955
#
 
    Female 129 (43.0) 57 (43.2%) 72 (42.9%) 
  Age group 
         < 60 years 99 (33.0%) 46 (34.8%) 53 (31.5%) 0.364 0.546
#
 
    ≥ 60 years 201 (67.0%) 86 (65.2%) 115 (68.5%) 
  ECOG PS (n=299) 
          <2 66 (75.0%) 120 (91.6%) 156 (92.9%) 0.163 0.686
#
 
     ≥2 22 (25.0%) 11 (8.4%) 12 (7.1%) 
   B-symptoms 
          Present 155 (51.7%) 63 (47.7%) 92 (54.8%) 1.465 0.226
#
 
     Absent 145 (48.3%) 69 (52.3%) 76 (45.2%) 
  LDH level (n=297) 
          Low (≤ 450 U/I) 153 (51.5%) 66 (50.8%) 87 (51.8%) 0.03 0.862# 
     High (> 450 U/I) 145 (48.5%) 64 (49.2%) 81 (48.2%) 
  Ann Arbor stage 
          1/II 164 (54.7%) 72 (54.5%) 92 (54.8%) 0.001 0.970
#
 
     III/IV 136 (45.3%) 60 (45.5%) 76 (45.2%) 
  Site of involvement 
          Nodal  171 (57.0%) 76 (57.6%) 95 (56.5%) 1.413 0.493
#
 
     Extranodal 123 (41.0%) 52 (39.4%) 71 (42.3%) 
       Both 6 (2.0%) 4 (3.0%) 2 (1.2%) 
  Extranodal involvement  
(n=299) 
         ≤ 1 site 270 (90.3%) 114 (87.0%) 155 (92.3%) 2.238 0.135# 
    > 1 site        29 (9.7%) 17 (13.0%) 13 (7.7%) 
  Standard IPI (n=298) 
         Low risk 127 (42.6%) 74 (44.0%) 53 (40.8%) 0.954 0.812
#
 
    Low to intermediate 92 (30.9%) 49 (29.2%) 43 (33.1%) 
      Intermediate to high 63 (21.1%) 37 (22.0%) 26 (20.0%) 
      High risk 16 (5.4%) 8 (4.8%) 8 (6.2%) 
  Revised IPI (n=298) 
         Very good  33 (11.1%) 15 (11.5%) 18 (10.7%) 0.056 0.972
#
 
    Good 186 (62.4%) 81(62.3%) 105(62.5%) 
       Poor 79 (26.5%) 34 (26.2%) 45(26.8%) 
  Outcome (n=298) 
          Dead 157 (52.7%) 64 (49.2%) 93 (55.4%) 2.238 0.294
#
 
     Alive 141 (47.3%) 66 (50.8%) 75 (44.6%)     
  # chi square test, * Fisher’s exact test 
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4.8  Characterization of EBV
+
 DLBCL patients 
14/300 (4.7%) of DLBCL patients were recorded as EBV positive. The mean age for the 
EBV
+
 DLBCL patients was 57 years (median 63 years, range: 27-82 years) as compared to 
65 years (median 66, range: 24-96 years) in EBV
-
 DLBCL patients. Four EBV
+ 
patients 
(29%) were aged less than 50 years. The clinical characteristics of both groups of DLBCL are 
shown in Table 4.6. I found that a significantly higher proportion of EBV
+
 DLBCL patients 
had B symptoms than did the EBV
-
 patients (p=0.009). Furthermore,I found that all of the 
EBV
+
 patients were of non-GCB subtype which was compared to 53.8% of EBV
-
 patients 
(p=0.001)(Table 4.6).  
2 (22.2%) of EBV
+
 patients had an ECOG performance status of >1. LDH levels were 
elevated in 7 (50.0%) patients and eight (57.1%) patients had advanced stage of disease. IPI 
scores of > 2 were seen in 4 (29.5%) cases. Four (28.6%) patients showed extranodal 
presentation and nine (64.3%) patients presented with nodal disease, one (7.1%) had both 
nodal and extranodal disease (Table 4.6). The sites for extranodal involvement were skin, 
colon, brain and posterior pharyngeal wall.  
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Table 4.6: Clinical characteristics of DLBCL patients by EBV status 
Clinical characteristic All patients 
(n=300) 
EBV+ DLBCL 
(n=14) 
EBV- DLBCL 
(n=286) 
p value 
Sex      
    Male 171 (57.0) 6 (42.8%) 164 (57.3%) 0.588
#
 
    Female 129 (43.0) 8 (57.1%) 122 (42.7%)  
Age     
    Mean 64.7 57 65 - 
    Median 66 63 66  
    Range 24-96 27-82 24-96  
Age group     
    < 60 years 99 (33.0%) 6 (42.9%) 93 (32.5%) 0.402* 
    ≥ 60 years 201 (67.0%) 8 (57.1%) 193 (67.5%)  
ECOG PS      
     <2 66 (22.0%) 7 (77.8%) 59 (74.7%) 1.000* 
     ≥2 22 (7.3%) 2 (22.2%) 20 (25.3%)  
 B-symptoms     
     Present 155 (51.7%) 12 (85.7%) 143 (50.0%) 0.009
#
 
     Absent 145 (48.3%) 2 (14.3%) 143 (50.0%)  
LDH level (n=297)     
     Low (≤ 450 U/I) 153 7 (50.0%) 146 (51.6%) 0.907# 
     High (> 450 U/I) 144 7 (50.0%) 137 (48.4%)  
Ann Arbor stage     
     1/II 164 (54.7%) 6 (42.9%) 158 (55.2%) 0.363
#
 
     III/IV 136 (45.3%) 8 (57.1%) 128 (44.8%)  
Subtype     
    GCB 132 (44.0%) 0 (0.0%) 132 (46.2%) 0.001* 
    Non GCB 168 (56.0%) 14 (100.0%) 154 (53.8%)  
Site of involvement     
     Nodal  171 (57.0%) 9 (64.3%) 162 (56.6%) 0.268
#
 
     Extranodal 123 (41.0%) 4 (28.6%) 119 (41.6%)  
     Both 6 (2.0%) 1 (7.1%) 5 (1.7%)  
Extranodal involvement (n=299)     
    ≤ 1 site 270 (90.6%) 12 (85.7%) 258 (90.5%) 0.553* 
    > 1 site        29 (9.4%) 2 (14.3%) 27 (9.5%)  
Standard IPI (n=298)     
    Low  127 (42.6%) 5 (35.7%) 122 (42.3%) 1.000* 
    Low to intermediate 92 (30.9%) 5 (35.7%) 87 (30.8%)  
    Intermediate to high 
    High 
Revised IPI (n=298) 
    Very good                                                                                     
    Good 
    Poor 
63 (21.1%) 
16 (5.4%) 
 
31 (10.3%) 
188 (62.7%) 
81 (27.0%) 
3 (21.4%) 
1 (7.1%) 
 
1 (7.1%) 
9 (64.3%) 
4 (28.6%) 
60 (21.3%) 
15 (5.3%) 
 
30 (10.5%) 
179 (62.6%) 
77 (26.9%) 
 
 
 
1.000* 
 
  
#
 chi square test, * Fisher’s exact test 
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4.8.1  Histological and phenotypic features of EBV+ DLBCL 
In nine nodal EBV
+ 
DLBCL cases, the normal lymph node architecture was completely 
effaced by diffuse or polymorphic proliferation of malignant large pleomorphic lymphoid 
cells. The extranodal cases also showed diffuse permeation by malignant cells. Extensive 
necrosis was observed in 10/14 (71.4%) cases. The malignant cells were surrounded by 
reactive cells namely lymphocytes, plasma cells and histiocytes. The malignant cells exhibit 
strong CD20, CD79α and CD30 expression. CD15 was negative. HRS-like cells with distinct 
nucleoli were present in six (42.8%) cases. Three (21.4%) cases showed angioinvasion. Ten 
cases (71.4%) showed morphology of conventional DLBCL of either the centroblastic or the 
immunoblastic subtype. Three cases (21.4%) were classified as plasmablastic DLBCL, 
comprising a uniform population of large transformed cells. In one case (7.1%), the large B 
cells were widely scattered, resembling T-cell/histiocyte-rich B-cell lymphoma. The 
immunophenotypic characteristics of 14 EBV
+ 
DLBCL cases are shown in Table 5.7-5.8. All 
the EBV
+ 
DLBCL cases were reviewed by Dr Stefan Dojcinov, a consultant pathologist from 
the University Hospital of Wales, Cardiff, UK. 
 
4.8.2  EBV latency pattern of EBV+ DLBCL 
Eight (57.1%) patients showed EBV latency III pattern (EBER+,LMP1+, EBNA2+), 2 
(14.3%) latency II (EBER+,LMP1+, EBNA2-) and 4 (28.6%) latency 1 (EBER+,LMP1-, 
EBNA2-) (Table 4.7).
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Table 4.7: EBV latency pattern, protein expression and clinical outcome of EBV
+ 
DLBCL  
No Age Sex
xx 
Site
e 
Immuno-
suppression 
 
Latency Eber Lmp1 Ebna2 CD10 BCL6 MUM1 
 
SPHK1 S1PR1 S1PR2 ABCC1 ATX Treatment   Follow  
up (mo) 
Outcome 
 
1 72 F N No 3 + + + - - + + + - + NA NA 0 Dead 
2 77 F N Yes 3 + + + - - + + + + - + NA 5 Dead 
3 78 F N Yes 1 + - - - + + + + + + + NA NA NA 
4 32 M N Yes 3 + + + - + + - - + + NA CHOP 5 Dead 
5 75 F N No 2 + + - - + + - + - - + NA 2 Dead 
6 82 F N No 3 + + + - + + - - + - + NA NA NA 
7 49 F N No 2 + + - - + + - - + - - NA NA NA 
8 64 F E Yes 3 + + + - - + - + - - + NA 1 Dead 
9 36 M N Yes 1 + - - - - + - + - - + RCHOP 9 Dead 
10 27 M N Yes 1 + - - - - + + + + - NA RCHOP 5 Dead 
11 65 M E Yes 3 + + + - - + - - + + - NA NA NA 
12 29 M N Yes 3 + + + - - + - - - - + NA NA NA 
13 54 M E No 1 + - - - - + + - + - - NA NA NA 
14 61 F E Yes 3 + + + - + + - + - + + surgery 16 Alive 
*NA : not available, bold cases are the EBV+ DLBCL-E patients 
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4.8.3  Immunosuppression 
Of the 14 EBV
+
 DLBCL cases, nine (64.3%) had a prior history of immunosuppression or of 
a haematological malignancy (Table 4.8). 3 patients were HIV positive, one had a bone 
marrow transplant for aplastic anaemia, one had a liver transplant, one had history of MALT 
lymphoma, two had a history of CLL and one had a history of low grade NHL. Nine patients 
were aged >50 years however, only four patients in this group had no prior evidence of 
immunosuppression or haematological malignancy and therefore met the criteria for a 
diagnosis of EBV
+
 DLBCL of the elderly (EBV
+
 DLBCL-E) which is described in further 
detail in section 4.8.8.  
 
Table 4.8: Immune status of EBV
+
 DLBCL cases 
EBV
+
 DLBCL 
patients (n=14) 
Non 
Immunosuppressed 
Immunosuppressed/ History of 
haematological malignancy 
Age > 50 yrs 4 (28.6%) 5 (35.7%) 
Age ≤ 50 yrs 1 (7.1%) 4 (28.6%) 
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4.8.4  Management and treatment response of EBV+ DLBCL 
Seven (50.0%) of EBV
+
 DLBCL patients were given chemotherapy, three (21.4%) had both 
chemotherapy and radiotherapy, one (7.1%) had surgery and three (21.4%) received palliative 
treatment. 71.2% of EBV
-
 DLBCL patients had complete remission compared to 35.7% in 
EBV
+
 DLBCL (p=0.006)( Table 4.9).  
 
Table 4.9: Management, treatment response and clinical outcome of DLBCL patients by 
EBV positivity 
 
All patients   
EBV+ 
DLBCL   
EBV- 
DLBCL   
ᵡ2 
value 
p value 
Management (n=288)      
    Chemotherapy 158 (54.9%) 7 (50.0%) 151 (55.1%) 0.854 0.931
#
 
    Radiotherapy 7 (2.4%) 0 (0.0%) 7 (2.6%)   
    Chemotherapy &  
radiotherapy 
63 (21.9%) 3 (21.4%) 60 (21.9%) 
  
    Surgery 14 (4.9%) 1 (7.1%) 13 (4.7%)   
    Palliative 46 (16.0%) 3 (21.4%) 43 (15.7%)   
      
Treatment response (n=288)     
    Complete remission 200 (66.7%) 5 (35.7%) 195 (71.2%) 12.302 0.006
#
 
    Partial remission 27 (9.0%) 4 (28.6%) 23 (8.4%)   
    Stable disease 14 (4.7%) 0 (0.0%) 14 (5.1%)   
    Progressive disease 47(15.7%) 5 (35.7%) 42 (15.3%)   
 
     
Clinical outcome (n=124) 
    Died of disease 57 (46.0%) 3 (25.0%) 54 (48.2%) 3.23 0.199
#
 
    Died of complications     4 (3.2%) 0 (0.0%) 4 (3.6%)   
    Died of unrelated cause 63 (50.8%) 9 (75.0%) 54 (48.2%)     
#
 chi square test  
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4.8.5  Correlation between clinical characteristics and overall survival   
In unadjusted univariate analysis, the presence of B symptoms correlated significantly with 
overall and event free survival (Figure 4.11). All patients who had B symptoms had 
significantly poorer OS and EFS than those without B symptoms (p<0.001). EBV
+
 patients 
had significantly shorter EFS than their EBV
-
 counterparts (p=0.033)(Figure 4.9). However, 
EBV latency type did not correlate with OS (p=0.886) and EFS (p=0.544)(Figure 4.10). 
Other clinical variables such as gender and ethnicity did not show any significant correlation 
with OS and EFS (Figure 4.15-4.16). Patients with bulky tumours have significantly poorer 
OS (p=0.004) and shorter EFS (p<0.001)(Figure 4.14). All patients with higher IPI showed 
poorer OS and EFS (p<0.001)(Figure 4.17). Patients with poor R-IPI index showed shorter 
EFS )p<0.001)(Figure 4.18). Patients treated with R-CHOP had significantly longer OS 
(p=0.006) and EFS (p=0.003) than those treated with CHOP alone (Figure 4.13).   
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Figure 4.9: The Kaplan Meier overall and event free survival curves by EBV positivity   
of DLBCL patients.    
p=0.184 
p=0.033 
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Figure 4.10: The Kaplan Meier overall and event free survival curves by EBV latency 
type of DLBCL patients. 
 
p=0.886 
p=0.544 
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Figure 4.11: The Kaplan Meier overall and event free survival curves by the presence of 
B symptoms of DLBCL patients.  
P<0.001 
P<0.001 
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Figure 4.12: The Kaplan Meier overall and event free survival curves by disease 
subtype of DLBCL patients. 
p=0.073 
p=0.056 
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Figure 4.13: The Kaplan Meier overall and event free survival curves by chemotherapy 
regime of DLBCL patients 
p=0.006 
p=0.003 
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Figure 4.14: The Kaplan Meier overall and event free survival curves by bulkiness of 
disease of DLBCL patients 
p=0.004 
P<0.001 
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Figure 4.15: The Kaplan Meier overall and event free survival curves by gender of 
DLBCL patients 
p=0.144 
p=0.061 
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Figure 4.16: The Kaplan Meier overall and event free survival curves by ethnicity of 
DLBCL patients 
p=0.809 
p=0.657 
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Figure 4.17: The Kaplan Meier overall and event free survival curves by IPI risk group 
of DLBCL patients 
P<0.001 
P<0.001 
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Figure 4.18: The Kaplan Meier overall and event free survival curves by revised IPI 
risk group of DLBCL patients 
p=0.073 
P<0.001 
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4.8.6  Prognostic factors for survival of DLBCL patients by simple Cox proportional 
hazards model 
To determine if each variable is a prognostic factor for survival of DLBCL patients, I used 
the univariate simple Cox proportional hazards model. Crude hazard ratio indicates the 
increase or decrease in the risk of death incurred by each variable. Table 4.11 shows that age, 
ECOG PS, presence of B symptoms, LDH levels, involvement of ≥ 1 extranodal site, IPI, R-
IPI and BCL6 positivity are prognostic factors for survival. A hazard ratio of > 1 shows a 
higher risk of death and a hazard ratio of <1 shows a lower risk of death. 
 
4.8.7  Prognostic factors for survival of DLBCL patients by multiple Cox proportional 
hazards model  
To exclude the confounders which may affect the significance of the analysis, I used the 
multiple Cox proportional hazards model. This analysis revealed that EBV positivity,  
presence of B symptoms, bulky disease, BCL6 and intermediate to high IPI were 
significantly associated with shorter time to death. The adjusted hazard ratio, 95% CI and p 
value are shown in Table 4.12.  
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Table 4.10: Prognostic factors of all DLBCL patients by Simple Cox proportional 
hazards model 
Potential prognostic 
factors 
Regression 
Coefficient 
Crude HR (95% CI) Wald 
Statistic 
p value 
Gender 0.233 1.263 (0.923, 1.728) 2.121 0.145 
Age 0.025 1.027 (1.013,1.037) 16.533 < 0.001 
EBV positivity 0.453 1.573 (0.801, 3.089) 1.728 0.189 
ECOG PS 0.797 2.218 (1.802, 2.731) 56.522 < 0.001 
B symptoms 0.777 2.174 (1.569, 3.011) 21.818 < 0.001 
LDH level 0.354 1.424 (1.027, 1.927) 4.490 0.034 
Ann Arbor stage 0.314 1.370 (1.185, 1.582) 18.231 < 0.001 
Subtype 0.290 1.336 (0.972, 1.837) 3.181 0.074 
Site of involvement 0.178 1.195 (0.894, 1.597) 1.441 0.230 
No. of extranodal 
involvement 
0.95 2.586 (1.667, 4.01) 17.999 < 0.001 
 Low risk IPI   35.036 < 0.001 
 Low to intermediate IPI 0.591 1.806 (1.196, 2.728) 7.893 0.005 
 Intermediate to high IPI 1.093 2.983 (1.937, 4.594) 24.476 < 0.001 
 High risk IPI 1.512 4.535 (2.393, 8.595) 21.027 < 0.001 
 Very good R-IPI   24.328 < 0.001 
 Good R-IPI 0.839 2.279 (1.265, 4.234) 4.197 0.006 
 Poor R-IPI 1.385 3.924 (2.138, 7.465) 18.848 < 0.001 
 CHOP chemotherapy 0.541 1.718 (1.035, 2.854) 4.375 0.036 
 CD10 -0.167 0.846 (0.61, 1.173) 1.004 0.316 
 BCL6 -0.659 0.517 (0.364, 0.736) 13.454 < 0.001 
 MUM1 0.283 1.328 (0.958, 1.841) 2.893 0.089 
 SPHK1 0.133 1.142 (0.832, 1.566) 0.677 0.411 
 S1PR1 0.161 1.174 (0.818 , 1.686) 0.756 0.385 
 ABCC1 -0.119 0.888 (0.645, 1.222) 0.533 0.465 
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Table 4.11: Prognostic factors for survival of all DLBCL patients by multiple Cox 
proportional hazards model 
Potential prognostic 
factors 
Regression 
Coefficient 
Adjusted HR (95% CI) Wald 
Statistic 
p value 
EBV positivity 0.743 2.102 (1.056, 4.185) 4.472 0.034 
B symptoms  0.422 1.525 (1.043, 2.230) 4.749 0.029 
Bulky disease 0.526 1.693 (1.174, 2.441) 7.933 0.005 
BCL6 -0.540 0.583 (0.402, 0.844) 8.154 0.004 
Low risk IPI   18.876 <0.001 
Low to intermediate IPI 0.479 1.615 (1.047,2.491)  4.694 0.335 
Intermediate to high IPI 0.809 2.247 (1.391,3.629) 10.948 <0.001 
High risk IPI 1.312 3.712 (1.905, 7.232) 14.851  <0.001 
 
 
 
 
 
 
 
 Chapter 4  Results    
170 
 
4.8.8  EBV
+
 DLBCL of the elderly 
4 out of 300 (1.3%) DLBCL patients fulfilled the 2008 WHO criteria of EBV
+
 DLBCL-E ie 
they were more than 50 years old and had no prior evidence of immunosuppression. Table 
4.7 showed the clinical characteristics of the EBV
+
 DLBCL-E cases in bold. The age range 
was 54-82 with a median age of 74 years. Two patients were male and two were female. One 
case was excluded because the patient was < 50 years. Two patients had EBV latency 3 
(EBER
+
, LMP1
+
, EBNA2
+
), one patient had latency type 1 (EBER
+
,LMP1
-
, EBNA2
-
) and the 
other had latency type 2 (EBER
+
,LMP1
+
, EBNA2
-
). Three patients had nodal presentation 
and one had extranodal involvement presenting as a midline butterfly lesion in the brain. One 
patient received chemotherapy with R-CHOP, one had R-CHOP with radiotherapy while the 
other two patients were given palliative treatment. One patient with progressive disease 
relapsed while the other three did not relapse. Two patients with progressive disease died and 
the median survival of this group was less than 1 month.   
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4.9  Expression of lipid signaling molecules in DLBCL 
SPHK1, S1PR1, ABCC1 and ATX were expressed in 51%, 73%, 43% and 21% of DLBCL 
patients, respectively (Figure 4.19). SPHK1, S1PR1, ABCC1 and ATX were expressed in the 
cytoplasm of malignant lymphoid cells.  
 
 
Figure 4.19: Expression of SPHK1, S1PR1, ABCC1 and ATX in DLBCL patients. 
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                         A     
             B     
Figure 4.20: Expression of SPHK1 and S1PR1 in DLBCL. SPHK1 (A) and S1PR1 (B) 
were localised to the cytoplasm of malignant cells (x400). 
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         A     
        B      
Figure 4.21: Expression of ABCC1 and ATX in DLBCL. ABCC1 (A) and ATX (B) were 
localised to the cytoplasm of malignant cells (x400). 
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4.9.1  Co-expression of lipid signaling molecules in DLBCL 
None of the lipid signaling molecules showed significant co-expression (Table 4.12).  
 
Table 4.12 Co-expression of lipid signaling molecules in DLBCL 
S1P signalling 
molecule 
Associated lipid molecule ᵡ2 value p value 
 S1PR1+ S1PR1-   
SPHK1+ 107 (49.1%) 45 (54.9%) 0.801 0.371
#
 
SPHK1- 111 (50.9%) 37 (45.1%)   
 ABCC1+ ABCC1-   
SPHK1+ 63 (48.5%) 88 (42.1%) 0.383 0.536
#
 
SPHK1- 67 (51.5%) 81 (47.9%)   
 ATX+ ATX-   
SPHK1+ 15 (50.0%) 56 (49.6%) 0.002 0.966
#
 
SPHK1- 15 (50.0%) 57 (50.4%)   
 ABCC1+ ABCC1-   
S1PR1+ 88 (67.7%) 129 (76.3%) 2.755 0.097
#
 
S1PR- 42 (32.3%) 40 (23.7%)   
 ATX+ ATX-   
S1PR1+ 21 (70.0%) 89 (78.8%) 1.025 0.311
#
 
S1PR- 9 (30.0%) 24 (29.2%)   
 ATX+ ATX-   
ABCC1+ 15 (50.0%) 39 (34.8%) 2.313 0.128
#
 
ABCC1- 15 (50.0%) 73 (65.2%)   
#
 chi square test, * Fisher’s exact test 
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4.9.2  Relationship between lipid signaling molecules and clinical characteristics  
Statistical analysis showed that SPHK1 expression was associated with lower ECOG 
performance status (p=0.042)(Table 4.13). There was no significant association between 
SPHK1 protein expression and any other clinical characteristics. Fewer patients with S1PR1 
expression had B symptoms (p=0.048) and more patients expressing S1PR1 protein had >1 
site of extranodal involvement (p=0.023). Significantly more S1PR1 positive patients were 
dead at last contact (p=0.049)(Table 4.14). ABBC1 expression was significantly less frequent 
in patients > 60 years (p=0.008) (Table 4.15). The expression of ATX was not significantly 
associated with any clinical characteristics (Table 4.16).   
The expression of SPHK1, S1PR1, ABCC1 and ATX were not significantly associated with 
EBV positivity (Table 4.17).  
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Table 4.13: SPHK1 expression and clinicopathological parameters 
Clinical characteristic All patients 
(n=300) 
SPHK1+ 
(n=152) 
SPHK1-  
(n=148) 
ᵡ2 value p value 
Sex       
    Male 171 (57.0) 83 (54.6%) 88 (59.5%) 0.721 0.396
#
 
    Female 129 (43.0) 69 (45.4%) 60 (40.5%)   
Age group      
    < 60 years 99 (33.0%) 46 (30.3%) 47 (31.8%) 0.078 0.780
#
 
    ≥ 60 years 201 (67.0%) 106 (69.7%) 101 (68.2%)   
ECOG PS (n=88)      
     ≤1 66 (75.0%) 145 (95.4%) 131 (89.1%) 4.149 0.042# 
     >1 22 (25.0%) 7 (4.6%) 16 (10.9%)   
 B-symptoms      
     Present 155 (51.7%) 73 (48.0%) 82 (55.4%) 1.635 0.201
#
 
     Absent 145 (48.3%) 79 (52.0%) 66 (44.6%)   
LDH level (n=297)      
     Low (≤ 450 U/I) 153 (51.5%) 82 (53.9%) 72 (51.4%) 0.843 0.359# 
     High (> 450 U/I) 144 (48.5%) 70 (46.1%) 76 (48.6%)   
Ann Arbor stage      
     1/II 164 (54.7%) 87 (57.2%) 77 (52.0%) 0.821 0.365
#
 
     III/IV 136 (45.3%) 65 (42.8%) 71 (48.0%)   
Subtype      
    GCB 132 (44.0%) 60 (39.5%) 72 (48.6%) 2.562 0.109
#
 
    Non GCB 168 (56.0%) 92 (60.5%) 76 (51.4%)   
Site of involvement      
     Nodal  171 (57.0%) 86 (56.6%) 85 (57.4%) 0.026 0.987* 
     Extranodal 123 (41.0%) 63 (41.4%) 60 (40.5%)   
     Both 6 (2.0%) 3 (2.0%) 3 (2.0%)   
Extranodal involvement  (n=299)     
    ≤ 1 site 270 (90.3%) 195 (89.9%) 75 (91.5%) 0.174 0.676# 
    > 1 site        29 (9.7%) 22 (10.5%) 7 (8.5%)   
Standard IPI      
    Low/Low-intermediate 219 (73.0%) 100 (65.8%) 83 (57.2%) 2.293 0.130
#
 
    High-intermediate/ High  81 (27.0%) 52 (34.2%) 62 (42.8%)   
Revised IPI      
    Very good/ Good 219 (73.0%) 126 (84.6%) 111 (84.1%) 0.012 0.913
#
 
     Poor 81 (27.0%) 23 (15.4%) 21 (15.9%)   
Outcome (n=298)      
     Dead 157 (52.7%) 82 (54.7%) 75 (47.5%) 2.437 0.296
#
 
     alive 141 (47.3%) 68 (45.3%) 83 (52.5%)     
  
#
 chi square test, * Fisher’s exact test 
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Table 4.14:  Relationship between S1PR1 expression and clinicopathological parameters 
Clinical characteristic All patients 
(n=300) 
S1PR1+ 
(n=152) 
S1PR1- 
(n=148) 
ᵡ2 
value 
p value 
Sex       
    Male 171 (57.0) 122 (56.0%) 49 (59.8%) 0.350 0.554
#
 
    Female 129 (43.0) 96 (44.0%) 33 (40.2%)   
Age group      
    < 60 years 99 (33.0%) 66 (30.3%) 27 (32.9%) 0.196 0.658
#
 
    ≥ 60 years 201 (67.0%) 152 (69.7%) 55 (67.1%)   
ECOG PS (n=88)      
     ≤1 66 (75.0%) 199 (91.7%) 77 (93.9%) 0.405 0.525# 
     >1 22 (25.0%) 18 (8.3%) 5 (6.1%)   
 B-symptoms      
     Present 155 (51.7%) 105 (48.2%) 50 (61.0%) 3.196 0.048
#
 
     Absent 145 (48.3%) 113 (51.8%) 32 (39.0%)   
LDH level (n=297)      
     Low (≤ 450 U/I) 154 (51.5%) 114 (52.3%) 40 (48.8%) 0.294 0.587# 
     High (> 450 U/I) 145 (48.5%) 104 (47.7%) 42 (51.2%)   
Ann Arbor stage      
     1/II 164 (54.7%) 120 (55.0%) 44 (53.7%) 0.046 0.830
#
 
     III/IV 136 (45.3%) 98 (45.0%) 38 (46.3%)   
Subtype      
    GCB 132 (44.0%) 97 (44.5%) 35 (42.7%) 0.079 0.778
#
 
    Non GCB 168 (56.0%) 121 (55.5%) 47 (57.3%)   
Site of involvement      
     Nodal  171 (57.0%) 122 (56.0%) 49 (59.8%) 0.602 0.740* 
     Extranodal 123 (41.0%) 91 (41.7%) 32 (39.0%)   
     Both 6 (2.0%) 5 (2.3%) 1 (1.2%)   
Extranodal involvement  (n=299)      
    ≤ 1 site 143 (48.0%) 95 (43.8%) 48 (58.5%) 5.194 0.023# 
    > 1 site        156 (52.0%) 122 (56.2%) 34 (41.5%)   
Standard IPI      
    Low/Low-intermediate 183 (61.0%) 133 (61.9%) 50 (61.0%) 0.02 0.889
#
 
    High-intermediate/ High  114 (39.0%) 82 (38.1%) 32 (39.0%)   
Revised IPI      
    Very good/ Good 237 (79.0%) 170 (83.3%) 67 (87.0%) 0.573 0.449
#
 
     Poor  44 (21.0%) 34 (16.7%) 10 (13.0%)   
Outcome (n=298)      
     Dead 157 (52.3%) 118 (54.1%) 39 (48.7%) 6.024 0.049
#
 
     Alive 141 (47.7%) 100 (45.9%) 41 (51.3%)     
#
 chi square test, * Fisher’s exact test 
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Table 4.15: Relationship between ABCC1 expression and clinicopathological 
parameters 
Clinical characteristic All patients 
(n=300) 
ABCC1+ 
(n=152) 
ABCC1- 
(n=148) 
ᵡ2 value p value 
Sex       
    Male 170 (56.9%) 77 (59.2%) 93 (55.0%) 0.529 0.467
#
 
    Female 129 (43.1%) 53 (40.8%) 76 (45.0%)   
Age group      
    < 60 years 93 (31.1%) 51 (39.2%) 42 (24.9%) 7.089 0.008
#
 
    ≥ 60 years 206 (68.9%) 79 (60.8%) 127 (75.1%)   
ECOG PS (n=298)      
     ≤1 275 (92.3%) 123 (95.3%) 152 (89.9%) 3.004 0.083# 
     >1 23 (7.7%) 6 (4.7%) 17 (10.1%)   
 B-symptoms       
     Present 154 (51.5%) 69 (53.1%) 85 (50.3%) 0.228 0.633
#
 
     Absent 145 (48.5%) 61 (46.9%) 84 (49.7%)   
LDH level (n=297)      
     Low (≤ 450 U/I) 154 (51.5%) 68 (52.3%) 86 (50.9%) 0.059 0.808# 
     High (> 450 U/I) 145 (48.5%) 62 (46.9%) 83 (49.7%)   
Ann Arbor stage      
     1/II 164 (54.8%) 70 (53.8%) 94 (55.6%) 0.093 0.760
#
 
     III/IV 135 (45.2%) 60 (46.2%) 75 (44.4%)   
Subtype      
    GCB 132 (44.1%) 58 (44.6%) 74 (43.8%) 0.02 0.886
#
 
    Non GCB 167 (55.9%) 72 (55.4%) 95 (56.2%)   
Site of involvement      
     Nodal  170 (56.9%) 79 (60.8%) 91 (53.8%) 1.534 0.464* 
     Extranodal 123 (41.1%) 49 (37.7%) 74 (43.8%)   
     Both 6 (2.0%) 2 (1.5%) 4 (2.4%)   
Extranodal involvement  
(n=299) 
     
    ≤ 1 site 143 (47.7%) 66 (51.2%) 76 (45.0%) 1.125 0.289# 
    > 1 site        156 (52.3%) 63 (48.8%) 93 (55.0%)   
Standard IPI      
    Low/Low-intermediate 183 (61.8%) 83 (64.3%) 100 (59.9%) 0.614 0.433
#
 
    High-intermediate/ High 113 (38.2%) 46 (35.7%) 67 (40.1%)   
Revised IPI      
    Very good/ Good 237 (84.3%) 105 (86.0%) 132 (83.0%) 0.446 0.504
#
 
     Poor 44 (15.7%) 17 (14.0%) 27 (17.0%)   
Outcome (n=298)      
     Dead 157 (52.3%) 68 (52.3%) 89 (53.0%) 0.066 0.967
#
 
     Alive 141 (47.7%) 62 (47.7%) 79 (47.0%)     
  
#
 chi square test, * Fisher’s exact test 
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Table 4.16:  Relationship between ATX expression and clinicopathological parameters 
Clinical characteristic All patients 
(n=143) 
ATX+ 
(n=30) 
ATX- 
(n=113) 
ᵡ2 value p value 
Gender      
    Male 77 (53.8%) 15 (50.0%) 62 (54.9%) 0.226 0.635
#
 
    Female 66 (46.2%) 15 (50.0%) 51 (45.1%)   
Age group      
    < 60 years 50 (35.0%) 7 (23.3%) 43 (38.1%) 2.259 0.133
#
 
    ≥ 60 years 93 (65.0%) 23 76.7%) 70 (61.9%)   
ECOG PS  (n=142)      
     <2 130 (91.5%) 28 (93.3%) 102 (91.1%) 0.156 0.692
#
 
     ≥2 12 (8.5%) 2 (6.7%) 10 (8.9%)   
 B-symptoms      
     Present 73 (51.0%) 18 (60.0%) 55 (48.7%) 1.217 0.270
#
 
     Absent 70 (49.0%) 12 (40.0%) 58 (51.3%)   
LDH level        
     Low (≤ 450 U/I) 74 (52.5%) 14 (46.7%) 60 (54.1%) 0.517 0.472# 
     High (> 450 U/I) 67 (47.5%) 16 (53.3%) 51 (45.9%)   
Ann Arbor stage      
     1/II 81 (56.6%) 15 (50.0%) 66 (58.4%) 0.682 0.409
#
 
     III/IV 62 (43.4%) 15 (50.0%) 47 (41.6%)   
Subtype      
    GCB 63 (44.1%) 11 (36.7%) 52 (46.0%) 0.841 0.359
#
 
    Non GCB 80 (55.9%) 19 (63.3%) 61 (54.0%)   
Site of involvement      
     Nodal  77 (53.8) 20 (66.7%) 57 (50.4%) 2.458 0.281* 
     Extranodal 62 (43.4%) 10 (33.3%) 52 (46.0%)   
     Both 4 (2.8%) 0 (0.0%) 4 (3.5%)   
No. extranodal involvement       
    ≤ 1 site 125 (88.0%) 27 (90.0%) 98 (87.5%)  1.000* 
    > 1 site        17 (12.0%) 3 (10.0%) 14 (27.5%)   
Standard IPI      
     Low 64 (45.54%) 10 (33.3%) 54 (48.6%) 2.581 0.461* 
     Low- intermediate 38 (27.0%) 10 (33.3%) 28 (25.2%)   
     High- intermediate 33 (23.4%) 9 (30.0%) 24 (21.6)   
     High 6 (4.3%) 1 (3.3%) 5 (4.5%)   
Revised IPI      
    Very good  16 (11.3%) 3 (10.0%) 13 (11.7%) 0.621 0.733
#
 
    Good 86 (61.0%) 17 (56.7%) 69 (62.2%)   
     Poor 39 (27.7%) 10 (33.3%) 29 (26.1%)   
Outcome        
     Dead 91 (64.5%) 19 (66.3%) 72 (64.9%) 0.024 0.876
#
 
     Alive 50 (35.5%) 11 (33.7%) 39 (35.1%)     
#
 Chi square, * Fisher’s exact test 
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Table 4.17: Expression of lipid signaling molecules in DLBCL by EBV positivity 
S1P signalling 
molecules 
EBER
+
 EBER
-
 ᵡ2 value p value 
SPHK1
+
 5 (35.7%) 147 (51.4%) 1.314 0.252
#
 
SPHK1
-
 9 (64.3%) 139 (48.6%)     
S1PR1
+
 8 (57.1%) 210 (73.4%) 1.782 0.219* 
S1PR1
-
 6 (42.9%) 76 (26.6%)     
ABCC1
+
 4 (28.6%) 126 (44.2%) 1.328 0.284
#
 
ABCC1
-
 10 (71.4%) 159 (55.8%)     
ATX
+
 3 (25.0%) 27 (20.6%) 0.127 0.716* 
ATX
-
 9 (75.0%) 104 (79.4%)   
#
 chi square test, * Fisher’s exact test 
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4.9.3  Correlation of SPHK1, S1PR1, ABCC1 and ATX expression with overall and 
event free survival 
Univariate analysis showed that none of the lipid signaling molecule expression correlated 
with significant OS and EFS (Figure 4.22-4.25). 
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Figure 4.22: The Kaplan Meier overall and event free survival curves of DLBCL 
patients by SPHK1 positivity. 
p=0.518 
p=0.597 
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Figure 4.23: The Kaplan Meier overall and event free survival curves of DLBCL 
patients by S1PR1 positivity. 
p=0.384 
p=0.654 
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Figure 4.24: The Kaplan Meier overall and event free survival curves of DLBCL 
patients by ABCC1 positivity. 
p=0.613 
p=0.858 
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Figure 4.25: The Kaplan Meier overall and event free survival curves of DLBCL 
patients by ATX positivity. 
p=0.962 
p=0.892 
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4.10  Discussion 
In the whole series of DLBCL, males were more commonly affected than females and 
majority of patients were aged ≥ 60 years. A higher proportion of DLBCL cases presented 
with nodal disease and less than 10% of cases had more than one site of extranodal 
involvement. I found that the frequency of non GCB subtype was higher than that of the GCB 
subtype (56% vs 44%) however this difference was not statistically significant. Analysis of 
subtypes in Western countries such as Norway, Sweden, Spain, Italy, France and the USA 
showed an incidence of the GCB subtype ranging from 42-58% which was in keeping with 
our study (Berglund et al., 2005; Chang et al., 2004; Hans et al., 2004). Shiozawa et al found 
that the non GCB subtype was more frequent in Asian countries (31-42%) compared to 
Western countries (Shiozawa et al., 2007). Shiozawa et al suggested that the difference 
between the Asian and Western distribution of DLBCL subtype may be due to different 
distribution of nodal and extranodal disease in these two populations.  
 
The impact of EBV on DLBCL patients 
In this series, 14/300 (4.7%) DLBCL patients were found to harbour EBV RNA by in situ 
hybridization, of these, 4 (1.3%) were defined as EBV
+
 DLBCL-E. This low incidence 
corroborates with the findings of Hoeller et al who reported an incidence of EBV
+
 DLBCL-E 
as 3.1%. in a European population (Hoeller et al., 2010). Gibson et al in the United States 
reported an incidence of less than 1% of DLBCL-E aged more than 60 from 2001 to 2007 
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(Gibson & Hsi 2009). A recent Turkish study reported an incidence of 5.3% of EBV
+
 
DLBCL and 3.5% of EBV
+
 DLBCL-E among 340 patients (Uner et al. 2011).  
There appears to be a striking difference in the incidence of EBV
+
 DLBCL-E in the Asian 
compared to European countries. For example, the incidence of 9% reported by Park et al in 
Korea is seven fold higher than in our series (Park et al., 2007). Kuze et al reported an 
incidence of 11.4% of EBV
+
 DLBCL-E in Japan (Kuze et al. 2000) and Oyama et al reported 
an incidence of 8.3% of EBV
+ 
B-cell LPDs (Oyama et al. 2007). Cho et al found that the 
incidence of EBV
+
 DLBCL-E was 7.5% in Korea (Cho et al. 2008).  
Our study showed that EBV positivity was significantly associated with disease subtype 
(p=0.001). All the EBV-positive cases were of non GCB subtype. This is in contrast with the 
findings of Hoeller et al which showed equal distribution of GCB and non GCB subtype in 
their series of EBV-positive cases (Hoeller et al., 2010). Our most intriguing finding is that 
EBV positivity showed inferior EFS compared to the EBV-negative counterpart (p=0.033). 
This corroborates with the findings of Oyama et al that EBV
+
 DLBCL had poorer prognosis 
and behaved aggressively than the EBV
-
 DLBCL (Oyama et al. 2003). In a larger study, 
Oyama et al found that the EBV
+ 
B-cell LPDs had aggressive clinical features, higher 
performance status and higher LDH levels. This group also had significantly inferior overall 
survival (Oyama et al. 2007). To the best of my knowledge, our study constitute the first 
analysis on the impact of EBV on DLBCL patients with respect to age, gender, stage of 
disease, subtype, presence or absence of B symptoms, ECOG PS, site of involvement, 
number of extranodal site involvement, IPI, R-IPI and clinical outcome in a single centre in 
the UK. 
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I found that the presence of B symptoms was significantly associated with EBV positivity. 
85.7% of EBV
+
 DLBCL had B symptoms and those with B symptoms had inferior OS and 
EFS (p<0.001). The presence of B symptoms were found to be a negative prognostic factor 
(Gibson & Hsi 2009), and Oyama et al showed that patients with presence of B symptoms 
had higher risk of death by univariate and multivariate analyses (Oyama et al. 2007) which 
was in keeping with my findings.  
In this study, EBV
+
 DLBCL was found to have lower mean age compared to EBV- negative
 
 
tumours. The median age for EBV
+
 DLBCL was 63 which was close to that of the Turkish 
study (64 years)(Uner et al. 2011). The EBV
-
 DLBCL patients had a higher median age of 66 
years. Age however showed no significant association with EBV positivity, which is in 
contrast with Asian studies; Oyama et al found that EBV
+ 
B- cell LPDs were more frequent 
in those aged > 60 years (Oyama et al. 2007) and Park et al also found that EBV
+
 DLBCL 
was more frequent in those aged > 60 years (Park et al., 2007). 
In the present series, the EBV positive cases showed EBER positivity in a majority of 
neoplastic cells. In this study I was able to evaluate the latency pattern of EBV using EBER, 
LMP1 and EBNA2 staining. EBV latency III was most frequently seen. This is in line with 
most reports which show that latency II and III are the most common forms of latency seen in 
EBV
+
 DLBCLs (Oyama et al. 2003; Oyama et al. 2007). Hoeller et al observed a worse 
survival outcome for patients with latency type III compared to latency type II and I. 
However I found that EBV latency pattern did not have any prognostic impact or a worse 
survival rate. This could be due to the low number of EBV positive cases in our series.  
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Sehn et al found that re-distribution of the IPI factors into a R-IPI in the era of R-CHOP gave 
a better prediction of outcome as they found an overlapping survival curves for two low risk 
groups and two high risk groups in IPI but not for R-IPI groups (Sehn et al. 2007). In R-IPI, 
three prognostic groups were identified; very good (IPI score 0), good (IPI score 1,2) and 
poor group (IPI score 3,4,5) with OS of 94%, 79% and 55%, respectively. In line with most 
studies, I found that IPI was an important prognostic indicator in DLBCL by univariate and 
multivariate analyses. High risk IPI and poor R-IPI have high hazard ratios of 4.5 and 3.9, 
respectively. By log rank test, higher IPI correlated significantly with shorter OS and EFS 
(p< 0.001) while poor R-IPI  correlated with shorter EFS (p< 0.001). Higher IPI and poor R-
IPI were found to be significantly associated with the presence of B symptoms, relapse, age > 
60 years, late stage of disease, LDH > 450 and ECOG ≥2. After considering only patients in 
the R-CHOP era, I found that IPI was still an important prognostic factor in determining 
survival of DLBCL patients which contradicts the finding of Sehn et al.  
Pfreundschuh and colleagues have shown that bulky disease has adverse prognostic 
significance in young good-prognosis patients (Pfreundschuh et al. 2008). A cut off point of 
10 cm has been able to distinguish two populations with EFS of significant difference in 
patients given R-CHOP chemotherapy. Looking at the entire DLBCL cases, I found that 
bulky disease has no impact on OS and EFS. Similarly, in patients aged < 60 years given R-
CHOP, bulky disease showed insignificant contribution to prognosis. Hence the role of bulky 
disease in the era of Rituximab merits further investigation.  
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The significance of CD10, BCL6 and MUM1 in DLBCL 
As microarray analysis is not yet feasible in daily routine diagnostic work, 
immunohistochemistry is useful in determining the subtype of DLBCL. In the pre-Rituximab 
era, the expression of CD10 (De Paepe et al. 2005) and BCL6 (Lossos et al. 2001) have been 
associated with good prognosis while MUM1 expression has been associated with adverse 
prognosis (Hans et al., 2004). Studies have shown that CD10 is expressed in the cytoplasm of 
tumour cells and is associated with improved survival and complete remission (Barrans, 
2002).  
BCL6 is a main regulator of germinal centre cell differentiation and is expressed in both 
centroblasts and centrocytes in the germinal centres. In DLBCL, BCL6 is overexpressed in 
the nucleus of 50-70% of cases, sparing the nucleolus. In this study, BCL6 protein was found 
to be expressed in 40% of DLBCL cases and its expression correlated significantly with 
superior OS (p=0.001) and EFS (p=0.002), hence is a good prognostic indicator.  
MUM1 is a lymphoid specific member of the interferon regulatory factor family of 
transcription factors. It is expressed in the nucleus of lymphocytes and plasma cells. It is also 
expressed in a subset or germinal centre cells indicating the late stage of germinal center B-
cell differentiation (Falini et al., 2011a; Tsuboi et al. 2000). Its critical role is regulating gene 
expression in response to signalling by interferons and other cytokines. MUM1 is also 
believed to play a role in plasma cell development. Most GCB and mantle cells are MUM1 
negative, nevertheless it is expressed in 40–50% of DLBCL cases indicating a non GCB 
subtype (Chang et al. 2004; Hans et al., 2004; Falini et al., 2011b). 
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In this study, I have looked at groups of patients in both the pre-Rituximab and post-
Rituximab era and found that DLBCL patients expressing BCL6 were associated with a 
favourable prognosis in both eras. In contrast to the findings of Hans et al, I found that 
MUM1 had no impact on survival. Differences in our results might be attributed to the study 
design; Han’s study was a multi-centre study and my study was a single-centre study. Hans et 
al used MUM1 antibody from Falini et al while my MUM1 antibody was from Dako. Hans et 
al applied the antibody onto tissue microarray slides while my study used whole tissue 
section. In contrast to the findings of De Paepe et al, I found that CD10 was not associated 
with better OS and EFS. De Paepe et al used a different CD10 clone of antibody as compared 
to my study, although our cutoff levels of 30% were similar. Therefore, it is important to 
redefine the cutoff levels for different antibodies in order to validate the predictive value of 
immunohistochemical staining in DLBCL.  
 
Lipid signalling molecules in DLBCL 
The expression of S1P signalling molecules have never been looked into in DLBCL. I found 
that SPHK1 was expressed in half of DLBCL cases while S1PR1 was expressed in 73% of 
cases. The most intriguing finding was that S1PR1 expression was associated with the 
presence of B symptoms, higher number of extranodal involvement and poorer clinical 
outcome suggesting it as a poor prognostic marker. The role of S1PR1 in contributing to 
poorer clinical outcome warrants further investigation. As of today, there are very limited 
studies on the contribution of S1P signaling molecules in lymphoma. It would be interesting 
to explore whether S1PR1 would be a possible prognostic marker in DLBCL. The expression 
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of S1PR1 across different subtypes of malignant lymphoma would also be helpful to 
determine the diagnostic importance of S1PR1.  
The need to use a a specific scoring system for S1P signaling molecules may have to be 
considered eg. using the semiquantitative Histo score which considers both percentage of 
positive tumour cells and the intensity of staining. For instance, a cut off value of 30% 
positivity is used in most studies with CD10,BCL6 and MUM1. A cut off value for positivity 
will have to be determined for expression of lipid signaling molecules in future studies. In 
this study I found that usage of polyclonal antibodies gave high background staining and 
nuclear positivity in some cases which made scoring difficult. Usage of monoclonal 
antibodies for all lipid signaling molecules needs to be considered. The higher rate of 
specificity of monoclonal antibodies might influence the significance in correlating protein 
expression with clinicopathological parameters of DLBCL. Taken together, this study has 
highlighted the possibility of future major studies in DLBCL. 
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CHAPTER 5 
RESULTS 
EXPRESSION IN EPITHELIAL MALIGNANCIES, OF LIPID 
SIGNALLING MOLECULES AND THEIR ASSOCIATION WITH 
CLINICOPATHOLOGICAL PARAMETERS 
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5.1 Introduction 
S1P is a lysophospholipid mediator of diverse cellular processes important for cancer 
development and progression. The major enzyme that regulates the phosphorylation of 
sphingosine to S1P is SPHK1. French et al were the first group to demonstrate the expression 
of SPHK1 mRNA in human tissue samples of breast, lung, prostate, colon, gastric and head 
and neck cancer. A two to three fold increase in SPHK1 expression was observed in cancer 
tissue compared to adjacent normal tissue (French et al., 2003). For this reason, SPHK1 was 
suggested to be an oncogene. Increased SPHK1 expression was also found to be associated 
with decreased survival in breast cancer (Ruckhäberle et al. 2008), gastric cancer (Li et al., 
2009) and glioblastoma multiforme patients (James R Van Brocklyn et al. 2005a). In prostate 
cancer, increased SPHK1 enzymatic activity was associated with higher prostate specific 
antigen (PSA) levels, higher tumour volumes and surgical failure (Malavaud et al. 2010). 
Strong SPHK1 expression was also observed in non small cell carcinoma of the lungs (K. R. 
Johnson et al. 2005) and in pancreatic adenocarcinoma (Guillermet-Guibert et al. 2009) 
compared to adjacent normal tissue. SPHK1 has also emerged as an important therapeutic 
target in cancer. (Van Brocklyn et al., 2005).  
The aim of this study was to: 
1) investigate the expression of lipid signalling molecules, including SPHK1, S1PR1, 
ABCC1 and ATX in breast, lung and bladder cancers. 
2) explore the relationship of the expression of these lipid signaling molecules with 
clinical characteristics and survival of the different types of cancer. 
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3) determine if there is any possible co-expression of these lipid signaling molecules in 
the different types of cancer. 
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5.2 Expression of lipid signalling molecules in breast cancer  
Immunohistochemistry was performed on 118 cases of primary breast cancer obtained from 
the Pathology Department of Queen Elizabeth Hospital, Birmingham. Each case was stained 
using antibodies to SPHK1, S1PR1, ABCC1 and ATX. Due to insufficient tissue sections, I 
was not able to perform S1PR2 staining. Immunohistochemical staining results were 
examined and scored according to the criteria set out in Section 2.2.4.4. Table 3.1 shows the 
clinical characteristics of breast cancer patients. 87/118 (73.7%) patients were histologically 
classified as infiltrating ductal carcinoma, not otherwise specified (NOS), 17/118 (14.4%) 
were infiltrating lobular carcinoma, 4/118 (3.4%) were mucinous carcinoma, 3/118 (2.5%) 
were medullary carcinoma, another 3/118 (2.5%) were ductal carcinoma in situ (DCIS) while 
1/ 118 (1%) respectively were tubular carcinoma, atypical medullary carcinoma, lubular 
papillary and mixed NOS and lobular subtype (Figure 5.3). 
A summary of the expression of lipid signalling molecules in breast cancer is shown in Figure 
5.2. SPHK1 was expressed in the majority (81%) of breast cancer patients and was localised 
within the cytoplasm and occasionally in the nucleus of malignant cells (Figure 5.4). SPHK1 
reactivity was not seen in the stroma. In eight cases, normal breast ducts were present in 
tumour samples and in 3 of these cases, normal breast epithelial cells also expressed SPHK1 
but at levels lower than observed in malignant cells. In the remaining 5 cases, normal breast 
epithelial cells lacked SPHK1 expression. SPHK1 was also expressed in fibroblasts, 
macrophages, plasma cells and endothelial cells lining the blood vessels serving as internal 
positive controls (Figure 5.4).  
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Although S1PR1 was expressed in only 12% of breast cancer patients, it was not expressed in 
normal breast epithelial cells. When present, S1PR1 was found on the cell membrane and the 
cytoplasm or tumour cells (Figure 5.5). S1PR1 was also strongly expressed in the endothelial 
cells of blood vessels.  
In 38 tumours expressing ABCC1, expression was generally higher than in normal mammary 
epithelium. When present, the expression of ABCC1 was observed on the cell membrane and 
in the cytoplasm of carcinoma cells as well as in the endothelial cells of blood vessels (Figure 
5.6).  
Autotaxin was expressed in in 76/118 (66.4%) cases. Staining intensity was stronger in breast 
cancer cells compared to normal breast epithelium (Figure 5.7). In 8 cases with normal breast 
ducts, 4 cases showed mild to moderate ATX expression in the ductal epithelium. ATX was 
5localised to the cytoplasm of breast cancer cells and staining was clearly observed within the 
endothelial cells of blood vessels  
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      Figure 5.1: Summary of the expression of lipid signalling molecules in breast cancer 
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Table 5.1: Clinical characteristics of breast cancer patients 
Characteristics All patients (%) 
Age  
     < 50 22 (18.6) 
     ≥ 50 96 (81.4) 
Surgery type  
     Mastectomy 73 (61.9) 
     Wire loop excision 45 (38.1) 
Tumour size  
     < 2 cm 49 (41.5) 
     ≥ 2 cm 69 (58.5) 
Nodal metastasis  
     Positive 43 (39.1) 
     Negative 67 (60.1) 
Tumour grade  
     1 17 (14.4) 
     2 59 (50.0) 
     3 42 (35.6) 
DCIS grade  
     Low 4 (3.4) 
     Intermediate 19 (16.1) 
     High 52 (44.1) 
     Not seen 43 (36.4) 
Tumour stage  
     Limited, I-II 107 (90.7) 
     Advanced, III-IV 11 (9.3) 
Side of tumour  
     Left 53 (44.9) 
     Right 65 (55.1) 
Vascular invasion  
     Present 37 (31.4) 
     Absent 81 (68.6) 
ER status  
     Positive 86 (72.9) 
     Negative 32 (27.1) 
PR status  
     Positive 34 (61.7) 
     Negative 26 (38.3) 
Nottingham Prognostic Index  
     < 3.4 33 (28.0) 
     ≥ 3.4 74 (62.7) 
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Figure 5.2: The histological subtypes of breast cancer patients 
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        A     
       B      
Figure 5.3: Expression of SPHK1 in normal breast tissue and breast cancer. A) Faint 
staining of SPHK1 in the cytoplasm of normal breast epithelium B) Strong SPHK1 expression 
in the cytoplasm of breast cancer cells  
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              A           
               B      
Figure 5.4:Expression of S1PR1 in normal breast tissue and breast cancer. A) Absent or 
faint expression of S1PR1 in the cytoplasm of normal breast ducts (x400) B) Strong S1PR1 
expression in the cytoplasm and cytoplasmic membrane of breast cancer cells (x400). 
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               A            
                B       
Figure 5.5: Expression of ABCC1 in normal breast tissue and in breast cancer. A) 
Absent ABCC1 expression in normal breast epithelial cells but strong positivity in the 
endothelial cells of blood vessels (arrowed; x400) B) Strong ABCC1 expression in the 
cytoplasm of breast cancer cells (x600). 
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 A                 
B  
Figure 5.6: Expression of ATX in normal breast tissue and in breast cancer. A) A case 
lacking ATX expression in normal breast epithelial cells (x400) B) Strong ATX expression in 
the cytoplasm of breast cancer cells and in endothelial cells of blood vessels(fine arrows) 
(x600). 
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5.2.1 Relationship between the expression of each lipid signalling molecules in breast 
cancer 
I next used chi square and Fisher’s exact tests to determine if there was any relationship 
between the expression of each lipid signalling molecule. The expression of ABCC1 was 
significantly associated with ATX expression (p =0.007). No other statistically significant 
associations were found (Table 5.2) 
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Table 5.2: Relationship between the expression of each lipid signalling molecules in 
breast cancer 
Lipid signalling 
molecule Associated lipid molecule p value  
 
S1PR1+ S1PR1- 
 SPHK1 + 11 (11.5) 85 (81.7) 0.776* 
SPHK1 - 3 (13.6) 19 (8.64) 
 
 
ABCC1+ ABCC1- 
 SPHK1 + 32 (33.3) 64 (66.7) 0.583
#
 
SPHK1 - 6 (27.3) 16 (72.7) 
  ATX+ ATX-  
SPHK1 + 65 (67.7) 31 (32.3) 0.118
#
 
SPHK1 - 11 (50.0) 11 (50.0)  
 
ABCC1+ ABCC1- 
 S1PR1+ 7 (50.0) 7 (50.0) 0.129* 
S1PR1- 31 (29.8) 73 (70.2) 
  ATX+ ATX-  
S1PR1+ 11 (78.0) 3 (21.4) 0.238 
S1PR1- 65 (62.5) 39 (37.5)  
 ATX+ ATX-  
ABCC1+ 31 (81.6) 7 (18.4) 0.007
#
 
ABCC1- 45 (56.2) 35 (43.8)  
*Fisher’s exact test, # chi square test 
5.2.2 Correlation between the expression of lipid signalling molecules in breast cancer 
and clinical characteristics 
Having established the prevalence of expression of the different lipid signalling proteins in 
breast cancer, I next studied the relationship of expression to various clinicopathological 
features, including age, surgery type, tumour size, nodal metastasis, tumour grade, ductal 
carcinoma in -situ (DCIS) grade, tumour grade, side of tumour, vascular invasion, ER and PR 
status and Nottingham Prognostic Index (NPI). I used chi-square and Fisher’s exact test to 
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determine if the expression of each individual lipid signalling protein was significantly 
associated with any of these clinicopathological variables. The results of this analysis are 
summarised in Table 5.3 - 5.6. I found no significant association between the expression of 
SPHK1 and any clinicopathological variables (Table 5.3). S1PR1 was significantly more 
likely to be expressed in patients with larger tumour size (p= 0.028) in those tumours 
obtained by mastectomy (p= 0.011), and in those with a higher NPI (p= 0.016)(Figure 5.4). 
The expression of ABCC1 showed no significant association with any clinicopathological 
variables (Table 5.5). More patients who had mastectomy were ATX positive 
(p=0.049)(Table 5.6).  
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Table 5.3: Relationship between SPHK1 expression in breast cancer and clinicopathological 
parameters 
Characteristics All patients 
(%) 
SPHK1 + SPHK1 - χ2 value p value 
Age      
     < 50 22 (18.6) 18 (18.8) 4 (18.2) 0.004 0.951* 
     ≥ 50 96 (81.4) 78 (81.2) 18 (81.8)   
Surgery type      
     Mastectomy 73 (61.9) 61 (63.5) 12 (54.5) 0.614 0.433
#
 
     Wire loop excision 45 (38.1) 35 (36.5) 10 (45.5)   
Tumour size      
     < 2 cm 49 (41.5) 41 (42.7) 8 (36.4) 0.297 0.586
#
 
     ≥ 2 cm 69 (58.5) 55 (57.3) 14 (63.6)   
Nodal metastasis      
     Positive 43 (39.1) 33 (36.3) 10 (52.6) 1.769 0.184
#
 
     Negative 67 (60.1) 58 (63.7) 9 (47.4)   
Tumour grade      
     1 17 (14.4) 13 (13.5) 4 (18.2) 0.376 0.829
#
 
     2 59 (50.0) 48 (50.0) 11 (50.0)   
     3 42 (35.6) 35 (36.5) 7 (31.8)   
DCIS grade      
     Low 4 (3.4) 4 (4.2) 0 (0.0) 0.676 0.937* 
     Intermediate 19 (16.1) 16 (16.7) 3 (13.6)   
     High 52 (44.1) 41 (42.7) 11 (50.0)   
     Not seen 43 (36.4) 35 (36.5) 8 (36.4)   
Tumour stage      
     Limited,I-II 107 (90.7) 88 (99.7) 19 (86.4) 0.590 0.428* 
     Advanced, III-IV 11 (9.3) 8 (8.3) 3 (13.6)   
Side of tumour      
     Left 53 (44.9) 45 (46.9) 8 (36.4) 0.799 0.371
#
 
     Right 65 (55.1) 51 (53.1) 14 (63.6)   
Vascular invasion      
     Present 37 (31.4) 27 (28.1) 10 (45.5) 2.497 0.114
#
 
     Absent 81 (68.6) 69 (71.9) 12 (54.5)   
ER status      
     Positive 86 (72.9) 70 (72.9) 16 (72.7) 0.000 0.986
#
 
     Negative 32 (27.1) 26 (27.1) 6 (27.3)   
PR status      
     Positive 34 (61.7) 26 (60.4) 22 (66.7) 0.159 0.752
#
 
     Negative 26 (38.3) 8(39.6) 4(33.3)   
Nottingham Prognostic 
Index 
     
     < 3.4 33 (28.0) 27 (30.7) 6 (31.6) 0.006 0.939
#
 
     ≥ 3.4 74 (62.7) 61 (69.3) 13 (68.4)   
*Fisher’s exact test, # chi square test 
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Table 5.4: Relationship between S1PR1 expression in breast cancer and 
clinicopathological parameters   
Characteristics All patients (%) S1PR1+ S1PR1- χ2 value p value 
Age      
     < 50 22 (18.6) 0 (0.0) 22 (21.2) 3.609 0.069* 
     ≥ 50 96 (81.4) 14 (100.0) 82 (78.8)   
Surgery type      
     Mastectomy 73 (61.9) 13 (92.9) 60 (57.7) 6.467 0.016
#
 
     Wire loop excision 45 (38.1) 1 (7.1) 44 (42.3)   
Tumour size      
     < 2 cm 49 (41.5) 2 (14.3) 47 (45.2) 4.854 0.028
#
 
     ≥ 2 cm 69 (58.5) 12 (85.7) 57 (54.8)   
Nodal metastasis      
     Positive 43 (39.1) 7 (53.8) 36 (37.1) 1.348 0.246
#
 
     Negative 67 (60.1) 6 (46.2) 61 (62.9)   
Tumour grade      
     1 17 (14.4) 0 (0.0) 17 (16.3) 3.215 0.200
#
 
     2 59 (50.0) 7 (50.0) 52 (50.0)   
     3 42 (35.6) 7 (50.0) 35 (33.7)   
DCIS grade      
     Low 4 (3.4) 0 (0.0) 4 (3.8) 1.258 0.733* 
     Intermediate 19 (16.1) 1 (7.1) 18 (17.3)   
     High 52 (44.1) 8 (57.1) 44 (42.3)   
     Not seen 43 (36.4) 5 (35.7) 38 (36.5)   
Tumour stage      
     Limited,I-II 107 (90.7) 12 (85.7) 95 (91.3) 0.459 0.618* 
     Advanced, III-IV 11 (9.3) 2  (14.3) 9 (8.7)   
Side of tumour      
     Left 53 (44.9) 6 (42.9) 47 (45.2) 0.027 0.869
#
 
     Right 65 (55.1) 8 (57.1) 57 (54.8)   
Vascular invasion      
     Present 37 (31.4) 6 (42.9) 31 (29.8) 0.968 0.364* 
     Absent 81 (68.6) 8 (57.1) 73 (70.2)   
ER status      
     Positive 86 (72.9) 10 (71.4) 76 (73.1) 0.017 1.000
#
 
     Negative 32 (27.1) 4 (28.6) 28 (26.9)   
PR status      
     Positive 34 (61.7) 6 (54.5) 31 (63.3) 0.284 0.784* 
     Negative 26 (38.3) 5 (45.5) 18 (36.7)   
Nottingham 
Prognostic Index 
     
     < 3.4 33 (28.0) 0 (0.0) 33 (35.1) 6.537 0.011* 
     ≥ 3.4 74 (62.7) 13 (100.0) 61 (64.9)   
*Fisher’s exact test, # chi square test 
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Table 5.5: Relationship between ABCC1 expression in breast cancer and 
clinicopathological variables 
Characteristics All patients 
(%) 
ABCC1+ ABCC1- χ2 value p value  
Age      
     < 50 22 (18.6) 4 (10.5) 18 (22.5) 2.435 0.119
#
 
     ≥ 50 96 (81.4) 34 (89.5) 62 (77.5)   
Surgery type      
     Mastectomy 73 (61.9) 24 (63.2) 49 (61.2) 0.040 0.842
#
 
     Wire loop excision 45 (38.1) 14 (36.8) 31 (38.8)   
Tumour size      
     < 2 cm 49 (41.5) 13 (34.2) 36 (45.0) 1.235 0.266
#
 
     ≥ 2 cm 69 (58.5) 25 (65.8) 44 (55.0)   
Nodal metastasis      
     Positive 43 (39.1) 14 (23.7) 29 (30.0) 0.037 0.458* 
     Negative 67 (60.1) 23 (65.8) 44 (61.2)   
Tumour grade      
     1 17 (14.4) 3 (7.9) 14(17.5) 3.044 0.218
#
 
     2 59 (50.0) 18 (47.4) 41 (51.3)   
     3 42 (35.6) 17 (44.7) 25 (31.2)   
DCIS grade      
     Low 4 (3.4) 1 (2.6) 3 (3.8) 2.502 0.474* 
     Intermediate 19 (16.1) 9 (23.7) 10 (12.5)   
     High 52 (44.1) 16 (42.1) 36 (45.0)   
     Not seen 43 (36.4) 12 (31.6) 31 (38.8)   
Tumour stage      
     Limited,I-II 107 (90.7) 35 (92.1) 72 (90.0) 0.134 1.000* 
     Advanced, III-IV 11 (9.3) 3 (7.9) 8 (10.0)   
Side of tumour      
     Left 53 (44.9) 18 (47.4) 35 (43.8) 0.136 0.712
#
 
     Right 65 (55.1) 20 (52.6) 45 (55.0)   
Vascular invasion      
     Present 37 (31.4) 10 (26.3) 27 (33.8) 0.662 0.416
#
 
     Absent 81 (68.6) 28 (73.7) 53 (66.2)   
ER status      
     Positive 86 (72.9) 28 (73.7) 58 (72.5) 0.018 0.892
#
 
     Negative 32 (27.1) 10 (26.3) 22 (27.5)   
PR status      
     Positive 34 (61.7) 13 (65.0) 24 (60.0) 0.141 0.707
#
 
     Negative 26 (38.3) 7 (35.0) 16 (40.0)   
Nottingham Prognostic 
Index 
     
     < 3.4 33 (28.0) 9 (26.5) 24 (32.9) 0.441 0.504
#
 
     ≥ 3.4 74 (62.7) 25 (73.5) 49 (67.1)   
  *Fisher’s exact test, # chi square test 
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Table 5.6: Relationship between ATX expression in breast cancer and clinicopathological 
variables 
Characteristics All patients (%) ATX+ ATX- χ2 value p value 
Age      
     < 50 22 (18.6) 12 (15.8) 10 (23.8) 1.147 0.284
#
 
     ≥ 50 96 (81.4) 64 (84.2) 32 (76.2)   
Surgery type      
     Mastectomy 73 (61.9) 52 (68.4) 21 (50.0) 3.891 0.049
#
 
     Wire loop excision 45 (38.1) 24 (31.6) 21 (50.0)   
Tumour size      
     < 2 cm 49 (41.5) 32 (42.1) 17 (40.5) 0.030 0.863
#
 
     ≥ 2 cm 69 (58.5) 44 (57.9) 25 (59.5)   
Nodal metastasis      
     Positive 43 (39.1) 26 (35.6) 17 (45.9) 1.100 0.294
#
 
     Negative 67 (60.1) 47 (64.4) 20 (54.1)   
Tumour grade      
     1 17 (14.4) 10 (13.2) 7 (16.7) 0.700 0.705
#
 
     2 59 (50.0) 37 (48.7) 22 (52.4)   
     3 42 (35.6) 29 (38.2) 13 (31.0)   
DCIS grade      
     Low 4 (3.4) 4 (5.3) 0 (0.0) 2.182 0.584* 
     Intermediate 19 (16.1) 12 (15.8) 7 (16.7)   
     High 52 (44.1) 34 (44.7) 18 (44.1)   
     Not seen 43 (36.4) 26 (34.2) 17 (36.4)   
Tumour stage      
     Limited,I-II 107 (90.7) 68 (89.5) 39 (92.9) 0.363 0.744* 
     Advanced, III-IV 11 (9.3) 8 (10.5) 3 (7.1)   
Side of tumour      
     Left 53 (44.9) 34 (44.7) 19 (45.2) 0.003 0.958
#
 
     Right 65 (55.1) 42 (55.3) 23 (54.8)   
Vascular invasion      
     Present 37 (31.4) 20 (26.3) 17 (40.5) 2.502 0.112
#
 
     Absent 81 (68.6) 56 (73.7) 25 (59.5)   
ER status      
     Positive 86 (72.9) 53 (69.7) 33 (78.6) 1.068 0.301
#
 
     Negative 32 (27.1) 23 (30.3) 9 (21.4)   
PR status      
     Positive 37 (61.7) 20 (54.1) 17 (73.9) 2.366 0.124
#
 
     Negative 23 (38.3) 17 (45.9) 6 (26.1)   
Nottingham Prognostic 
Index 
     
     < 3.4 33 (30.8) 21 (30.0) 12 (32.4) 0.067 0.796
#
 
     ≥ 3.4 74 (69.2) 49 (70.0) 25 (67.6)   
*Fisher’s exact test, # chi square test 
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5.2.3 Relationship between the expression of each lipid signalling molecules and overall 
survival 
All the breast cancer patients were followed up for 10 years. At the time of analysis, 41/118 
(34.7%) patients had died. I explored the influence of various factors including the expression 
of lipid signalling molecules on overall survival (OS) in this cohort of breast cancer patients 
using the Kaplan Meier method and log-rank test. The Kaplan Meier curves for each clinical 
characteristics and lipid signalling molecules are shown in Figure. 5.8-5.11. The patients who 
had mastectomy had poorer overall survival compared to those who had wireloop excision 
(p=0.033). Patients with NPI of 3.4 or greater had significantly poorer OS (p=0.008). Other 
clinical characteristics including age group, stage and grade of tumour, lymph node status, 
side of tumour, ER and PR status showed no significant association with OS. Patients with 
presence of vascular invasion by tumour showed a borderline significant association with 
poorer OS (p= 0.058). A log rank test revealed that there was no significant association 
between the expression of SPHK1, S1PR1, ABCC1 and ATX with OS (Figure 5.11).
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Figure 5.7 The Kaplan Meier overall survival curves by age group, type of surgery, 
tumour stage and grade of breast cancer patients. 
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Figure 5.8: The Kaplan Meier overall survival curves by lymph node status, side of 
tumour, vascular invasion and NPI of breast cancer patients. 
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Figure 5.9: Kaplan Meier overall survival curves by ER and PR status of breast cancer 
patients. 
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Figure 5.10: The Kaplan Meier overall survival curves by SPHK1, S1PR1 ABCC1 and 
ATX expression in breast cancer patients. 
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5.3  Expression of lipid signalling molecules in bladder cancer 
I also had available to me 56 cases of primary transitional cell carcinoma of the urinary 
bladder obtained from the Pathology Department of the Queen Elizabeth Hospital. Each 
sample was stained for expression of SPHK1, S1PR1, ABCC1 and ATX. Patient 
demographics are shown in Table 5.7 and in Figure 5.12. Although 58.9% of tumours were 
smaller than 3 cm and 53.6% were in stage Ta, 62.5% were of high grade morphology. A 
summary of the expression of the lipid signalling molecules in bladder cancer is shown in 
Figure 5.13. 95% of cases expressed SPHK1 while 91% of cases were positive for S1PR1. 
ABCC1 was expressed in 45% of cases and ATX was expressed in 85% of cases. 
SPHK1 expression was observed in the cytoplasm and nucleus of both normal urothelium 
and malignant cells. SPHK1 expression was also seen in fibroblasts, macrophages, plasma 
cells and endothelial cells lining the blood vessels which served as internal positive control 
(Figure 5.14). S1PR1 was expressed in both normal urothelium and malignant cells with 
localisation to the cytoplasm (Figure 5.15). Normal urothelium was either negative or showed 
only low levels of ABCC1, whereas in ABCC1 positive tumours, levels of expression in 
tumour cells were higher than in normal cells (Figure 5.16). ATX was weakly expressed in 
normal urothelium but was strongly expressed in malignant cells and endothelial lining of 
blood vessels (Figure 5.17). 
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Table 5.7: Clinical characteristics of 56 cases of transitional cell carcinoma of the 
bladder  
Characteristic All patients (%) 
Tumour size 
 Range (cm) 0.5-15 
< 3 cm 33 (58.9) 
≥ 3 cm 21 (37.5) 
Unknown 2 (3.6) 
Tumour grade 
 Grade 1 14 (25.0) 
Grade 2 7 (12.5) 
Grade 3 35 (62.5) 
Tumour stage 
 Ta 30 (53.6) 
T1 15 (26.8) 
T2-T4 11 (19.6) 
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A   
B   
C   
Figure 5.11: The clinicopathological characteristics of bladder cancer patients 
according to tumour A) size, B) grade and C) stage. 
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Figure 5.12: The summary of expression of lipid signalling molecules in bladder cancer. 
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                      A          
                    B            
Figure 5.13: SPHK1 expression in normal urothelium and in bladder cancer. SPHK1 is 
expressed in both A) the normal urothelium (x400) B) and in the nucleus and cytoplasm of 
bladder cancer cells (x400). 
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                  A              
                  B            
Figure 5.14: S1PR1 expression in normal urothelium and in bladder cancer A) Strong 
expression of S1PR1 in the cytoplasm and cytoplasmic membrane of normal urothelium 
(x400) B) Moderate S1PR1 expression in the cytoplasm and cytoplasmic membrane of 
bladder cancer cells. Note strong S1PR1 staining in the endothelial cells of blood vessels 
(arrowed) (x400).  
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                      A               
                       B           
Figure 5.15: ABCC1 expression in normal urothelium and bladder cancer A) Absence of 
ABCC1 expression in normal urothelium but strong ABCC1 expression in the blood vessels 
(arrowed)(x400) B) Strong ABCC1 expression in the cytoplasm of bladder cancer cells 
(x400). 
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     A                       
    B   ……   .  
Figure 5.16: ATX expression in bladder cancer. A) Normal urothelium exhibited mild 
ATX expression (x 600). B) Strong ATX expression was observed in bladder cancer and the 
staining was localised to the cytoplasm of malignant cells. (x 600). 
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5.3.1 Relationship between the expression of lipid signalling molecules in bladder cancer and 
clinicopathological parameters 
Having established the prevalence of expression of the different lipid signalling molecules in 
bladder cancer, I next studied the relationship between expression and clinicopathological 
features, including tumour size, tumour stage and tumour grade. I used Fisher’s exact test to 
determine if the expression of each individual lipid signalling molecule was significantly 
associated with any of these clinicopathological features. No significant associations were 
found. The results of this analysis are summarised in Tables 5.8 - 5.11. 
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Table 5.8: SPHK1 expression in bladder cancer in relation to tumour size, grade and 
stage. 
Characteristic 
All patients 
(%) SPHK1 + SPHK1 - p value   
Tumour size 
    < 3 cm 33 (58.9) 31 (58.5) 2 (66.7) 1.000
*
 
≥ 3 cm 21 (37.5) 20 (37.7) 1 (33.3) 
 Unknown 2 (3.6) 2 (3.8) 0 (0.0) 
 Tumour grade 
    Grade 1 14 (25.0) 13 (24.5) 1 (33.3) 1.000
*
 
Grade 2 7 (12.5) 7 (13.2) 0 (0.0) 
 Grade 3 35 (62.5) 33 (62.3) 2 (66.7) 
 Tumour stage 
    Ta 30 (53.6) 29 (54.7) 1 (33.3) 0.267
*
 
T1 15 (26.8) 13 (24.5) 2 (66.7) 
 T2-T4 11 (19.6) 11 (20.8) 0 (0.0) 
 
 *Fisher’s exact test 
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Table 5.9: S1PR1 expression in bladder cancer in relation to tumour size, grade and 
stage. 
Characteristic 
All patients 
(%) S1PR1+ S1PR1- p value 
Tumour size 
    < 3 cm 33 (58.9) 31 (60.8) 2 (40.0) 0.475
*
 
≥ 3 cm 21 (37.5) 18 (35.3) 3 (60.0) 
 Unknown 2 (3.6) 2 (3.9) 0 (0.0) 
 Tumour grade 
    Grade 1 14 (25.0) 13 (25.5) 1 (20.0) 0.808
*
 
Grade 2 7 (12.5) 6 (11.8) 1 (20.0) 
 Grade 3 35 (62.5) 32 (62.7) 3 (60.0) 
 Tumour stage 
    Ta 30 (53.6) 27 (52.9) 3 (60.0) 1.000
*
 
T1 15 (26.8) 14 (27.5) 1 (20.0) 
 T2-T4 11 (19.6) 10 (19.6) 1 (20.0) 
 
  *Fisher’s exact test 
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Table 5.10: ABCC1 expression in bladder cancer in relation to tumour size, grade and 
stage. 
Characteristic 
All patients 
(%) ABCC1+ ABCC1- p value 
Tumour size 
    < 3 cm 33 (58.9) 15 (60.0) 18 (58.1) 0.316
*
 
≥ 3 cm 21 (37.5) 8 (32.0) 13 (41.9) 
 Unknown 2 (3.6) 2 (8.0) 0 (0.0) 
 Tumour grade 
    G1 14 (25.0) 9 (36.0) 5 (16.1) 0.223
*
 
G2 7 (12.5) 2 (8.0) 5 (16.1) 
 G3 35 (62.5) 14 (56.0) 21 (67.7) 
 Tumour stage 
    Ta 30 (53.6) 15 (60.0) 15 (48.4) 0.424
*
 
T1 15 (26.8) 7 (28.0) 8 (25.8) 
 T2-T4 11 (19.6) 3 (12.0) 8 (25.8) 
 
*Fisher’s exact test 
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Table 5.11: ATX expression in bladder cancer in relation to tumour size, grade and 
stage 
Characteristic 
All patients  
(%) ATX+ ATX- p value 
Tumour size 
        < 3 cm 33 (58.9) 29 (80.0) 4 (56.9) 0.700* 
    ≥ 3 cm 21 (37.5) 20 (39.2) 1 (20.0) 
     Unknown 2 (3.6) 2 (3.9) 0 (0.0) 
 Tumour grade 
        G1 14 (25.0) 11 (21.6) 3 (60.0) 0.204* 
    G2 7 (12.5) 7 (13.7) 0 (0.0) 
     G3 35 (62.5) 33 (64.7) 2 (40.0) 
 Tumour stage 
        Ta 30 (53.6) 27 (52.9) 3 (60.0) 1.000* 
    T1 15 (26.8) 14 (27.5) 1 (20.0) 
     T2-T4 11 (19.6) 10 (19.6) 1 (20.0)  
*Fisher’s exact test 
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5.4 Expression of lipid signalling molecules in lung cancer  
Finally I performed immunohistochemistry for SPHK1, S1PR1, ABCC1 and ATX on 68 
cases of lung cancer obtained as a tissue microarray from the Department of Pathology and 
Laboratory of Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, 
Olomouc, Czech Republic. However due to tissue losses during sectioning and staining 
procedures, the number of cases analysed varied between each marker. The lung cancer 
patients comprised five histological subtypes; squamous cell carcinoma, adenocarcinoma, 
small cell, large cell and anaplastic carcinoma. The clinical characteristics of lung cancer 
patients are shown in Table 5.12. 
Figure 5.18 provides a summary of the expression of each lipid signalling molecule. SPHK1 
was expressed in 19/61 cases (31.1%). In all positive cases the expression was of moderate 
intensity compared to the positive control which was the endothelial lining of blood vessels. 
SPHK1 was localised to the nucleus and cytoplasm of malignant cells. SPHK1 was also seen 
in the cytoplasm of normal respiratory epithelium lining the bronchi. However in these cells, 
the cytoplasmic expression was of mild to moderate intensity. The apical surface of normal 
respiratory epithelium showed intense SPHK1 staining. Prominent SPHK1 staining was also 
observed within the alveolar macrophages and in nerve bundles. S1PR1 was weakly 
expressed in all cases. (S1PR1 downregulation in lung cancer wil be further discussed in the 
discussion section). Endothelial lining of blood vessels served as internal positive control for 
S1PR1 staining. Cytoplasmic expression of ABCC1 was weak in normal respiratory 
epithelium and arterioles but strong ABCC1 expression was observed in the cytoplasm of 
malignant cells in 85% of cases. ATX was expressed in 38% of lung cancer patients and 
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staining was localised in the cytoplasm of malignant cells. Moderate ATX staining was also 
seen in normal respiratory epithelium.  
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Table 5.12: Clinical characteristics of lung cancer patients 
Characteristics All patients 
n=68 (%) 
Age  
    < 70 60 (88.2) 
    ≥ 70 8 (11.8) 
Gender  
    Male 55 (80.9) 
    Female 13 (19.1) 
Histological subtype  
    Squamous cell carcinoma 28 (41.2) 
    Adenocarcinoma 29 (42.6) 
    Small cell carcinoma 3 (4.4) 
    Large cell carcinoma 6 (8.8) 
    Anaplastic carcinoma 2 (2.9) 
Tumour stage  
    Limited,I-II 20 (35.7) 
    Advanced, III-IV 36 (64.3) 
Nodal metastasis  
    Positive 33 (58.9) 
    Negative 23 (41.1) 
Distant metastasis  
    Positive 6 (10.7) 
    Negative 50 (89.3) 
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Figure 5.17: Summary of the expression of lipid signalling molecules in lung cancer. 
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Figure 5.18: SPHK1 expression in normal lung and lung cancer A) Weak expression of 
SPHK1 in the cytoplasm of normal bronchial lining epithelium (x400) B) Strong SPHK1 
expression in the cytoplasm of lung adenocarcinoma (x400)  
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                      B 
  
Figure 5.19: ABCC1 expression in normal lung tissue and lung cancer A) Weak ABCC1 
expression in normal respiratory epithelium (x400) and B) Strong ABCC1 expression in 
malignant cells (x400). 
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A                       
 
B              
Figure 5.20: ATX expression in normal lung tissue and lung cancer A) Moderate to 
strong ATX expression was observed in the bronchiolar lining cells (x 600) B) Strong ATX 
expression was seen in lung cancer (x 600). 
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5.4.1 Expression of lipid signalling molecules in lung cancer and their relationship with 
clinicopathological parameters 
Tables 5.13 to 5.15 summarise the expression of each lipid signalling molecule in lung cancer 
in relation to clinicopathological parameters. ABCC1 expression was commonly seen in 
adenocarcinoma subtype of lung cancer (Table 5.14, p= 0.015) and ATX positivity was more 
common in patients of advanced stage of disease (Table 5.15, p=0.015). No other significant 
associations were observed. 
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Table 5.13: Expression of SPHK1 in lung cancer in relation to clinicopathological 
parameters 
Characteristics All patients 
n=61 (%) 
SPHK1 + SPHK1 - χ2 value p value 
Age      
    < 70 51 (83.6) 16 (84.2) 35 (83.3) 0.007 0.624* 
    ≥ 70 10 (16.4) 3 (15.8) 7 (16.7)   
Gender      
    Male 48 (80.3) 17 (89.5) 32 (75.6) 1.461 0.309* 
    Female 12 (19.7) 2 (10.5) 10 (24.4)   
Histological subtype      
    Squamous cell carcinoma 27 (44.3) 9 (47.4) 18 (42.9) 2.853 0.678* 
    Adenocarcinoma 26 (42.6) 8 (42.1) 18 (42.9)   
    Small cell carcinoma 2 (3.3) 0 (0.0) 2 (4.8)   
    Large cell carcinoma 5 (8.2) 1 (5.3) 4 (9.5)   
    Anaplastic carcinoma 1 (1.6) 1 (5.3) 0 (0.0)   
Tumour stage      
    Limited,I-II 16 (32.0) 3 (20.0) 13 (37.1) 1.418 0.328* 
    Advanced, III-IV 34 (68.0) 12 (80.0) 22 (62.9)   
Nodal metastasis      
    Positive 30 (60.0) 10 (66.7) 20 (57.1) 0.397 0.529
#
 
    Negative 20 (40.0) 5 (33.3) 15 (42.9)   
Distant metastasis      
    Positive 6 (12.0) 2 (13.3) 4 (11.4) 0.036 1.000* 
    Negative 43 (80.0) 13 (86.7) 31 (88.6)   
#chi square test, *Fisher’s exact test 
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Table 5.14: Expression of ABCC1 in lung cancer in relation with clinicopathological 
parameters 
Characteristics All patients 
n=68 (%) 
ABCC1+ ABCC1- χ2 value p value 
Age      
    < 70 60 (88.2) 52 (89.7) 8 (80.0) 0.766 0.381* 
    ≥ 70 8 (11.8) 6 (10.3) 2 (20.0)   
Gender      
    Male 55 (80.9) 46 (79.3) 9 (90.0) 0.630 0.427* 
    Female 13 (19.1) 12 (20.7) 1 (10.0)   
Histological subtype      
    Squamous cell carcinoma 28 (41.2) 23 (39.7) 5 (50.0) 10.788 0.015* 
    Adenocarcinoma 29 (42.6) 28 (48.3) 1 (10.0)   
    Small cell carcinoma 3 (4.4) 1 (1.7) 2 (20.0)   
    Large cell carcinoma 6 (8.8) 5 (8.6) 1 (10.0)   
    Anaplastic carcinoma 2 (2.9) 1 (1.7) 1 (10.0)   
Tumour stage      
    Limited,I-II 20 (35.7) 18 (38.3) 2 (22.2) 0.850 0.466* 
    Advanced, III-IV 36 (64.3) 29 (61.7) 7 (79.8)   
Nodal metastasis      
    Positive 33 (58.9) 27 (57.4) 6 (66.7) 0.261 0.723* 
    Negative 23 (41.1) 20 (42.6) 3 (33.3)   
Distant metastasis      
    Positive 6 (10.7) 5 (10.6) 1 (11.1) 0.002 0.669* 
    Negative 50 (89.3) 42 (89.4) 8 (88.9)   
*Fisher’s exact test 
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Table 5.15: Expression of ATX in lung cancer in relation to clinicopathological 
parameters 
Characteristics All patients 
n=63 (%) 
ATX+ ATX- χ2 value p value 
Age      
    < 70 52 (82.5) 20 (83.3) 32 (82.1) 0.017 1.000* 
    ≥ 70 11 (17.5) 4 (16.7) 7 (17.9)   
Gender      
    Male 50 (79.4) 17 (70.8) 33 (84.6) 1.723 0.214* 
    Female 13 (20.6) 7 (29.2) 6 (15.4)   
Histological subtype      
    Squamous cell carcinoma 28 (44.4) 9 (37.5) 19 (48.7) 4.052 0.375* 
    Adenocarcinoma 25 (39.7) 13 (54.2) 12 (30.8)   
    Small cell carcinoma 2 (3.2) 0 (0.0) 2 (5.1)   
    Large cell carcinoma 7 (11.1) 2 (8.3) 5 (12.8)   
    Anaplastic carcinoma 1 (1.6) 0 (0.0) 1 (2.6)   
Tumour stage      
    Limited,I-II 19 (37.3) 3 (15.8) 16 (50.0) 5.969 0.015
#
 
    Advanced, III-IV 32 (62.7) 16 (84.2) 16 (50.0)   
Nodal metastasis      
    Positive 30 (58.8) 12 (63.2) 18 (56.2) 0.235 0.628* 
    Negative 21 (41.2) 7 (36.8) 14 (35.9)   
Distant metastasis      
    Positive 6 (11.8) 4 (21.1) 2 (6.2) 2.467 0.179* 
    Negative 45 (88.2) 15 (78.9) 30 (93.8)   
#Chi square test, *Fisher’s exact test 
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       A  
       B  
Figure 5.21: Expression of A) SPHK1 B) S1PR1 in breast, bladder and lung cancer 
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Figure 5.22: Expression of A) ABCC1 and B) ATX in breast, bladder and lung cancer 
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5.5  Discussion 
Expression of lipid signaling molecules in breast cancer 
In this study I have shown that SPHK1, which is the key regulator of S1P formation is 
overexpressed in the majority of breast cancer (81.4%). Breast cancer patients with tumours 
expressing high levels of cytoplasmic SPHK1 had significantly shorter recurrence times than 
those who expressed low levels of cytoplasmic SPHK1 with a difference in recurrence time 
of 10.5 years, suggesting that the overexpression of SPHK1 is a poor prognostic factor in 
breast cancer (Watson et al., 2010). Ling’s group has found that SPHK1 mRNA levels 
increase with advanced stage breast cancer which suggest increased S1P levels during disease 
progression (Ling et al. 2011). In contrast to Ling’s findings, I found that SPHK1 expression 
was not significantly associated with stage of breast cancer or with any other 
clinicopathological parameters. SPHK1 expression also did not show any significant 
association with survival which also contradicts the findings of Ruckhaberle et al who found 
that SPHK1 expression was associated with reduced patient survival (Ruckhäberle et al. 
2008).  
Export of S1P is mediated by ABCC1 and ABCG2 transporters. In this study, I found that 
ABCC1 was overexpressed in only 38% of cases; these data suggest that other S1P 
transporters are likely to be involved in transporting S1P in breast cancer cells.  
Although I found that S1PR1 was expressed in only 14% of breast cancers, its expression 
showed a significant association with poor prognostic factors i.e. larger tumour size, and a 
higher Nottingham Prognostic Index. Strong membranous S1PR1 has been reported to be 
associated with shorter time to recurrence in breast cancer patients (Watson et al., 2010). 
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High cytoplasmic S1PR1 expression level was also associated with shorter disease-specific 
survival. The findings of Watson et al. suggest that there might be stimulation of a pathway 
including SPHK1, S1PR1 and ERK-1/2 which might drive the progression of breast cancer 
(Watson et al., 2010).  
Yang’s group has shown that ATX mRNA was overexpressed about 4.3 times more in 
cancerous as compared to normal breast tissues (Yang et al. 2002). ATX also affects motility 
dependent processes such as invasion and metastasis of breast cancer cells as well as 
angiogenesis (Nam et al. 2000). In this study I found that ATX positive breast cancer patients 
were more likely to undergo mastectomy than wire-loop excision (p= 0.049) however ATX 
was not associated with poorer OS. Previous work by Liu and others supports a role of LPA, 
ATX, LPA receptors and lipid phosphate phosphatases in cancer ( Liu et al. 2009; Yu et al. 
2008; Kitayama et al. 2004), therefore served as possible therapeutic targets for anti-cancer 
therapeutics. Among the therapeutics under development are monoclonal antibodies against 
LPA, ATX inhibitors and LPA receptor antagonists (M. Murph & Mills 2007). 
Lpathomab
TM
,, a monoclonal antibody targeting LPA has been developed and hopefully to 
enter clinical trials soon.  
Expression of lipid signaling molecules in bladder cancer 
I found that SPHK1 was expressed in 91.6% and S1PR1 was expressed in 91.1% of bladder 
cancer. J82 cells were shown to express S1PR1 and S1PR3 mRNA which regulate thrombin 
and LPA-stimulated motility. S1P caused enhancement of thrombin-stimulated migration in 
bladder cancer cells. Exogenous S1P and SPPC also caused a rapid and transient increase in 
intracellular Ca2+ in J82 cells but did not stimulate the growth of these cells (Rümenapp et 
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al. 2000). Stimulation of cell growth was however observed after treatment with LPA and 
thrombin.  
ABCC1 expression was seen in 44.6% of bladder cancer cases and is also expressed in the 
endothelial lining cells of blood vessels. Scherman et al had shown that the expression of 
ABCC1 in endothelial cells of microvessels in the brain play a role in the blood brain barrier 
hence it has been a critical target for central nervous system (CNS) pharmaceuticals 
(Scherrmann 2005). Little is known about the role ABCC1 in bladder cancer. 
ATX was expressed in 85% of bladder cancer and in the endothelial lining of blood vessels. 
ATX was found to be essential for angiogenesis (van Meeteren et al. 2006) and endothelial 
cell migration (Ptaszynska et al 2011). For bladder cancer, no clinical data was available to 
correlate the expression of these lipid molecules with overall survival. 
Expression of lipid signaling molecules in lung cancer 
SPHK1 mRNA levels were shown to be higher in lung cancer compared to their normal 
tissue counterparts (French et al.,2003a). The present study has shown that SPHK1 is 
overexpressed in 31% of lung cancers. SPHK1 over-expression was found in all histological 
subtypes of lung cancer except for small cell carcinoma. Johnson et al found that all 25 cases 
(100%) of non small cell lung cancer (NSCLC) stained with SPHK1 antibody showed 
overwhelmingly positive SPHK1 expression as compared to adjacent normal lung tissue 
(Johnson et al., 2005). The up-regulation of SPHK1 was confirmed at the mRNA level by 
cDNA profiling array. Nine out of 20 patients showed an elevation of more than two fold 
when tumour tissues were compared to adjacent normal tissues. In my study I have observed 
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the localization of SPHK1 staining in a variety of structures in lung tissue. The apical surface 
of normal respiratory epithelium displayed intense SPHK1 staining indicating a role for 
SPHK1 in the ciliary movement in aiding mucociliary clearance. SPHK1 was also seen in the 
serous glands but was absent in the mucous glands. This is not surprising as Boujaoude’s 
group has found that the cystic fibrosis transmembrane conductance regulator was mainly 
localised to the serous cells and later it was discovered that this regulator protein could 
regulate the transport of S1P (which is produced by abundant SPHK1 in serous glands) across 
the plasma membrane of cells (Boujaoude et al. 2001). As serous cells produce abundant 
protein with antimicrobial, anti-inflammatory, antiprotease and antioxidant properties, it is 
possible that secreted S1P plays a role in these physiological and pathological functions. In 
this study, strong SPHK1 expression was also seen in the cytoplasm of alveolar macrophages 
which supports the findings of S1P as a physiological activator of alveolar macrophages 
(Hornuss et al., 2001).  
S1PR1 was found to be strongly expressed in normal respiratory epithelium, however in this 
study I found that S1PR1 was weakly staining in lung cancer. It is plausible that S1PR1-
mediated S1P signalling could negatively regulate tumour progression or growth. In support 
of this, it has been shown that S1PR1 signalling is downregulated in intestinal tumourigenesis 
(Sabino Zani et al., 2006). Furthermore, analysis of S1PR1 expression on ONCOMINE 
(www.oncomine.org) reveals the findings of Selamat’s group that S1PR1 was downregulated 
in 47/117 (40.1%) of lung cancer patients via gene expression microarray. In another gene 
expression analysis study by Garber’s group showed that S1PR1 was downregulated in 51 
out of 73 (70%) lung cancer mRNA.(www.oncomine.org). Therefore, it can be speculated 
that S1PR1 signalling inhibits proliferation and survival in lung cancer. With this limited 
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study of mine, it is not known which signalling pathways might mediate the tumour 
suppressive role of S1PR1 in these malignancies, but this will be the subject of future 
investigastions in determining its potential for therapeutic intervention.  
My finding showed that S1PR2 was expressed in 3% of lung cancer. The downregulation of 
S1PR2 has been shown to induce the formation of Diffuse large B cell lymphoma in 
transgenic mice (Cattoretti et al., 2010). ATX was overexpressed in 38% of lung cancer 
which is in keeping with the findings of Yang and co-workers who found ATX mRNA 
expression in eight out of 12 (58%) lung cancer cell lines. Strong ATX expression was 
observed mainly in poorly differentiated lung carcinomas. I found that lung cancer patients 
expressing ATX were more likely to present at advanced stage of disease. The impact of the 
overexpression of ATX in lung cancer warrants further investigation. 
Taken together, my findings show that the levels of expression of lipid signalling proteins 
differ in different epithelial malignancies. Their expression pattern however provide clues as 
how these lipid signalling molecules may play a role in the pathogenesis of breast, bladder 
and lung cancer, for instance, S1PR1 and ATX may be a prognostic marker in breast cancer 
and lung cancer, respectively. The role of each signalling molecules in these malignancies 
warrants further investigation.  
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Main findings 
In this study I have profiled the expression of different lipid signalling molecules in two 
common haematological malignancies; HL and DLBCL and in three types of epithelial 
cancers. I  found that S1PR1 was commonly expressed in both HL and DLBCL. I have also 
shown that in breast cancer, S1PR1 was associated with larger tumour size and higher NPI 
which suggest that S1PR1 is a poor prognostic marker in breast cancer. Given the availability 
of S1PR1 antagonists, my findings suggest that S1PR1 could be a therapeutic target in S1PR1 
positive cancers. ATX is also an interesting lipid molecule to be studied further. ATX was 
commonly expressed in breast and bladder cancer and its expression was significantly 
associated with advanced stage of lung cancer.  
Using gene expression I managed to show that anti-S1P, Sphingomab could restore the B cell 
receptor phenotype in HL L591 cell line and the downregulation of S1PR3 and S1PR5 by 
Sphingomab suggests that these two S1P signaling pathways are possible therapeutic targets 
for Sphingomab in cancer therapeutics. 
I confirmed previous reports that EBV positivity was significantly associated with shorter 
time to death in DLBCL patients. Presence of more than one extranodal site of disease and 
intermediate to high IPI were also associated with poorer overall survival. 
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Future work 
More detail analysis are required to determine the contribution of these lipid molecules in 
cancers. Using S1PR agonist/antagonists, we could explore their effects in the epithelial 
tumours, HL and DLBCL cell lines that over-express either one or more of the S1P receptors. 
The impact includes viability, proliferation, migration and apoptosis. Over-expression or 
knockdown experiments could be performed to see the cell signalling pathways regulated by 
these lipid molecules. Particularly in HL, we need to explore how SPHK1 mediates the 
oncogenicity of S1PR1 and in lung cancer, which signaling pathway mediates the 
downstream effects of S1PR1 downregulation. Alternatively, Sphingomab could also be used 
to explore in more detail how blockade of S1P influences the phenotypic changes induced by 
S1P. Measurement of S1P pre and post Sphingomab treatment would be useful in cell lines of 
different tumours.  
It would be interesting to investigate if there are any differences in the morphology of the 
EBV
+
 DLBCL vs the EBV
- 
DLBCL and also the GCB subtype of DLBCL vs the Non GCB 
subtype. Due to low number of EBV positive DLBCL cases, perhaps a multicenter study in 
the UK would be beneficial to investigate further if EBV positivity is a poor prognostic 
indicator in DLBCL. In view of the high positivity of S1PR1 in DLBCL, I would also like to 
investigate further if S1PR1 could be a diagnostic and prognostic marker in DLBCL. Perhaps 
S1PR1 expression across normal lymphoid tissues and different subtypes of lymphoma 
would be helpful to begin with. 
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Table A1: List of genes downregulated after 2 hours of treatment with Sphingomab. 
Transcript 
ID 
Gene symbol Gene description p value fold 
change 
2472054 GDF7 growth differentiation factor 7 0.009862 1.260554 
2351465 PROK1 prokineticin 1 0.011611 1.269725 
3960042 SSTR3 somatostatin receptor 3 0.0122 1.218627 
3514879 TPTE2P2 transmembrane phosphoinositide 3-phosphatase and  tensin homolog 2 
pseudogene 2 
0.012462 1.244277 
3335751 TSGA10IP testis specific, 10 interacting protein 0.012702 1.213711 
2948683 SFTA2 surfactant associated 2 0.012729 1.356907 
3829398 CHST8 carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8 0.013025 1.206956 
4044363 CNR2 cannabinoid receptor 2 (macrophage) 0.013971 1.303814 
3870824 LAIR1 leukocyte-associated immunoglobulin-like receptor 1 0.014486 1.208251 
3886598 KCNK15 potassium channel, subfamily K, member 15 0.014953 1.210646 
3721010 IGFBP4 insulin-like growth factor binding protein 4 0.015167 1.260658 
2391005 C1orf159 chromosome 1 open reading frame 159   0.015732 1.211752 
3882614 C20orf144 chromosome 20 open reading frame 144 0.015822 1.664164 
3677103 PRSS27 protease, serine 27 0.016525 1.205747 
3708597 SPEM1 spermatid maturation 1 0.017765 1.263845 
3830306 HAMP hepcidin antimicrobial peptide 0.018071 1.218567 
3774906 SECTM1 secreted and transmembrane 1 0.018105 1.220535 
3952762 CLDN5 claudin 5 0.018175 1.317094 
3868681 KLK1 kallikrein 1 0.018794 1.227132 
3415744 IGFBP6 insulin-like growth factor binding protein 6 0.018848 1.250835 
3707127 MED11 mediator complex subunit 11 0.019065 1.279871 
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3273100 DUX4L4 double homeobox 4 like 4 | double homeobox 4 like 7   0.022343 1.420224 
3850406 S1PR5 sphingosine-1-phosphate receptor 5 0.023181 1.361607 
4035762 TTTY14 testis-specific transcript, Y-linked 14  0.024681 1.255197 
3416353 HOXC8 homeobox C8 0.024789 1.247533 
3273126 DUX4L4 double homeobox 4 like 4   0.024917 1.380069 
3907210 MATN4 matrilin 4 0.026837 1.20311 
3270840 MGMT O-6-methylguanine-DNA methyltransferase 0.028647 1.247005 
3923857 KRTAP10-9 keratin associated protein 10-9   0.028845 1.217307 
2949993 BTNL2 butyrophilin-like 2 (MHC class II associated) 0.028901 1.219368 
3356328 ADAMTS15 ADAM metallopeptidase with thrombospondin type 1 motif, 15 0.029037 1.202927 
3762185 HILS1 histone linker H1 domain, spermatid-specific 1 0.029184 1.260129 
3453513 WNT10B wingless-type MMTV integration site family, member 10B 0.030785 1.365521 
3838665 RCN3 reticulocalbin 3, EF-hand calcium binding domain 0.031084 1.216106 
3662710 CCL17 chemokine (C-C motif) ligand 17 0.031084 1.234359 
2502686 MARCO macrophage receptor with collagenous structure 0.031093 1.220807 
2505618 CFC1B cripto, FRL-1, cryptic family 1B   0.032203 1.202504 
3956984 ZMAT5|CABP7 zinc finger, matrin-type 5 | calcium binding protein 7 0.033461 1.226454 
2435989 S100A8 S100 calcium binding protein A8 0.034439 1.245579 
3709384 GUCY2D guanylate cyclase 2D, membrane (retina-specific) 0.0355 1.250199 
3841901 NLRP2 NLR family, pyrin domain containing 2 0.036825 1.202427 
3557198 CEBPE CCAAT/enhancer binding protein (C/EBP), epsilon 0.03805 1.219558 
3849190 ACTL9 actin-like 9 0.03834 1.349617 
3886576 WISP2 WNT1 inducible signaling pathway protein 2 0.039883 1.276118 
3818446 CRB3 crumbs homolog 3 (Drosophila) 0.04086 1.251961 
3377737 KCNK7 potassium channel, subfamily K, member 7 0.041239 1.2048 
3851840 KLF1 Kruppel-like factor 1 (erythroid) 0.042253 1.253656 
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3629416 RASL12 RAS-like, family 12 0.042753 1.214962 
3866106 GNG8 guanine nucleotide binding protein (G protein), gamma 8 0.043184 1.225943 
2357961 BOLA1 bolA homolog 1 (E. coli) 0.04507 1.216382 
3678316 ZNF500 zinc finger protein 500 0.045433 1.216138 
3014227 BHLHA15 basic helix-loop-helix family, member a15 0.04549 1.246796 
3837825 KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 0.046201 1.239692 
3815116 PALM paralemmin 0.046403 1.233797 
2536874 GAL3ST2 galactose-3-O-sulfotransferase 2 0.047326 1.234331 
3656151 MYLPF myosin light chain, phosphorylatable 0.047578 1.236727 
3868033 TSKS testis-specific serine kinase substrate 0.048042 1.204195 
3015778 EPO erythropoietin 0.04934 1.209653 
2711604 CPN2 carboxypeptidase N, polypeptide 2 0.04948 1.303106 
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Table A2: List of genes downregulated after 12 hours of treatment with Sphingomab 
Transcript 
ID 
Gene symbol Gene description p value fold change 
3893642 LIME1 Lck interacting transmembrane adaptor 1 0.003311 1.217527 
3551407 HHIPL1 HHIP-like 1 0.003581 1.285045 
2900116 HIST1H2BO histone cluster 1, H2bo 0.003746 1.425556 
3842278 ZNF524 zinc finger protein 524 0.003747 1.271449 
3031345 LRRC61 leucine rich repeat containing 61 0.003793 1.226793 
3358241 SCT secretin 0.003846 1.231226 
3934614 KRTAP12-4 keratin associated protein 12-4 0.003891 1.25782 
2381264 MOSC2 MOCO sulphurase C-terminal domain containing 2 0.004499 1.264808 
3948528 UPK3A uroplakin 3A 0.004565 1.220747 
3871127 TNNI3 troponin I type 3 (cardiac) 0.004632 1.214861 
3733590 SOX9 SRY (sex determining region Y)-box 9 0.004825 1.220222 
3715460 PYY2 peptide YY, 2 (seminalplasmin) 0.005055 1.207429 
2551189 SIX2 SIX homeobox 2 0.005447 1.24847 
3740462 RILP Rab interacting lysosomal protein 0.005509 1.200214 
3472389 LHX5 LIM homeobox 5 0.005999 1.268392 
3867326 MAMSTR MEF2 activating motif and SAP domain containing  
transcriptional regulator 
0.006184 1.237335 
3817602 TNFAIP8L1 tumor necrosis factor, alpha-induced protein 8-like 1 0.006684 1.301432 
3837081 NPAS1 neuronal PAS domain protein 1 0.007362 1.215552 
3609098 LOC643797 AGVR6190 0.007457 1.328855 
3685373 ERN2 endoplasmic reticulum to nucleus signaling 2 0.007756 1.204761 
3285119 FZD8 frizzled homolog 8 (Drosophila) 0.007865 1.227744 
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3255938 OPN4 opsin 4 0.007882 1.409973 
3762125 SAMD14|PDK2 sterile alpha motif domain containing 14 | 
 pyruvate dehydrogenase kinase, isozyme 2 
0.007905 1.2012 
2326846 TRNP1 TMF1-regulated nuclear protein 1 0.007907 1.213377 
2528159 WNT10A wingless-type MMTV integration site family, member 10A 0.007953 1.237534 
3868681 KLK1 kallikrein 1 0.008011 1.228527 
2929699 RAB32  0.008168 1.234358 
3178545 C9orf47|S1PR3 chromosome 9 open reading frame 47 | 
 sphingosine-1-phosphate receptor 3 
0.008434 1.300196 
2323882 PLA2G2F phospholipase A2, group IIF 0.008557 1.234817 
3195059 LCNL1 lipocalin-like 1 0.008587 1.211874 
3732721 LOC440461|LOC146880 SH3 domain containing 20 pseudogene | hypothetical  
LOC146880 
0.008615 1.211667 
3250726 KIAA1274  0.008933 1.265024 
3303774 LBX1 ladybird homeobox 1 0.008945 1.32143 
3815710 EFNA2 ephrin-A2 0.009018 1.241684 
3950832 ADM2 adrenomedullin 2 0.009071 1.245749 
3837536 CRX|TPRX1 cone-rod homeobox | tetra-peptide repeat homeobox 1 0.009716 1.200623 
3962145 TNFRSF13C tumor necrosis factor receptor superfamily, member 13C 0.00985 1.389514 
3738306 NPB neuropeptide B 0.010505 1.286477 
3334125 COX8A cytochrome c oxidase subunit VIIIA (ubiquitous) 0.010821 1.231539 
3158377 ZNF251|SCRT1| 
C8ORFK29 
zinc finger protein 251 | scratch homolog 1, zinc finger protein  
(Drosophila) | hypothetical LOC340393 
0.010853 1.231619 
3855320 MGC10814 0.010995 1.323741 
2824144 FLJ11235  0.01107 1.255503 
3913737 NKAIN4 Na+/K+ transporting ATPase interacting 4 0.011415 1.238623 
3861905 IL28B|IL28A interleukin 28B (interferon, lambda 3) | interleukin 28A 0.011464 1.308605 
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 (interferon, lambda 2) 
3756723 KRTAP2-4|KRTAP2-1| 
KRTAP2-2|LOC730755| 
KAP2.1B 
keratin associated protein 2-4 | keratin associated protein 2-1  
| keratin associated protein 2-2 |  
keratin associated protein 2-4-like  
| keratin associated protein 2.1B 
0.011555 1.314308 
3934344 LOC100129890 similar to hCG1750329 0.011582 1.201524 
3893250 BIRC7 baculoviral IAP repeat-containing 7 0.012068 1.237511 
3846390 RAX2 retina and anterior neural fold homeobox 2 0.012184 1.312011 
3119792 MAPK15 mitogen-activated protein kinase 15 0.012503 1.261976 
3954567 POM121L10P|POM121L1P
| 
POM121L4P|POM121L8P| 
POM121L9P 
POM121 membrane glycoprotein-like 10, pseudogene | 
 POM121 membrane glycoprotein-like 1, pseudogene | 
 POM121 membrane glycoprotein-like 4 pseudogene |  
POM121 membrane glycoprotein-like 8 pseudogene |  
POM121 membrane glycoprotein-like 9, pseudogene 
0.012561 1.337372 
3066613 ATXN7L1 ataxin 7-like 1 0.012572 1.366192 
3720388 PNMT phenylethanolamine N-methyltransferase 0.012576 1.201561 
3671506 OSGIN1 oxidative stress induced growth inhibitor 1 0.012584 1.284828 
2470805 MYCN v-myc myelocytomatosis viral related oncogene, 
 neuroblastoma derived (avian) 
0.012615 1.452516 
3118838 FLJ43860  0.013007 1.249176 
3841102 PRKCG protein kinase C, gamma 0.013405 1.216666 
3328349 ACCS 1-aminocyclopropane-1-carboxylate synthase homolog  
(Arabidopsis)(non-functional) 
0.013472 1.210305 
3907210 MATN4 matrilin 4 0.013619 1.200984 
3722039 RAMP2 receptor (G protein-coupled) activity modifying protein 2 0.013889 1.23828 
2460422 FAM89A family with sequence similarity 89, member A 0.014317 1.201617 
2994981 PRR15 proline rich 15 0.014523 1.211084 
3995088 FATE1 fetal and adult testis expressed 1 0.014788 1.210464 
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3414315 AQP5 aquaporin 5 0.015169 1.221794 
3692280 IRX3|IRX1|IRX5 iroquois homeobox 3 | iroquois homeobox 1  
| iroquois homeobox 5 
0.015261 1.224307 
3995765 DUSP9 dual specificity phosphatase 9 0.015427 1.203419 
3415273 C12orf44 chromosome 12 open reading frame 44 0.015579 1.206711 
2318242 LOC100130071 GSQS6193 0.015593 1.272391 
3832865 NCCRP1 non-specific cytotoxic cell receptor protein 1 homolog (zebrafish) 0.015781 1.216984 
3773426 NPTX1 neuronal pentraxin I 0.015963 1.216617 
2820884 GPR150 G protein-coupled receptor 150 0.016136 1.210947 
2904836 LHFPL5 lipoma HMGIC fusion partner-like 5 0.016209 1.22619 
3602299 NEIL1|MAN2C1 nei endonuclease VIII-like 1 (E. coli) | 
 mannosidase, alpha, class 2C, member 1 
0.016295 1.261569 
3870990 GP6 glycoprotein VI (platelet) 0.016467 1.223216 
2359431 LCE1F late cornified envelope 1F 0.01661 1.418236 
2487963 ANKRD53 ankyrin repeat domain 53 0.016653 1.205573 
4026624 PNCK pregnancy up-regulated non-ubiquitously  
expressed CaM kinase 
0.016701 1.202712 
3098549 SOX17 SRY (sex determining region Y)-box 17 0.016875 1.219817 
3378851 GPR152 G protein-coupled receptor 152 0.017317 1.356891 
3951117 ACR acrosin 0.017661 1.209925 
3717775 CDK5R1 cyclin-dependent kinase 5, regulatory subunit 1 (p35) 0.018152 1.221159 
3871389 FAM71E2 family with sequence similarity 71, member E2 0.018229 1.285293 
3316057 DRD4 dopamine receptor D4 0.018604 1.292633 
3851801 RTBDN retbindin 0.018637 1.246632 
3710406 SHISA6 shisa homolog 6 (Xenopus laevis) 0.018775 1.209048 
3442249 C12orf53 chromosome 12 open reading frame 53 0.018827 1.35486 
3194470 EGFL7|MIR126 EGF-like-domain, multiple 7 | microRNA 126 0.019038 1.205783 
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3704567 CBFA2T3|PABPN1L core-binding factor, runt domain, alpha subunit 2; 
 translocated to, 3 | poly(A) binding protein,  
nuclear 1-like (cytoplasmic) 
0.019507 1.277086 
2407359 EPHA10 EPH receptor A10 0.019562 1.286812 
3384248 FAM181B family with sequence similarity 181, member B 0.019808 1.22163 
3475383 HPD 4-hydroxyphenylpyruvate dioxygenase 0.020065 1.25692 
3580357 ANKRD9 ankyrin repeat domain 9 0.020122 1.202218 
2697863 RBP1 retinol binding protein 1, cellular 0.020342 1.287323 
3902552 FOXS1 forkhead box S1 0.020563 1.323761 
3882823 ASIP agouti signaling protein 0.020566 1.316178 
3394315 C1QTNF5|MFRP C1q and tumor necrosis factor related protein 5 | 
 membrane frizzled-related protein 
0.020683 1.23662 
3756709 KRTAP2-2|KRTAP2-1| 
KRTAP2-4|LOC730755| 
KAP2.1B 
keratin associated protein 2-2 |  
keratin associated protein 2-1 | 
 keratin associated protein 2-4 | 
 keratin associated protein 2-4-like | 
 keratin associated protein 2.1B 
0.020739 1.316847 
3013894 DLX6 distal-less homeobox 6 0.020786 1.211607 
2391425 DVL1 dishevelled, dsh homolog 1 (Drosophila) 0.020844 1.205483 
2534509 RAMP1 receptor (G protein-coupled) activity modifying protein 1 0.021133 1.211694 
3193942 OBP2A|OBP2B odorant binding protein 2A | odorant binding protein 2B 0.021156 1.360897 
3657552 TP53TG3|TP53TG3B TP53 target 3 | TP53 target 3B 0.02174 1.315799 
3338192 CCND1 cyclin D1 0.021794 1.234254 
3639601 RGMA RGM domain family, member A 0.021905 1.263049 
3334633 SLC22A11 solute carrier family 22 (organic anion/urate transporter), 
 member 11 
0.021991 1.209618 
2528774 SLC4A3 solute carrier family 4, anion exchanger, member 3 0.022069 1.201502 
3892788 C20orf200 chromosome 20 open reading frame 200 0.022131 1.210422 
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2888304 CLTB clathrin, light chain B 0.022425 1.233716 
2887930 FLJ16171  0.022596 1.387873 
3444593 PRB3|PRB4|PRB1 
|PRB2 
proline-rich protein BstNI subfamily 3 | 
 proline-rich protein BstNI subfamily 4 | 
 proline-rich protein BstNI subfamily 1 | 
proline-rich protein BstNI subfamily 2 
0.022859 1.290559 
3590239 DLL4 delta-like 4 (Drosophila) 0.02382 1.206722 
3402444 LTBR lymphotoxin beta receptor (TNFR superfamily, member 3) 0.024521 1.211369 
2323172 IGSF21 immunoglobin superfamily, member 21 0.024764 1.25627 
3015911 TRIP6 thyroid hormone receptor interactor 6 0.02486 1.202228 
3336220 PELI3 pellino homolog 3 (Drosophila) 0.024892 1.220248 
3655687 PRRT2 proline-rich transmembrane protein 2 0.026067 1.204707 
3874168 GNRH2 gonadotropin-releasing hormone 2 0.026152 1.210199 
3334919 MRPL49 mitochondrial ribosomal protein L49 0.026638 1.317266 
2406662 C1orf113|FAM176B chromosome 1 open reading frame 113 | 
 family with sequence similarity 176, member B 
0.027471 1.272064 
3642946 SOLH small optic lobes homolog (Drosophila) 0.027509 1.20925 
3708223 BCL6B B-cell CLL/lymphoma 6, member B 0.027617 1.230321 
3208349 FOXD4L2|FOXD4L3| 
FOXD4L4|FOXD4L6| 
FOXD4L5|FOXD4L1 
forkhead box D4-like 2 | forkhead box D4-like 3 |  
forkhead box D4-like 4 | forkhead box D4-like 6 |  
forkhead box D4-like 5 | forkhead box D4 |  
forkhead box D4-like 1 
0.027665 1.308214 
3643679 TPSD1 tryptase delta 1 0.027787 1.31544 
3839171 FLJ26850  0.02788 1.252255 
2600237 OBSL1 obscurin-like 1 0.027933 1.324396 
3688270 PRSS36 protease, serine, 36 0.027938 1.212274 
3642687 HBQ1 hemoglobin, theta 1 0.028009 1.300179 
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3944758 CDC42EP1 CDC42 effector protein (Rho GTPase binding) 1 0.028487 1.313417 
3760552 RPRML reprimo-like 0.028595 1.253123 
3953196 DGCR6L DiGeorge syndrome critical region gene 6-like |  
DiGeorge syndrome critical region gene 6 
0.028787 1.21309 
2487882 VAX2 ventral anterior homeobox 2 0.029701 1.217993 
3847462 FUT6 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 0.030036 1.20603 
3917582 KRTAP6-3 keratin associated protein 6-3 0.030772 1.213945 
3886598 KCNK15 potassium channel, subfamily K, member 15 0.031553 1.24118 
2984543 PRR18 proline rich 18 0.031723 1.218871 
2408437 CITED4 Cbp/p300-interacting transactivator, with Glu/ 
Asp-rich carboxy-terminal domain, 4 
0.032592 1.21 
2961647 HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 0.033109 1.220903 
2898096 HDGFL1 hepatoma derived growth factor-like 1 0.03343 1.248323 
3226208 PIP5KL1 phosphatidylinositol-4-phosphate 5-kinase-like 1 0.03359 1.326992 
3726114 DLX4 distal-less homeobox 4 0.033732 1.260217 
4003155 ARX aristaless related homeobox 0.03413 1.223033 
3839464 CLEC11A C-type lectin domain family 11, member A 0.03445 1.202796 
3923857 KRTAP10-9|KRTAP10-2| 
KRTAP10-11 
keratin associated protein 10-9 | keratin associated protein 10-2  
| keratin associated protein 10-11 
0.034535 1.218608 
3672609 FOXF1 forkhead box F1 0.034812 1.233776 
2756630 CPLX1 complexin 1 0.035126 1.256843 
3913335 C20orf166|MIR1-1| 
MIR133A2 
chromosome 20 open reading frame 166 | microRNA 1-1 | 
 microRNA 133a-2 
0.035607 1.225886 
2776305 NKX6-1 NK6 homeobox 1 0.036162 1.213078 
3894545 SDCBP2 syndecan binding protein (syntenin) 2 0.036284 1.204013 
3832906 IL29|IL28B interleukin 29 (interferon, lambda 1) | interleukin 28B  
(interferon, lambda 3) 
0.036921 1.223719 
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3867629 CGB5|CGB7|CGB8| 
NTF4 
chorionic gonadotropin, beta polypeptide 5 | chorionic gonadotropin, 
 beta polypeptide 7 | chorionic gonadotropin, beta polypeptide 8 | 
 neurotrophin 4 
0.037355 1.272945 
3638699 C15orf38|AP3S2 chromosome 15 open reading frame 38 |  
adaptor-related protein complex 3, sigma 2 subunit 
0.037422 1.236693 
2357961 BOLA1 bolA homolog 1 (E. coli) 0.037485 1.279794 
3902674 TSPY26P testis specific protein, Y-linked 26, pseudogene 0.038466 1.514903 
3652749 HS3ST2 heparan sulfate (glucosamine) 3-O-sulfotransferase 2 0.038743 1.242699 
3554396 SIVA1  0.039938 1.201848 
3817420 SHD Src homology 2 domain containing transforming protein D 0.040109 1.207889 
4027501 CTAG1A|CTAG1B| 
CTAG2 
cancer/testis antigen 1A | cancer/testis antigen 1B |  
cancer/testis antigen 2 
0.040506 1.201531 
3755316 MLLT6|LOC100129395 myeloid/lymphoid or mixed-lineage leukemia  
(trithorax homolog, Drosophila); translocated to, 6 | NS5ATP13TP1 
0.040588 1.551177 
3459604 PPM1H protein phosphatase, Mg2+/Mn2+ dependent, 1H 0.040599 1.293173 
3687232 C16orf54 chromosome 16 open reading frame 54 0.040995 1.302866 
3555675 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) 0.041045 1.244802 
3098454 MRPL15 mitochondrial ribosomal protein L15 0.042518 1.283998 
3886576 WISP2 WNT1 inducible signaling pathway protein 2 0.042769 1.251165 
2844461 LTC4S|MAML1 leukotriene C4 synthase | mastermind-like 1 (Drosophila) 0.043166 1.272022 
3415193 GRASP|GRASPOS GRP1 (general receptor for phosphoinositides 1)- 
associated scaffold protein | GRP1- 
associated scaffold protein opposite strand 
0.043383 1.212265 
2445876 NCRNA00083 non-protein coding RNA 83 0.043434 1.207612 
2745712 LOC441046 glucuronidase, beta pseudogene 0.043753 1.241513 
3834439 DMRTC2 DMRT-like family C2 0.043889 1.21691 
2939232 TUBB2B tubulin, beta 2B 0.044542 1.227506 
2915133 TPBG trophoblast glycoprotein 0.044752 1.281001 
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3677164 TCEB2 transcription elongation factor B (SIII),  
polypeptide 2 (18kDa, elongin B) 
0.044821 1.218621 
3663033 TEPP testis, prostate and placenta expressed 0.045603 1.200095 
3377886 CFL1 cofilin 1 (non-muscle) 0.045678 1.204996 
3914050 STMN3 stathmin-like 3 0.045741 1.213972 
3762185 HILS1 histone linker H1 domain, spermatid-specific 1 0.045748 1.214339 
3119765 ZNF707 zinc finger protein 707 0.046298 1.24442 
3672646 FOXC2 forkhead box C2 (MFH-1, mesenchyme forkhead 1) 0.047194 1.230515 
3707141 ZMYND15 zinc finger, MYND-type containing 15 0.047294 1.22945 
3279089 C10orf111 chromosome 10 open reading frame 111 0.047306 1.222135 
3902871 C20orf203 chromosome 20 open reading frame 203 0.047619 1.220926 
3852022 LYL1 lymphoblastic leukemia derived sequence 1 0.047664 1.343057 
2648305 P2RY1 purinergic receptor P2Y, G-protein coupled, 1 0.047797 1.269203 
3016316   0.04788 1.263108 
3923896 KRTAP10-12|KRTAP10-4| 
KRTAP10-6|KRTAP10-7 
keratin associated protein 10-12 | keratin associated protein 10-4 | 
 keratin associated protein 10-6 | keratin associated protein 10-7 
0.048039 1.226683 
2451931 GOLT1A golgi transport 1A 0.048085 1.218571 
3584393 C15orf2 chromosome 15 open reading frame 2 0.048664 1.27735 
3817072 GIPC3 GIPC PDZ domain containing family, member 3 0.049246 1.208209 
3456840 PPP1R1A protein phosphatase 1, regulatory (inhibitor) subunit 1A 0.049263 1.284999 
3735089 LOC643008 0.049389 1.210745 
3695315 CDH16 cadherin 16, KSP-cadherin 0.049445 1.2186 
3554496 PLD4 phospholipase D family, member 4 0.049683 1.260256 
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